<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jats2jats3.xsl?><?ConverterInfo.Version 1?><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Explor Target Antitumor Ther</journal-id><journal-id journal-id-type="iso-abbrev">Explor Target Antitumor Ther</journal-id><journal-id journal-id-type="publisher-id">ETAT</journal-id><journal-title-group><journal-title>Exploration of Targeted Anti-tumor Therapy</journal-title></journal-title-group><issn pub-type="epub">2692-3114</issn><publisher><publisher-name>Open Exploration Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">10344901</article-id><article-id pub-id-type="doi">10.37349/etat.2023.00140</article-id><article-id pub-id-type="publisher-manuscript">1002140</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Capitalizing glycomic changes for improved biomarker-based cancer diagnostics</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1170-3962</contrib-id><name><surname>Silva</surname><given-names>Maria Lu&#x000ed;sa S.</given-names></name><role>Conceptualization</role><role>Investigation</role><role>Data curation</role><role>Writing&#x02014;original draft</role><role>Writing&#x02014;review and editing</role><role>Formal analysis</role><xref rid="I1" ref-type="aff"/><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Seth</surname><given-names>Arun</given-names></name><role>Academic Editor</role><aff>University of Toronto, Canada</aff></contrib></contrib-group><aff id="I1">Unidade de Aprendizagem ao Longo da Vida, Universidade Aberta, 1269-001 Lisboa, Portugal</aff><author-notes><corresp id="cor1">
<bold>*Correspondence:</bold> Maria Lu&#x000ed;sa S. Silva, Unidade de Aprendizagem ao Longo da Vida, Universidade Aberta, 1269-001 Lisboa, Portugal. <email>mluisasilva@portugalmail.pt</email></corresp></author-notes><pub-date pub-type="ppub"><year>2023</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2023</year></pub-date><volume>4</volume><issue>3</issue><fpage>366</fpage><lpage>395</lpage><history><date date-type="received"><day>10</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>24</day><month>2</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2023.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract><p>Cancer serum biomarkers are valuable or even indispensable for cancer diagnostics and/or monitoring and, currently, many cancer serum markers are routinely used in the clinic. Most of those markers are glycoproteins, carrying cancer-specific glycan structures that can provide extra-information for cancer monitoring. Nonetheless, in the majority of cases, this differential feature is not exploited and the corresponding analytical assays detect only the protein amount, disregarding the analysis of the aberrant glycoform. Two exceptions to this trend are the biomarkers &#x003b1;-fetoprotein (AFP) and cancer antigen 19-9 (CA19-9), which are clinically monitored for their cancer-related glycan changes, and only the AFP assay includes quantification of both the protein amount and the altered glycoform. This narrative review demonstrates, through several examples, the advantages of the combined quantification of protein cancer biomarkers and the respective glycoform analysis, which enable to yield the maximum information and overcome the weaknesses of each individual analysis. This strategy allows to achieve higher sensitivity and specificity in the detection of cancer, enhancing the diagnostic power of biomarker-based cancer detection tests.</p></abstract><kwd-group><kwd>Cancer</kwd><kwd>biomarkers</kwd><kwd>aberrant glycosylation</kwd><kwd>assays</kwd><kwd>sensitivity</kwd><kwd>specificity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p id="p-1">Glycosylation of newly synthesized proteins and lipids is an essential process that occurs within cells, which enables to modify the intrinsic characteristics of the precursor molecules and to modulate diverse biological events [<xref rid="B1" ref-type="bibr">1</xref>]. In the case of proteins, and among other roles, glycosylation (1) allows to change protein polarity and solubility due to the hydrophilic nature of the glycan, (2) controls the tertiary structure of proteins by influencing their folding, (3) protects proteins from the action of proteolytic enzymes, (4) provides information about protein localization in the cell, (5) mediates events of protein recognition by other proteins and by the immune system, allowing it to distinguish between proteins from normal and from altered or non-self cells, and (6) many glycans act as receptors for viruses, bacteria, and parasites [<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>].</p><p id="p-2">Protein glycosylation can be of two types, namely <italic toggle="yes">O</italic>- and <italic toggle="yes">N</italic>-glycosylation, depending on the way the glycan is covalently attached to the protein backbone, and includes diverse pathways, in which several glycosyltransferases and glycosidases take part [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. The presence of specific glycosylation enzymes in cells of different tissues or organs results in the production of diverse glycoproteomes, which can distinguish the location where glycoproteins were synthesized [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Furthermore, in several pathological processes, alterations in glycan synthesis and in glycosylation pathways lead to the production of aberrant glycoproteins, whose presence can be indicative of a disease state. In fact, protein glycosylation changes that occur in a cell during the transformation into a disease state tend to produce more marked effects than alterations in protein expression, which can be explained by two reasons. First, glycans are metabolic products whose levels are directly dependent on the expression of the respective glycosyltransferases. Therefore, up- or down-regulation of the corresponding enzyme results in an amplified effect. Second, changes in protein glycosylation pathways have the potential to disturb all glycoproteins produced in the affected cell [<xref rid="B8" ref-type="bibr">8</xref>]. Aberrant glycosylation of proteins has been observed in diabetes, Alzheimer&#x02019;s disease, and several autoimmune diseases including rheumatoid arthritis and systemic lupus erythematosus, cardiovascular, respiratory, renal, and hepatic diseases, and cancer [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>]. It has also been associated with stress and chronic inflammatory states [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>].</p><p id="p-3">In cancer development, a high number of alterations in protein glycosylation has been reported, which are attributed to (1) the altered expression of glycosyltransferases, (2) changes in the tertiary conformation of the protein backbone and of the glycan chain, (3) the variability of acceptor substrates, (4) the availability and abundance of the sugar nucleotide donors and cofactors and/or (5) the localization of the pertinent glycosyltransferases in the Golgi apparatus [<xref rid="B15" ref-type="bibr">15</xref>]. Changes in protein glycosylation comprise (1) the increase in sialylation (especially in &#x003b1;2,6- and &#x003b1;2,3-linked sialylation) and polysialic acid synthesis, (2) the increase in fucosylation, (3) the increase in <italic toggle="yes">O</italic>- and <italic toggle="yes">N</italic>-linked glycan branching (such as the synthesis of complex &#x003b2;1,6-branched <italic toggle="yes">N</italic>-linked glycans), (4) the shortening of <italic toggle="yes">O</italic>-glycans (with the synthesis of the disaccharide Thomsen-Friedenreich antigen [T antigen] and the monosaccharide <italic toggle="yes">N</italic>-acetylgalactosamine [GalNAc; Thomsen nouveau antigen (Tn antigen)], as well as their sialylated forms sialyl-T antigen [ST antigen] and sialyl-Tn antigen [STn antigen], respectively), (5) alterations in the synthesis of histo-blood group-related antigens [loss of A and B antigens and changes in the Lewis family antigens, namely an increased expression or neoexpression of sialyl Lewis a antigen (SLe<sup>a</sup>), SLe<sup>x</sup> and SLe<sup>y</sup>], and (6) the increase in <italic toggle="yes">Helix pomatia</italic> agglutinin (HPA)-binding glycans [<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B18" ref-type="bibr">18</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>].</p><p id="p-4">When the aberrant glycoforms are exclusively produced by cancer cells, they can be used as cancer biomarkers, providing thus the required specificity for the monitorization of the disease. Their detection in blood or other biological specimens, including biopsy samples, has the potential to be useful for the diagnosis, prognosis, and/or therapy management, according to the sensitivity and selectivity of the glycobiomarkers.</p><p id="p-5">Currently, several serological biomarkers that are used in the clinical practice for cancer diagnosis and/or monitoring are glycoproteins (<xref rid="t1" ref-type="table">Table 1</xref>). Though all these glycoproteins have shown to present abnormal glycosylation in cancer, this differential feature is not exploited, and the majority of the corresponding analytical assays only detect the total protein level (through an immunoassay) and not the aberrant glycoform. Solely &#x003b1;-fetoprotein (AFP) and cancer antigen 19-9 (CA19-9) are clinically monitored for their glycan changes, and only the AFP assay includes quantification of both protein level and altered glycoform. On the other hand, the aberrant and cancer-associated glycoforms have shown, so far, limited applicability in cancer screening and diagnosis, as a result of their relatively low specificity [<xref rid="B15" ref-type="bibr">15</xref>].</p><table-wrap position="float" id="t1"><label>Table 1</label><caption><p>Cancer glycobiomarkers approved for clinical practice, for which aberrant glycoforms have already been reported (these two criteria&#x02014;approval by official entities and presenting aberrant glycoforms associated with cancer) were used to select the markers to be included in the table)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
<bold>Serological glycobiomarker</bold>
</th><th rowspan="1" colspan="1">
<bold>Cancer type(s)</bold>
</th><th rowspan="1" colspan="1">
<bold>Altered glycosylation</bold>
</th><th rowspan="1" colspan="1">
<bold>Type of detection</bold>
</th><th rowspan="1" colspan="1">
<bold>Clinical applications</bold>
</th><th rowspan="1" colspan="1">
<bold>References</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AFP-L3</td><td rowspan="1" colspan="1">
<p>Germ-cell hepatoma non-seminomatous</p>
<p>Testicular carcinoma</p>
</td><td rowspan="1" colspan="1">Core fucosylation of AFP-L3</td><td rowspan="1" colspan="1">AFP concentration and AFP-L3 glycoform concentration</td><td rowspan="1" colspan="1">
<p>Diagnosis</p>
<p>Prognosis</p>
<p>Staging</p>
<p>Recurrence detection</p>
<p>Therapy monitoring</p>
</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B34" ref-type="bibr">34</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<p>CA15-3 (MUC1)</p>
<p>CA27.29 (MUC1)</p>
</td><td rowspan="1" colspan="1">Breast carcinoma</td><td rowspan="1" colspan="1">Increased level of mannosylated <italic toggle="yes">N</italic>-glycans, sialylated <italic toggle="yes">O</italic>-glycans, truncated <italic toggle="yes">O</italic>-glycans (T, Tn, and respective sialylated derivatives)</td><td rowspan="1" colspan="1">MUC1 concentration (both assays use different antibodies that recognize diverse epitopes of the protein)</td><td rowspan="1" colspan="1">Therapy monitoring</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B35" ref-type="bibr">35</xref>&#x02013;<xref rid="B37" ref-type="bibr">37</xref>]</td></tr><tr><td rowspan="1" colspan="1">CA19-9</td><td rowspan="1" colspan="1">
<p>Pancreatic carcinoma</p>
<p>Colorectal carcinoma</p>
<p>Other gastrointestinal cancers, in combination with other biomarkers</p>
</td><td rowspan="1" colspan="1">Increased expression of SLe<sup>a</sup></td><td rowspan="1" colspan="1">SLe<sup>a</sup> concentration</td><td rowspan="1" colspan="1">
<p>Therapy monitoring</p>
<p>Recurrence detection</p>
<p>Tumour burden assessment</p>
</td><td rowspan="1" colspan="1">[<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B38" ref-type="bibr">38</xref>&#x02013;<xref rid="B44" ref-type="bibr">44</xref>]</td></tr><tr><td rowspan="1" colspan="1">CA125 (MUC16)</td><td rowspan="1" colspan="1">Ovarian carcinoma</td><td rowspan="1" colspan="1">Increased expression of truncated <italic toggle="yes">O</italic>-glycans (Tn, STn, T, ST, and core 2), Le<sup>x</sup> antigen expression, increased expression of bi-antennary complex-type and high mannose-type <italic toggle="yes">N</italic>-glycans</td><td rowspan="1" colspan="1">MUC16 concentration</td><td rowspan="1" colspan="1">
<p>Prognosis</p>
<p>Recurrence detection</p>
<p>Therapy monitoring</p>
</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B51" ref-type="bibr">51</xref>]</td></tr><tr><td rowspan="1" colspan="1">CEA</td><td rowspan="1" colspan="1">
<p>Colorectal carcinoma</p>
<p>Gastric carcinoma</p>
<p>Pancreatic carcinoma</p>
<p>Breast carcinoma</p>
<p>Lung carcinoma</p>
</td><td rowspan="1" colspan="1">Increased fucosylation and sialylation, increased expression of mannose, Le<sup>x</sup>, SLe<sup>x</sup>, Le<sup>y</sup>, and T antigen, increased branched <italic toggle="yes">N</italic>-glycans</td><td rowspan="1" colspan="1">CEA concentration</td><td rowspan="1" colspan="1">
<p>Staging</p>
<p>Prognosis</p>
<p>Recurrence detection</p>
<p>Therapy monitoring</p>
</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B52" ref-type="bibr">52</xref>&#x02013;<xref rid="B57" ref-type="bibr">57</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<p>Total PSA</p>
<p>Pro2PSA and free PSA</p>
</td><td rowspan="1" colspan="1">Prostate carcinoma</td><td rowspan="1" colspan="1">Altered fucosylation and sialylation, H2 epitope, increase in GalNAc content, LacdiNAc structure, &#x003b1;2,3-sialic acid on the terminal galactose of <italic toggle="yes">N</italic>-linked oligosaccharides</td><td rowspan="1" colspan="1">Total PSA and free PSA concentration</td><td rowspan="1" colspan="1">
<p>Screening</p>
<p>Diagnosis (with digital rectal examination)</p>
<p>Pro2PSA and free PSA are used to discriminate cancer from benign disease</p>
</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B58" ref-type="bibr">58</xref>&#x02013;<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td rowspan="1" colspan="1">Tg</td><td rowspan="1" colspan="1">Thyroid carcinoma</td><td rowspan="1" colspan="1">Increased LCA-reactive Tg, altered sialylation and fucosylation, &#x003b2;1,6-branching of glycans, altered content and structure of poly-LacNAc chains, <italic toggle="yes">O</italic>-GlcNAcylation</td><td rowspan="1" colspan="1">Tg concentration</td><td rowspan="1" colspan="1">Therapy monitoring</td><td rowspan="1" colspan="1">[<xref rid="B23" ref-type="bibr">23</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B62" ref-type="bibr">62</xref>&#x02013;<xref rid="B69" ref-type="bibr">69</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>MUC1: mucin 1; CEA: carcinoembryonic antigen; LCA: <italic toggle="yes">Lens culinaris</italic> agglutinin; Le<sup>x</sup>: Lewis x antigen; PSA: prostate-specific antigen; LacdiNAc: GalNAc&#x003b2;1,4-GlcNAc; Tg: thyroglobulin; LacNAc: <italic toggle="yes">N</italic>-acetyllactosamine; <italic toggle="yes">O</italic>-GlcNAcylation: <italic toggle="yes">O</italic>-linked-<italic toggle="yes">N</italic>-acetylglucosaminylation</p></fn></table-wrap-foot></table-wrap><p id="p-6">This review aims to present several examples where the combined quantification of protein cancer biomarkers and the respective glycoform analysis have been performed, and which enable to clearly demonstrate the advantages of this approach <italic toggle="yes">versus</italic> the sole quantification of the protein concentration.</p></sec><sec id="s2"><title>Improved cancer diagnosis and monitoring based on the use of specific serum glycobiomarkers</title><sec id="t2-1"><title>AFP and AFP-L3</title><p id="p-7">AFP is an oncofoetal glycoprotein, largely expressed in foetal yolk sac and liver during embryonic development. Its concentration gradually decreases after birth to &#x0003c; 10 ng/mL in 12&#x02013;18 months. During pregnancy, AFP levels rise again in maternal serum. AFP levels may also increase in several pathological situations, such as hepatocellular carcinoma (HCC), as well as in other gastrointestinal, lung, and testicular carcinomas [<xref rid="B70" ref-type="bibr">70</xref>]. Furthermore, it has also been reported to increase in benign liver diseases, namely in acute and chronic viral hepatitis and cirrhosis [<xref rid="B70" ref-type="bibr">70</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>].</p><p id="p-8">Although it is not specifically produced in HCC, AFP has been historically used as a tumour marker for this disease [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B73" ref-type="bibr">73</xref>]. Nevertheless, AFP expression may vary significantly in HCC, in a range from normal to &#x0003e; 100,000 ng/mL [<xref rid="B74" ref-type="bibr">74</xref>]. Up to 30% of HCC patients show normal AFP values at the time of diagnosis, remaining low even in advanced disease [<xref rid="B75" ref-type="bibr">75</xref>], and independently of the tumour size at diagnosis [<xref rid="B76" ref-type="bibr">76</xref>]. This results in large numbers of false negatives and low sensitivity of the test for HCC diagnosis [<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>]. On the other hand, elevated AFP levels may be found in liver benign diseases, as mentioned before, resulting in high numbers of false positives and low specificity [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B76" ref-type="bibr">76</xref>]. Together, these findings rule out the use of AFP for HCC diagnosis and for screening purposes [<xref rid="B76" ref-type="bibr">76</xref>].</p><p id="p-9">To improve the sensitivity and the diagnostic power of AFP for HCC, its glycoforms have been investigated using lectin electrophoretic techniques. It was found that AFP presents a distinctive affinity for LCA and, accordingly, three glycoforms can be separated, namely AFP-L1, AFP-L2, and AFP-L3. AFP-L1 does not bind to LCA and is the major glycoform of AFP in the serum of chronic hepatitis and cirrhosis. AFP-L2 is mostly resultant from yolk sac tumours and is also produced during pregnancy, showing an intermediate affinity for LCA [<xref rid="B78" ref-type="bibr">78</xref>]. AFP-L3 is the LCA-bound fraction of AFP, being produced in HCC even at early stages [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>].</p><p id="p-10">AFP-L3 presents &#x003b1;1,6 core fucosylation on the reducing terminus of <italic toggle="yes">N</italic>-acetylglucosamine of AFP molecule, and this altered glycosylation provides the reactivity towards LCA (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Elevated AFP-L3 levels in HCC result from overexpression of fucosyltransferase 8 (Fut 8; responsible for core fucosylation of proteins in the liver) [<xref rid="B79" ref-type="bibr">79</xref>] and also from the increased release of AFP-L3 from hepatocytes into plasma in HCC [<xref rid="B80" ref-type="bibr">80</xref>].</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>Glycan structures present in normal and cancer-associated glycoforms of the glycoproteins that are used in the clinic as cancer biomarkers. Lectins used for the selective binding of specific glycoforms are indicated next to the respective glycoform. Con A: concanavalin A; SBA: soybean agglutinin; PHA-E: <italic toggle="yes">Phaseolus vulgaris</italic> erythroagglutinin; LTA: <italic toggle="yes">Lotus tetragonolobus</italic> agglutinin; UEA: <italic toggle="yes">Ulex europaeus</italic> agglutinin; NPA: <italic toggle="yes">Narcissus pseudonarcissus</italic> agglutinin; MAA: <italic toggle="yes">Maackia amurensis</italic> agglutinin; PHA-L: <italic toggle="yes">Phaseolus vulgaris</italic> leucoagglutinin; SNA: <italic toggle="yes">Sambucus nigra</italic> agglutinin; WFA: <italic toggle="yes">Wisteria floribunda</italic> agglutinin; PhoSL: <italic toggle="yes">Pholiota squarrosa</italic> lectin; AAL: <italic toggle="yes">Aleuria aurantia</italic> lectin; TJA: <italic toggle="yes">Trichosanthes japonica</italic> agglutinin</p></caption><graphic xlink:href="etat-04-1002140-g001" position="float"/></fig><p id="p-11">AFP-L3 has shown to be a highly specific biomarker for HCC, allowing to differentiate HCC from cirrhosis, and also serves as a predictive marker for the development of HCC during the follow-up of patients with cirrhosis [<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>]. The AFP-L3 percentage of the total AFP (AFP-L3%), calculated as [(AFP-L3/total AFP) &#x000d7; 100], has been used as a marker for early diagnosis of HCC, for therapy evaluation and to predict the prognosis of HCC [<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>], being particularly useful in the &#x0201c;diagnostic dilemma&#x0201d; of cases with total AFP concentrations between 10 ng/mL and 200 ng/mL and to exclude HCC in benign conditions with elevated AFP [<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B34" ref-type="bibr">34</xref>]. The clinical performance of the AFP-L3% biomarker <italic toggle="yes">versus</italic> total AFP for the diagnosis and monitoring of HCC is presented in <xref rid="t2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="t2"><label>Table 2</label><caption><p>Clinical performance of AFP-L3% <italic toggle="yes">versus</italic> AFP as serological biomarkers for HCC (representative examples published since 2007)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
<bold>Assay</bold>
</th><th rowspan="1" colspan="1">
<bold>Sensitivity (%)</bold>
</th><th rowspan="1" colspan="1">
<bold>Specificity (%)</bold>
</th><th rowspan="1" colspan="1">
<bold>Other analytical features and advantages</bold>
</th><th rowspan="1" colspan="1">
<bold>Limitations</bold>
</th><th rowspan="1" colspan="1">
<bold>Reference</bold>
</th></tr></thead><tbody><tr><td colspan="6" rowspan="1">AFP total concentration quantification</td></tr><tr><td rowspan="1" colspan="1">Multiple reaction monitoring&#x02014;MS</td><td rowspan="1" colspan="1">76.0 (optimum cut-off 6.00 ng/mL)</td><td rowspan="1" colspan="1">77.5 (optimum cut-off 6.00 ng/mL)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">59.0 (optimum cut-off 5.90 ng/mL)</td><td rowspan="1" colspan="1">89.5 (optimum cut-off 5.90 ng/mL)</td><td rowspan="1" colspan="1">Total AFP concentration range from 0.3 ng/mL to 4,000 ng/mL</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">33.6 (cut-off 200 ng/mL)</td><td rowspan="1" colspan="1">98.0 (cut-off 200 ng/mL)</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td colspan="6" rowspan="1">AFP-L3% quantification</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">72.4 (cut-off 7.7%)</td><td rowspan="1" colspan="1">90.9 (cut-off 7.7%)</td><td rowspan="1" colspan="1">Sensitivity and specificity remained practically constant, independently of the AFP total concentration</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>]</td></tr><tr><td rowspan="1" colspan="1">Liquid chromatography&#x02014;parallel reaction monitoring&#x02014;MS</td><td rowspan="1" colspan="1">80.8 (cut-off 18.6%)</td><td rowspan="1" colspan="1">100 (cut-off 18.6%)</td><td rowspan="1" colspan="1">
<p>Early detection of HCC with higher accuracy than &#x003bc;TAS</p>
<p>Analytical performance identical to &#x003bc;TAS conventional system with better sensitivity and accuracy</p>
</td><td rowspan="1" colspan="1">
<p>Sample preparation prior to MS analysis is required</p>
<p>More time-consuming than microarray systems</p>
</td><td rowspan="1" colspan="1">[<xref rid="B83" ref-type="bibr">83</xref>]</td></tr><tr><td rowspan="1" colspan="1">Multiple reaction monitoring&#x02014;MS</td><td rowspan="1" colspan="1">81.0 (optimum cut-off 0.132%)</td><td rowspan="1" colspan="1">89.5 (optimum cut-off 0.132%)</td><td rowspan="1" colspan="1">
<p>Early detection of HCC (screening)</p>
<p>Lower incidence of false negatives compared to LiBA assay</p>
<p>AFP-L3 concentration range from 0.132% to 100%, with a LLOQ of 0.051 ng/mL AFP</p>
</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">61.5 (optimum cut-off 0.500%)</td><td rowspan="1" colspan="1">90.0 (optimum cut-off 0.500%)</td><td rowspan="1" colspan="1">AFP-L3 concentration range from 0.5% to 99.5%, with a LLOQ of 0.3 ng/mL AFP</td><td rowspan="1" colspan="1">AFP-L3% cannot be reported if the total AFP concentration is &#x0003c; 0.3 ng/mL, even in cases of high AFP-L3 concentrations</td><td rowspan="1" colspan="1">[<xref rid="B81" ref-type="bibr">81</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">
<p>41.5 (cut-off 5% and total AFP concentration &#x0003c; 20 ng/mL)</p>
<p>36.2 (cut-off 5% and total AFP concentration &#x0003c; 10 ng/mL)</p>
</td><td rowspan="1" colspan="1">
<p>85.1 (cut-off 5% and total AFP concentration &#x0003c; 20 ng/mL)</p>
<p>88.5 (cut-off 5% and total AFP concentration &#x0003c; 10 ng/mL)</p>
</td><td rowspan="1" colspan="1">
<p>Better diagnostic performance than the conventional LiBA system assay for low serum total AFP concentrations (&#x0003c; 20 ng/mL)</p>
<p>AFP-L3% correlated with poor prognosis and low survival rate</p>
<p>LLOQ of 0.3 ng/mL AFP</p>
</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B84" ref-type="bibr">84</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA &#x003bc;TAS (Wako i-30 autoanalyzer)</td><td rowspan="1" colspan="1">
<p>60.0 (optimum cut-off 7% and total AFP concentration 200 ng/mL)</p>
<p>41.1 (optimum cut-off 7% and total AFP concentration &#x0003c; 20 ng/mL)</p>
</td><td rowspan="1" colspan="1">
<p>90.3 (optimum cut-off 7% and total AFP concentration 200 ng/mL)</p>
<p>91.9 (optimum cut-off 7% and total AFP concentration &#x0003c; 20 ng/mL)</p>
</td><td rowspan="1" colspan="1">
<p>More sensitive in discriminating HCC than the corresponding LiBA system and total AFP concentration assays, even for low total AFP concentrations</p>
<p>Has predictive value for long-time survival</p>
<p>Short-time and automated assay</p>
</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B82" ref-type="bibr">82</xref>]</td></tr><tr><td rowspan="1" colspan="1">LiBA (Wako LiBASys clinical autoanalyzer)</td><td rowspan="1" colspan="1">
<p>71 (cut-off &#x02265; 10%)</p>
<p>33 (cut-off &#x02265; 35%)</p>
</td><td rowspan="1" colspan="1">
<p>63 (cut-off &#x02265; 10%)</p>
<p>100 (cut-off &#x02265; 35%)</p>
</td><td rowspan="1" colspan="1">
<p>Total AFP concentration range from 10 ng/mL to 200 ng/mL, with a LLOQ of 0.8 ng/mL AFP and 0.5% AFP-L3</p>
<p>AFP-L3%, in combination with the AFP level, increases the specificity of diagnosis of HCC in individuals with indeterminate increases of total AFP level (10&#x02013;200 ng/mL)</p>
</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">[<xref rid="B27" ref-type="bibr">27</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>-: blank cell; LLOQ: lower limit of quantification; MS: mass spectrometry; LiBA: liquid-phase binding assay; &#x003bc;TAS: micro-total assay system</p></fn></table-wrap-foot></table-wrap><p id="p-12">Comparing the results obtained for AFP-L3% and total AFP quantification, when performed on the same samples, it is clear that AFP-L3% has superior behaviour, with improved sensitivity and specificity, demonstrating the benefits of quantifying this glycobiomarker instead of only measuring the total protein concentration.</p><p id="p-13">Recent studies on fucosylated glycoforms of other liver-secreted proteins, namely haptoglobin, kininogen, &#x003b1;1-antitrypsin and Golgi protein 73 have shown the promising potential of these glycobiomarkers for differential diagnosis of HCC <italic toggle="yes">versus</italic> cirrhosis with improved sensitivity and specificity [<xref rid="B85" ref-type="bibr">85</xref>, <xref rid="B86" ref-type="bibr">86</xref>]. In addition, the monosialylated AFP (msAFP) has also proved to be more specific than AFP, showing the potential to be a diagnostic marker for HCC in nondiagnostic AFP conditions [<xref rid="B87" ref-type="bibr">87</xref>].</p></sec><sec id="t2-2"><title>MUC1 and its cancer-associated glycoforms</title><p id="p-14">MUC1 is a heavily glycosylated transmembrane protein (with 50% to 90% of its molecular mass corresponding to carbohydrates), that belongs to the MUC family. It is physiologically expressed in breast tissue, specifically on the glandular or luminal epithelial cells of the mammary gland, as well as in the apical surfaces of simple secretory epithelia of gastrointestinal, respiratory, urinary, and reproductive tracts [<xref rid="B88" ref-type="bibr">88</xref>], protecting the underlying epithelia.</p><p id="p-15">In most human epithelial cancers, MUC1 is overexpressed and exhibits aberrant glycosylation [<xref rid="B89" ref-type="bibr">89</xref>&#x02013;<xref rid="B92" ref-type="bibr">92</xref>]. In breast cancer cells there is increased sialylation of MUC1, which results in truncation of sugar branches that would be otherwise elongated. Therefore, MUC1 presents mainly core 1 <italic toggle="yes">O</italic>-glycans (namely T antigen) in opposition to the extensively branched core 2 <italic toggle="yes">O</italic>-glycans carried by normal MUC1, and the Tn antigen is also overexpressed, as well as the respective sialylated derivatives (ST and STn antigens) [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B93" ref-type="bibr">93</xref>&#x02013;<xref rid="B95" ref-type="bibr">95</xref>]. There is also an increased expression of high-mannose-type <italic toggle="yes">N</italic>-glycans [<xref rid="B96" ref-type="bibr">96</xref>]. In cancers located in other tissues, different aberrant glycosylation of MUC1 occurs [<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B97" ref-type="bibr">97</xref>].</p><p id="p-16">The CA15-3 assay detects the soluble forms of MUC1 (the peptide backbone), and it is used for therapy monitoring in patients with metastatic disease [<xref rid="B98" ref-type="bibr">98</xref>&#x02013;<xref rid="B100" ref-type="bibr">100</xref>]. Since the referred forms are also secreted from cells in other tumours and diseases, the assay lacks the required specificity for breast cancer. Besides, the assay also presents low sensitivity for <italic toggle="yes">in situ</italic> or low stage disease, as the levels of the soluble forms of MUC1 rarely increase at the early stages of breast cancer. Therefore, it cannot be used for screening or early detection purposes [<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B98" ref-type="bibr">98</xref>]. A related assay, known as CA27.29, also detects the soluble forms of MUC1 but uses a different antibody and a different detection strategy. Both assays originate similar but not identical results [<xref rid="B101" ref-type="bibr">101</xref>]. Although it seems that the CA27.29 assay has greater sensitivity than the CA15-3 assay [<xref rid="B102" ref-type="bibr">102</xref>], its routine use is yet not recommended due to insufficient data [<xref rid="B100" ref-type="bibr">100</xref>, <xref rid="B103" ref-type="bibr">103</xref>].</p><p id="p-17">Aberrant glycoforms of MUC1 have been evaluated in order to be used as breast cancer biomarkers with improved clinical performance over the conventional CA15-3 and CA27.29 assays. An antibody-lectin sandwich assay was designed to detect the aberrant glycosylation of MUC1 in sera from breast cancer patients, using an antibody to capture the protein and the lectin Con A to detect high mannose <italic toggle="yes">N</italic>-glycans present in MUC1 [<xref rid="B35" ref-type="bibr">35</xref>]. The results revealed that mannosylated <italic toggle="yes">N</italic>-glycans of cancer-associated MUC1 were the most effective targets for the antibody-lectin sandwich assay. In addition, it was shown that the glycosylation level increased with the progression of the disease and the assay efficiently discriminated breast cancer stage I (sensitivity: 63%, specificity: 69%), IIA (sensitivity: 77%, specificity: 75%), IIB (sensitivity: 69%, specificity: 86%) and III (sensitivity: 80%, specificity: 65%) from benign breast disease. There were no differences in the mannosylated <italic toggle="yes">N</italic>-glycan level of MUC1 between the normal and the benign groups. Immunodetection of the MUC1 protein revealed no differences between the groups in a sandwich enzyme-linked immunosorbent assay (ELISA) using two different anti-MUC1 antibodies, confirming that the increased response of cancer samples in the developed assay was due to the increased <italic toggle="yes">N</italic>-glycosylation of MUC1 rather than to an increased concentration of MUC1. The enhanced sensitivity of the developed assay <italic toggle="yes">versus</italic> the current ELISA CA15-3 assay was justified by the heavy glycosylation of MUC1 that resulted in an amplified analytical signal. Although a larger sample size is needed to validate the reported findings, the study demonstrated the advantages of detecting the aberrant glycosylation of the biomarker instead of the total protein concentration.</p></sec><sec id="t2-3"><title>MUC16 and its cancer-associated glycoforms</title><p id="p-18">MUC16 is a large membrane glycoprotein that belongs to the MUC family. It is highly <italic toggle="yes">O</italic>-glycosylated, with a carbohydrate content accounting for approximately 77% of the total weight of the MUC [<xref rid="B104" ref-type="bibr">104</xref>]. CA125 is an epitope present on MUC16, which is detected by specific monoclonal antibodies, such as OC125 and M11, used in CA125 immunoassays [<xref rid="B105" ref-type="bibr">105</xref>]. MUC16 is physiologically expressed by secretory epithelial cells of the eye, oral cavity, heart, lung, gastric tract, gall bladder, cervix, and uterus, providing lubrification and protection to the epithelial surfaces [<xref rid="B106" ref-type="bibr">106</xref>]. In healthy populations, CA125 serum levels are &#x0003c; 35 U/mL [<xref rid="B107" ref-type="bibr">107</xref>], and the values tend to decline with aging and menopause. On the other hand, elevated CA125 levels can be found in healthy women, during the follicular phase of the menstrual cycle [<xref rid="B108" ref-type="bibr">108</xref>] and during the first trimester of pregnancy [<xref rid="B109" ref-type="bibr">109</xref>], and in non-malignant diseases such as cirrhosis, hepatitis, endometriosis, and ovarian cysts [<xref rid="B110" ref-type="bibr">110</xref>&#x02013;<xref rid="B112" ref-type="bibr">112</xref>].</p><p id="p-19">During cancer development, MUC16 is aberrantly expressed, both in its amount and glycosylation [<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B114" ref-type="bibr">114</xref>]. Aberrant MUC16 has been reported to be produced in diverse carcinomas such as ovarian, lung, breast, gastrointestinal, kidney, cervical, uterine, and endometrial [<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>]. Cancer-associated CA125 antigen presents both <italic toggle="yes">N</italic>- and <italic toggle="yes">O</italic>-glycosylation, with <italic toggle="yes">N</italic>-linked glycans being mainly composed of bi-antennary complex-type and high mannose-type oligosaccharide chains, and <italic toggle="yes">O</italic>-glycans are, predominantly, mono- and disialylated core type 1 (Gal&#x003b2;1,3-GalNAc) and core type 2 glycans [Gal&#x003b2;1,3-(GlcNAc&#x003b2;1,6)-GalNAc]. The majority of <italic toggle="yes">O</italic>-glycans are sialylated and/or fucosylated, and carry a maximum of two fucoses or two sialic acids, or two fucoses and two sialic acids. The Le<sup>x</sup> epitope is also present, both in <italic toggle="yes">O</italic>- and <italic toggle="yes">N</italic>-glycans [<xref rid="B47" ref-type="bibr">47</xref>].</p><p id="p-20">Since MUC16 can be overexpressed in a variety of non-ovarian cancers and benign diseases, the CA125 assay shows poor specificity for ovarian cancer diagnosis and frequently presents false positives. Additionally, the assay has also low sensitivity for ovarian cancer, as around 50% of patients with early stages of ovarian cancer do not express elevated CA125 values, resulting in false negatives [<xref rid="B115" ref-type="bibr">115</xref>]. Therefore, the CA125 assay is not recommended for screening ovarian cancer in asymptomatic women. However, it is recommended for screening women with a family history of ovarian cancer, in conjunction with other imaging tests. Furthermore, CA125 testing is recommended as an adjunct to discriminate between benign and malignant suspicious pelvic masses, particularly in postmenopausal women. In spite of its limited sensitivity and specificity for ovarian cancer, CA125 concentration correlates with disease stage, tumour size, and prognosis, so its measurement is recommended and useful for monitoring the response to therapeutic treatment and for evaluation of disease status and detection of recurrence. As CA125 concentration may vary due to differences in calibration, assay design, and reagent specificities, it is recommended that the same assay method should be used throughout for a single patient [<xref rid="B99" ref-type="bibr">99</xref>].</p><p id="p-21">Other serum biomarkers have been proposed for ovarian cancer detection, namely human epididymis protein 4 (HE4), alone or in combination with CA125, but the available data are insufficient to conclude a significant improvement in the clinical performance of the assays <italic toggle="yes">versus</italic> the CA125 assay alone [<xref rid="B116" ref-type="bibr">116</xref>]. Multiple-marker based algorithms, namely ROMA and OVA1, have also been developed and approved to assess ovarian cancer risk in women with a pelvic mass, showing increased benefit over the traditional CA125 assay. However, they are not recommended for ovarian cancer screening or diagnosis and the results must be interpreted together with an independent clinical and radiological evaluation [<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>].</p><p id="p-22">The glycosylation profile of CA125 antigen from human amniotic fluid and from a human ovarian carcinoma cell line 3 (OVCAR-3) was compared, using lectin-affinity chromatography [<xref rid="B46" ref-type="bibr">46</xref>]. The results showed a higher abundance of <italic toggle="yes">O</italic>-glycans in the CA125 antigen from the ovarian cancer cells, with higher expression of GalNAc and lower expression of Gal&#x003b2;1,3-GalNAc, compared to the amniotic fluid samples. Also, the terminal GalNAc&#x003b2;1,4-GlcNAc structure was found to be predominantly present in ovarian cancer cells. High-mannose-type and bisecting GlcNAc <italic toggle="yes">N</italic>-glycans were also found to be more abundant in ovarian cancer cells. Although this was a preliminary study, it demonstrated the differential glycosylation pattern between CA125 antigens from normal and cancer origins, and the potential use of a lectin-based assay to discriminate CA125 glycoforms and to complement the total CA125 concentration test, improving its diagnostic performance towards the detection of ovarian cancer. In another study, a sandwich ELISA was developed to measure the level of STn antigen expressed on MUC16, which allowed to differentiate between patients with endometriosis and ovarian cancer [<xref rid="B50" ref-type="bibr">50</xref>]. An anti-MUC16 monoclonal antibody was used for capture and an anti-STn monoclonal antibody was used for detection. It was shown that STn antigen was noticeably detectable in the MUC16-enriched fractions from OVCAR-3 cells but negligible in those from peritoneal fluid of patients with endometriosis, and that the level of STn-MUC16 was significantly higher in the samples from patients with ovarian cancer, compared with the samples from patients with endometriosis. These results were consistent with immunohistochemical analysis. Furthermore, the levels of MUC16 and STn-MUC16 were compared for different clinical stages and cytological grades of ovarian cancer, and it was found that an elevated level of STn-MUC16 was more closely associated with an advanced clinical stage and cytological grade than that of MUC16 concentration alone. The level of STn-MUC16 discriminated patients with endometriosis and with ovarian cancer, with 44% sensitivity and 100% specificity.</p><p id="p-23">A microarray-based platform has also been developed for profiling specific aberrant glycoforms including T, Tn, and STn antigens, present on CA125 (MUC16) and CA15-3 (MUC1) [<xref rid="B51" ref-type="bibr">51</xref>]. A blinded cohort study of patients with elevated CA125 levels (30&#x02013;500 kU/L) and a pelvic mass, from the UK Ovarian Cancer Population Study (UKOPS), was performed by analysing a combined glycoform profile that comprised STn-CA125, ST-CA125, and STn-CA15-3 (the three best-performing glycoforms). Glycoprofiling analysis was able to distinguish benign ovarian neoplasms from invasive epithelial ovarian/tubule cancer with a specificity of 61.1% at 90% sensitivity, whereas the CA125 specificity for the commercial assay was only 41.3% at the same sensitivity. The developed microarray assay thus showed its potential to improve the differential diagnosis of ovarian cancer and to significantly reduce the number of patients elected for further testing. A refinement of this study was achieved through the use of proximity-ligation assay (PLA), in which aberrant glycoforms (Tn, STn, and T) of MUC16 and MUC1 in ovarian cancer tissue were detected [<xref rid="B119" ref-type="bibr">119</xref>]. PLA reactions for Tn-MUC16, STn-MUC16, Tn-MUC1, and STn-MUC1 were negative in benign lesions but often positive in borderline and malignant lesions. The developed assay allowed to improve the analytical performance of the previous microarray assay, increasing the sensitivity to 72% and 83% in two series of samples, with 100% specificity. The described examples reinforce the usefulness of employing the analysis of MUC16 aberrant glycoforms to improve the clinical performance of MUC16 as a biomarker for ovarian cancer.</p></sec><sec id="t2-4"><title>CA19-9</title><p id="p-24">The CA19-9 antibody recognizes a glycan epitope present in MUC-type glycoproteins in serum, and in glycolipids (monosialogangliosides) in tissues. The immunodeterminant structure is SLe<sup>a</sup> [Sia&#x003b1;2,3-Gal&#x003b2;1,3-(Fuc&#x003b1;1,4)-GlcNAc], a sialylated glycoform of the Le<sup>a</sup> blood group antigen [<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>]. The CA19-9 antibody reacts with some normal tissues, namely the pancreatic, gall bladder, and gastric epithelia, showing that CA19-9 can be expressed under physiological conditions [<xref rid="B120" ref-type="bibr">120</xref>]. Nevertheless, CA19-9 is also expressed in cancer, for example, carried by MUCs which are known to play a role in cancer progression and metastization [<xref rid="B121" ref-type="bibr">121</xref>].</p><p id="p-25">CA19-9 has been extensively reported to be a useful diagnostic aid for pancreatic cancer and it is the gold standard biomarker for this disease, being used to discriminate malignant from benign disorders of the pancreas [<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>]. Elevated levels of CA19-9 in pancreatic cancer patients have also been associated with disease recurrence [<xref rid="B44" ref-type="bibr">44</xref>] and poor prognosis [<xref rid="B39" ref-type="bibr">39</xref>]. CA19-9 can also be elevated in other gastrointestinal, ovarian, and hepatocellular cancers, although its routine measurement in such cases is not recommended [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B121" ref-type="bibr">121</xref>]. However, elevated CA19-9 levels can also be found in benign diseases (and even in healthy individuals, depending on their genetic variation for the expression of CA19-9 and related epitopes) [<xref rid="B122" ref-type="bibr">122</xref>], and in about 20% of the patients with pancreatic adenocarcinoma its level may be normal [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B121" ref-type="bibr">121</xref>].</p><p id="p-26">Due to its insufficient specificity and sensitivity, CA19-9 is not recommended for screening, diagnosis, staging, surveillance, or treatment monitoring of patients with pancreatic or colorectal cancer (CRC) [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B103" ref-type="bibr">103</xref>]. However, it can be used to monitor the response to therapy for locally advanced metastatic pancreatic cancer and the increase in CA19-9 levels may indicate disease progression [<xref rid="B40" ref-type="bibr">40</xref>].</p><p id="p-27">CA19-9 is a carbohydrate and, thus, the aberrant glycosylation associated with cancer is already capitalized in this biomarker. Still, the clinical performance of CA19-9 in the early diagnosis of pancreatic cancer can be further extended if other cancer-associated aberrant glycans and proteins are detected in combination with CA19-9. In fact, a wide range of glycosylation alterations have been associated with pancreatic cancer such as increased expression of SLe<sup>x</sup> antigen, increased expression of truncated <italic toggle="yes">O</italic>&#x02011;glycans (Tn and STn), increased branched and fucosylated <italic toggle="yes">N</italic>&#x02011;glycans, upregulation of specific proteoglycans and galectins, and increased <italic toggle="yes">O</italic>&#x02011;GlcNAcylation (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B123" ref-type="bibr">123</xref>]. For example, it was shown that CA19-9 expression in MUC5AC and MUC1 proteins may be increased, independently of protein elevation, and that the combined measurement of MUC5AC and CA19-9 presents better performance and improved specificity to differentiate pancreatic cancer subjects from controls [<xref rid="B124" ref-type="bibr">124</xref>, <xref rid="B125" ref-type="bibr">125</xref>]. At a threshold of 96% specificity, 78% and 83% of pancreatic cancer patients showed increased expression of CA19-9 in MUC5AC and MUC1, respectively [<xref rid="B124" ref-type="bibr">124</xref>]. The complementary relationship between protein and glycan elevations resulted in better sensitivities achieved when both glycan and protein were measured, <italic toggle="yes">versus</italic> measuring just the protein. In comparison, the median sensitivity of CA19-9 for the diagnosis of pancreatic cancer calculated from pooled data is 79% (70&#x02013;90%) with a median specificity of 82% (68&#x02013;91%) [<xref rid="B43" ref-type="bibr">43</xref>]. Furthermore, the combined detection of CA19-9 and other cancer-associated aberrant glycostructures, namely wheat germ agglutinin (WGA)-binding glycans in serum MUCs [<xref rid="B126" ref-type="bibr">126</xref>], CA242 [<xref rid="B127" ref-type="bibr">127</xref>], CA72-4 [<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>] or SLe<sup>x</sup> [<xref rid="B130" ref-type="bibr">130</xref>, <xref rid="B131" ref-type="bibr">131</xref>] enabled to increase the sensitivity and specificity of the assays, compared to the measurement of CA19-9 alone. The advantageous combination of CA19-9 with other cancer-associated proteins or glycostructures has also been demonstrated for the detection of gastric cancer [<xref rid="B132" ref-type="bibr">132</xref>&#x02013;<xref rid="B134" ref-type="bibr">134</xref>].</p></sec><sec id="t2-5"><title>CEA and its cancer-associated glycosylation</title><p id="p-28">CEA is a highly glycosylated (with approximately 60% carbohydrate content) complex glycoprotein belonging to the immunoglobulin gene superfamily [<xref rid="B135" ref-type="bibr">135</xref>]. It is an oncofoetal antigen, produced by the intestinal tissue of a normal foetus, but expressed in normal adults only in trace amounts. Being a cell surface immunoglobulin, CEA functions are related with cell adhesion, intercellular recognition, and attachment, exerting also immunoregulatory roles [<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B136" ref-type="bibr">136</xref>]. CEA has been detected in the glycocalyx of surface epithelial cells of normal colon mucosa [<xref rid="B137" ref-type="bibr">137</xref>], and more than 95% of the normal population expresses CEA in levels below 5 ng/mL. Smoking habits somewhat increase CEA normal serum values, and CEA tends also to slightly increase in older people [<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B139" ref-type="bibr">139</xref>]. CEA can also be increased in non-malignant diseases, such as liver, gastrointestinal, renal, and other chronic diseases [<xref rid="B138" ref-type="bibr">138</xref>, <xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>].</p><p id="p-29">CEA is also expressed in diverse carcinomas including breast [<xref rid="B142" ref-type="bibr">142</xref>], gastric [<xref rid="B143" ref-type="bibr">143</xref>], pancreatic [<xref rid="B144" ref-type="bibr">144</xref>], renal [<xref rid="B145" ref-type="bibr">145</xref>], and lung [<xref rid="B146" ref-type="bibr">146</xref>]. In colon carcinogenesis, CEA overexpression contributes to disturb the normal histological architecture of colonic epithelium [<xref rid="B147" ref-type="bibr">147</xref>] and facilitates cellular migration and metastization [<xref rid="B148" ref-type="bibr">148</xref>].</p><p id="p-30">Both in benign and malignant diseases there is no progressive increase in CEA levels, with values higher than 10 ng/mL being rarely observed [<xref rid="B138" ref-type="bibr">138</xref>]. In addition, although CEA is expressed in the great majority of CRCs, its levels are usually normal at the time of diagnosis due to the first-pass effect in CEA metabolization [<xref rid="B149" ref-type="bibr">149</xref>]. In spite of its low specificity and sensitivity for CRC diagnosis, CEA has been extensively used as the main biomarker for CRC, as well as for tumours of the gastrointestinal tract. Although it is not recommended for CRC screening, it can be used for staging (as increased serum levels correlate with advanced stages) and for surgical treatment planning. Elevated preoperative CEA may correlate with poorer prognosis and it is recommended that postoperative serum CEA testing may be performed every 2&#x02013;3 months in patients with stage II or III disease or for &#x02265; 2 years after diagnosis, as an increase in postoperative CEA level may indicate recurrence. CEA is the marker of choice for monitoring metastatic CRC during systemic therapy [<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B99" ref-type="bibr">99</xref>, <xref rid="B150" ref-type="bibr">150</xref>].</p><p id="p-31">CEA exhibits extensive glycosylation on asparagine residues with up to 28 complex <italic toggle="yes">N</italic>-linked multi-antennary glycan chains with Le<sup>x</sup> and SLe<sup>x</sup> structural motifs [<xref rid="B57" ref-type="bibr">57</xref>], with the glycofraction consisting mainly of <italic toggle="yes">N</italic>-acetylglucosamine, mannose, galactose, fucose and sialic acid [<xref rid="B150" ref-type="bibr">150</xref>]. <italic toggle="yes">O</italic>-glycosylation is quantitatively less important than <italic toggle="yes">N</italic>-glycosylation [<xref rid="B55" ref-type="bibr">55</xref>]. The <italic toggle="yes">N</italic>-glycosylation profile of CEA purified from human colon carcinoma cells and from human liver metastases of CRC cells was analyzed by MS, showing distinctive features <italic toggle="yes">versus</italic> normal CEA <italic toggle="yes">N</italic>-glycosylation pattern, namely simultaneously increased bisection and branching, incomplete galactosylation or poly-LacNAc elongation on highly branched structures, moderate levels of sialylation and high levels of fucosylation (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B53" ref-type="bibr">53</xref>]. Overexpression of bi-antennary, tri-antennary, and tetra-antennary structures carrying sialic acid and fucose residues, as well as terminal SLe<sup>x</sup> structure, were also reported in another study, where CEA from samples of human CRC tissue were analyzed (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B54" ref-type="bibr">54</xref>]. In this study, approximately 50% of CEA glycans presented core fucosylation. The glycosylation of CEA from normal <italic toggle="yes">versus</italic> tumour colon tissue was also characterized using a different approach, based on lectin binding and ELISA assays [<xref rid="B55" ref-type="bibr">55</xref>]. The results revealed that tumour-associated CEA contained high levels of Le<sup>x</sup> and Le<sup>y</sup> antigens (proved by the strong binding of LTA and UEA, respectively), as well as increased expression of mannose (shown by increased binding of NPA) and &#x003b2;1,6-branched <italic toggle="yes">N</italic>-glycans (demonstrated by strong binding of PHA-L). MAA binding was higher for the cancer samples, evidencing increased expression of sialic acid (<xref rid="fig1" ref-type="fig">Figure 1</xref>). The study demonstrated the feasibility of differential detection of tumour-associated CEA using lectin-based ELISA assays and a panel of lectins. A high-density lectin microarray comprising 56 lectins was also developed for the analysis of the glycosylation pattern of CEA from tumour tissues of CRC patients [<xref rid="B56" ref-type="bibr">56</xref>]. The results showed different CEA glycosylation profiles between normal and cancer tissues, with CEA from tumour tissues presenting the higher expression of fucose (both terminal and core), mannose and T antigen, and lower expression of GalNAc, <italic toggle="yes">N</italic>-acetylglucosamine, galactose, and branched and bisecting <italic toggle="yes">N</italic>-glycans. Moreover, a combinatorial assessment of nine lectins was found to be sufficient to distinguish CRC tumour tissues from tumour-adjacent normal tissues with 83% sensitivity and around 90% specificity. The reported clinical performance surpassed the average performance of the total CEA concentration assay (sensitivity of ~80% and specificity of ~70%) [<xref rid="B151" ref-type="bibr">151</xref>]. Additionally, the developed assay showed that alterations in the glycosylation pattern of CEA correlated well with CRC tumorigenesis and progression and that specific glycans were differently expressed on CEA in a stage-dependent manner. In spite of the scarce quantitative studies regarding the improved performance of CEA cancer-associated glycoforms over the conventional total CEA concentration assay, the above-referred studies corroborate the importance of glycosylation analysis of CEA to enhance the clinical performance of this CRC biomarker.</p></sec><sec id="t2-6"><title>PSA and its cancer-associated glycoforms</title><p id="p-32">PSA is a glycoprotein primarily expressed in prostate tissue [<xref rid="B152" ref-type="bibr">152</xref>]. It is produced almost exclusively by the luminal epithelial cells of prostatic glandular tissue in benign and malignant situations, which results in its low specificity in discriminating both. Most frequently, elevated values of PSA are indicative of benign prostatic hyperplasia (BPH), being also elevated in cases of urinary retention, prostatitis, and ejaculation [<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>].</p><p id="p-33">Total PSA serum concentration remains the most commonly used cancer biomarker for early detection of prostate cancer, and to monitor therapeutic response, aggressiveness, and recurrence [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>]. Nonetheless, its use is limited since there is no single cut-off value that simultaneously yields the high sensitivity and specificity required for a screening test [<xref rid="B157" ref-type="bibr">157</xref>&#x02013;<xref rid="B159" ref-type="bibr">159</xref>]. In fact, there is a continuum of risk associated with PSA level and no PSA cut-off point can be clearly defined at which biopsy is recommended [<xref rid="B160" ref-type="bibr">160</xref>]. Furthermore, total PSA concentration cannot discriminate between potentially aggressive and indolent prostate cancers [<xref rid="B161" ref-type="bibr">161</xref>]. Due to its poor specificity, total PSA quantification is often associated with the risk of overdiagnosis [<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B162" ref-type="bibr">162</xref>] which leads to overtreatment and the associated side effects such as sexual dysfunction, urinary incontinence, bowel problems, together with increased healthcare costs [<xref rid="B163" ref-type="bibr">163</xref>].</p><p id="p-34">Other molecular forms of PSA and their ratios, namely free PSA and percent free PSA, proenzyme PSA (proPSA), its derivatives, and the prostate health index, as well as PSA derived-parameters and kinetics (PSA-density, PSA-velocity and PSA-doubling time), have been developed and tested, aiming to improve the specificity of the assays for the diagnosis of prostate cancer and for the differentiation between indolent and aggressive prostate cancers. Although these novel biomarkers have shown better clinical performance than total PSA quantification, allowing to reduce unnecessary biopsies while maintaining high specificity for prostate cancer [<xref rid="B164" ref-type="bibr">164</xref>&#x02013;<xref rid="B167" ref-type="bibr">167</xref>], they also present some technical and clinical limitations [<xref rid="B168" ref-type="bibr">168</xref>, <xref rid="B169" ref-type="bibr">169</xref>].</p><p id="p-35">The PSA glycosylation profile has been investigated in order to detect cancer-specific alterations that can be employed as efficient prostate cancer glycobiomarkers. Several differences in glycosylation have been found between PSA from normal and from tumour origins (<xref rid="fig1" ref-type="fig">Figure 1</xref>), namely in the outer ends of bi-antennary complex structures. PSA produced in cancer cells shows a higher fucose content (core fucose linked &#x003b1;1,6 to GlcNAc) and the oligosaccharides are neutral (do not contain sialic acid), in contrast to normal PSA glycans, which are sialylated. Fucose is also linked &#x003b1;1,2 to galactose, forming the H2 epitope, absent in PSA from normal cells. This is related with the expression of &#x003b1;1,2-fucosyltransferase in tumour cells. There is also an increase in GalNAc content in PSA from tumour cells (from 25% to 65%) [<xref rid="B58" ref-type="bibr">58</xref>]. Furthermore, a sialic acid-&#x003b1;2,3-galactose linkage was found as an additional terminal carbohydrate structure, which is detected by MAA [<xref rid="B60" ref-type="bibr">60</xref>]. The main glycosylation changes found in PSA from cancer origin and the advantages of detecting the aberrant glycoforms over the conventional detection of PSA protein concentration are presented in <xref rid="t3" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="t3"><label>Table 3</label><caption><p>Main glycosylation changes found in PSA from cancer origin and the advantages of the corresponding detection assays over the conventional PSA tests (representative examples published since 2007)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">
<bold>Alteration in glycosylation (<italic toggle="yes">versus</italic> normal PSA)</bold>
</th><th rowspan="1" colspan="1">
<bold>Assay</bold>
</th><th rowspan="1" colspan="1">
<bold>Reported main advantages over PSA conventional detection</bold>
</th><th rowspan="1" colspan="1">
<bold>Limitations</bold>
</th><th rowspan="1" colspan="1">
<bold>Reference</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Increased total fucosylation</td><td rowspan="1" colspan="1">Solid-phase permethylation and MALDI-MS</td><td rowspan="1" colspan="1">Pre-screening method to aid early PC detection</td><td rowspan="1" colspan="1">
<bold>-</bold>
</td><td rowspan="1" colspan="1">[<xref rid="B170" ref-type="bibr">170</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<p>Higher content of &#x003b1;2,3-linked sialic acid</p>
<p>Lower content of &#x003b1;2,6-linked sialic acid</p>
</td><td rowspan="1" colspan="1">Lectin immunosorbent assay, using SNA, MAA-I, and MAA-II</td><td rowspan="1" colspan="1">
<p>Low limits of detection (0.04&#x02013;1.35 ng/mL) and good reproducibility (%CVs &#x0003c; 10%)</p>
<p>Total SNA assay (AUC = 0.71) performed better than %fPSA (AUC = 0.54) in its diagnostic grey zone between 10% and 20%</p>
<p>Direct analysis of PSA glycosylation in sera</p>
<p>High-throughput assay</p>
<p>Sufficient limit of detection to analyze PSA sialylation in non-cancer sera with &#x0003c; 10 ng/mL of PSA</p>
</td><td rowspan="1" colspan="1">
<p>A larger sample size would be needed to validate the reported findings</p>
<p>The assay should be completed with the inclusion of immunosorbent assays using lectins that recognize other carbohydrate moieties (e.g., fucose)</p>
</td><td rowspan="1" colspan="1">[<xref rid="B171" ref-type="bibr">171</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased expression of &#x003b1;1,2-linked fucose and &#x003b2;-GalNAc residues</td><td rowspan="1" colspan="1">Lectin-affinity chromatography and ELISA, using TJA-II</td><td rowspan="1" colspan="1">TJA-II-bound PSA content and TJA-II binding ratios (%) could be used to discriminate between PC and BPH with more than a 95% probability</td><td rowspan="1" colspan="1">
<bold>-</bold>
</td><td rowspan="1" colspan="1">[<xref rid="B61" ref-type="bibr">61</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased fucosylation of fPSA</td><td rowspan="1" colspan="1">Enzyme-linked immunosorbent lectin assay, using UEA-I</td><td rowspan="1" colspan="1">
<p>92% Specific and 69% sensitive for PC over BPH; in comparison, fPSA measurement was 70% specific and 56% sensitive (threshold set to 25% tPSA) for PC over BPH (PSA in the range of 4&#x02013;10 ng/mL)</p>
<p>Methodology compatible with equipment available in the majority of biomedical laboratories</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B172" ref-type="bibr">172</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<p>Increased levels of core-fucosylated bi-antennary glycans and &#x003b1;2,3-linked sialic acids</p>
<p>Decreased tri-antennary tri-galactosylated glycans and tetra-antennary tetra-sialylated glycans with outer arm fucose</p>
</td><td rowspan="1" colspan="1">Serum <italic toggle="yes">N</italic>-glycome release followed by NP- and ccc with fluorescence detection</td><td rowspan="1" colspan="1">
<p>All chromatographic peaks significantly differentiated PC patients from BPH patients, with improved AUC values over PSA itself</p>
<p>The glycan level may work in a more general patient population than the free/total PSA ratio</p>
<p>Decreases in tri-antennary tri-galactosylated glycans and/or bisected core fucosylated biantennary monosialylated glycans and increases in tetra-antennary tetra-sialylated glycans correlated with tumour spread and patients&#x02019; survival</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B173" ref-type="bibr">173</xref>]</td></tr><tr><td rowspan="1" colspan="1">GalNAc&#x003b2;1&#x02212;4GlcNAc-linked PSA (LacdiNAc-PSA)</td><td rowspan="1" colspan="1">Immunoassay system with SPFS, using anti-PSA IgG antibody to capture PSA and WFA for the detection of LacdiNAc</td><td rowspan="1" colspan="1">
<p>Limit of quantification of 0.256 pg/mL tPSA, with a dynamic range of at least five digits and limit of detection of LacdiNAc-PSA of 20.0 pg/mL</p>
<p>AUC for LacdiNAc-PSA (0.851) was significantly greater than that for tPSA (0.559), and the optimum cut-off gave low false positivity (40.7%) and high sensitivity (88.4%), with specific distinction between PC and BPH within the PSA grey zone (4.0&#x02013;20.0 ng/mL PSA)</p>
<p>Comparing with recently reported PSA assays, LacdiNAc-PSA was significantly better than pro-PSA and fPSA</p>
<p>Reduced assay time and minimum consumption of reagents</p>
</td><td rowspan="1" colspan="1">
<p>A larger sample size would be needed to validate the reported findings</p>
<p>The detection could be further improved by reducing the influence of nonspecific reactions between fluorescently labelled WFA and serum proteins</p>
</td><td rowspan="1" colspan="1">[<xref rid="B174" ref-type="bibr">174</xref>]</td></tr><tr><td rowspan="1" colspan="1">&#x003b1;2,3-Linked sialylation as an additional terminal <italic toggle="yes">N</italic>-glycan on fPSA (S2,3PSA)</td><td rowspan="1" colspan="1">Magnetic microbead-based immunoassay, using anti-human fPSA monoclonal antibody (8A6) for capture and anti-&#x003b1;2,3-linked sialic acid monoclonal antibody (HYB4) for detection</td><td rowspan="1" colspan="1">AUC of 0.84, a sensitivity of 90.6%, and specificity of 64.2% for the diagnosis of PC with S2,3PSA (higher than those with PSA or %fPSA)</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B175" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased fucosylation of PSA</td><td rowspan="1" colspan="1">Lectin-affinity capturing of fucosylated glycoprotein (using AAL) and protein-antibody immunoreactivity</td><td rowspan="1" colspan="1">
<p>The fucosylated PSA achieved a better predictive power (AUC = 0.7056) when compared with tPSA (AUC = 0.6558)</p>
<p>Using the ratio of fucosylated PSA as a predictive marker, it achieved even better performance when compared with the total serum PSA, in discriminating aggressive from non-aggressive tumours</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B176" ref-type="bibr">176</xref>]</td></tr><tr><td rowspan="1" colspan="1">
<p>Decrease in core fucose</p>
<p>Increase in &#x003b1;2,3-sialic acid percentage of PSA</p>
</td><td rowspan="1" colspan="1">Free PSA immunopurification followed by enzyme-linked lectin assay with PhoSL (detection of core fucosylation) and SNA lectin-affinity chromatography (detection of PSA &#x003b1;2,3-linked sialic acid level)</td><td rowspan="1" colspan="1">
<p>A cut-off value of 0.86 of the PSA core fucose ratio could distinguish high-risk PC patients from BPH with 90% sensitivity and 95% specificity, with an AUC of 0.94</p>
<p>A cut-off value of 30% of the &#x003b1;2,3-sialic acid percentage of PSA discriminated between high-risk PC and the groups of BPH, low-, and intermediate-risk PC, with a sensitivity of 85.7% and specificity of 95.5%, and an AUC of 0.97 (better than using tPSA or %fPSA in the diagnostic grey zone)</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B177" ref-type="bibr">177</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased &#x003b1;2,3-linked sialyl <italic toggle="yes">N</italic>-glycan-carrying PSA ratio (%S2,3PSA)</td><td rowspan="1" colspan="1">Automated micro-total immunoassay system (&#x003bc;TAS system) using MAA</td><td rowspan="1" colspan="1">
<p>The limit of detection of S2,3PSA was 0.05 ng/mL with a %CV &#x0003c; 3.1%</p>
<p>The AUC for the detection of PC for the S2,3PSA ratio (%S2,3PSA) with a cut-off value of 43.85% (0.8340) was much superior than the total PSA (AUC = 0.5062)</p>
<p>The optimum cut-off point giving high specificity (72.0%) at 80% sensitivity was determined to be 42.20% of %S2,3PSA (significantly higher than that for conventional PSA testing)</p>
<p>Assay time &#x0003c; 10 min</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B178" ref-type="bibr">178</xref>]</td></tr><tr><td rowspan="1" colspan="1">Increased fucosylation of PSA</td><td rowspan="1" colspan="1">Lectin immunoassays using LCA and AAL followed by clinical PSA immunoassay</td><td rowspan="1" colspan="1">
<p>Fucosylated PSA-AAL had the best performance (AUC = 0.909), followed by total PSA (AUC = 0.881), fucosylated PSA-LCA (AUC = 0.839), %fucosylated PSA-AAL (AUC = 0.822), and %fucosylated PSA-LCA (AUC = 0.594)</p>
<p>Fucosylated PSA-AAL, %fucosylated PSA-AAL, and fucosylated PSA-LCA levels could be effective biomarkers to differentiate aggressive PC from non-aggressive disease</p>
<p>The combined use of fucosylated PSA and %fucosylated PSA could be used in place of tPSA with potentially improved performance in identifying aggressive disease</p>
</td><td rowspan="1" colspan="1">A larger sample size would be needed to validate the reported findings</td><td rowspan="1" colspan="1">[<xref rid="B179" ref-type="bibr">179</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>AUC: area under the curve; CV: coefficient of variation; %fPSA: percentage of free PSA; MALDI-MS: matrix-assisted laser desorption/ionization MS; NP: normal phase; PC: prostate cancer; SPFS: surface plasmon field-enhanced fluorescence spectrometry; tPSA: total PSA; WAX: weak anion exchange; IgG: immunoglobulin G; HPLC: high-performance liquid chromatography</p></fn></table-wrap-foot></table-wrap><p id="p-36">From <xref rid="t3" ref-type="table">Table 3</xref>, we can conclude that the detection of PSA glycoforms shows superior clinical performance and significant advantages over PSA tests, in terms of increased sensitivity and specificity, particularly when PSA concentration is in the diagnostic grey zone, being useful to distinguish between aggressive and indolent prostate cancers and to avoid unnecessary biopsies [<xref rid="B180" ref-type="bibr">180</xref>].</p></sec><sec id="t2-7"><title>Tg and its cancer-associated glycoforms</title><p id="p-37">Tg is a glycoprotein (with around 10% of its molecular weight comprised of carbohydrates) produced by thyroid cells, being the most abundant glycoprotein in the thyroid gland. Tg plays an essential role in the synthesis of thyroid hormones since it is the initial block to which iodine is incorporated to form triiodothyronine (T3) and thyroxine (T4) [<xref rid="B181" ref-type="bibr">181</xref>]. Tg is predominantly <italic toggle="yes">N</italic>-glycosylated (although it also shows <italic toggle="yes">O</italic>-glycosylation), containing 20 putative <italic toggle="yes">N</italic>-glycosylation sites [<xref rid="B182" ref-type="bibr">182</xref>]. The main types of glycans in human Tg are high-mannose and bi-antennary complex-type structures [<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>], and the majority of carbohydrate chains are sialylated [<xref rid="B185" ref-type="bibr">185</xref>]. <italic toggle="yes">O</italic>-glycans in Tg are still not fully identified [<xref rid="B186" ref-type="bibr">186</xref>]. The glycan components of Tg are important for the physiological functions of this glycoprotein, including Tg transport, hormone synthesis, and Tg antigenicity [<xref rid="B187" ref-type="bibr">187</xref>&#x02013;<xref rid="B189" ref-type="bibr">189</xref>]. For example, sialylation was found to significantly affect the immunoreactivity and solubility of Tg, being also important for the binding to its transmembrane transporter [<xref rid="B186" ref-type="bibr">186</xref>, <xref rid="B190" ref-type="bibr">190</xref>].</p><p id="p-38">Measurement of Tg serum concentration is the routine procedure in the follow-up of patients with thyroid carcinoma, since elevated levels of serum Tg after total thyroidectomy indicate residual or recurrent disease [<xref rid="B191" ref-type="bibr">191</xref>]. It can also be used for the diagnosis of several thyroid benign conditions [<xref rid="B186" ref-type="bibr">186</xref>]. Serum Tg quantification is performed by immunometric methods, which include immunoradiometric and immunochemiluminometric assays [<xref rid="B192" ref-type="bibr">192</xref>, <xref rid="B193" ref-type="bibr">193</xref>]. Although most recent methods are very sensitive, detecting Tg concentrations down to 0.1 ng/mL, they present several limitations [<xref rid="B194" ref-type="bibr">194</xref>]. First, as they are based on monoclonal anti-Tg antibodies, and assays from different providers use diverse antibodies that recognize different Tg epitopes, a significant variability in results is observed when diverse assays are used [<xref rid="B193" ref-type="bibr">193</xref>, <xref rid="B195" ref-type="bibr">195</xref>]. Therefore, it is recommended that serum Tg should be assessed in the same laboratory and using the same assay during the follow-up of an individual patient [<xref rid="B191" ref-type="bibr">191</xref>]. In addition, monoclonal anti-Tg antibodies are produced from normal thyroid tissue-derived Tg, which present epitopes that differ from the plasma-derived Tg produced by thyroid tumours, and this can result in false negatives in the presence of thyroid carcinoma [<xref rid="B196" ref-type="bibr">196</xref>]. A second major limitation relates with the fact that 25&#x02013;30% of patients with differentiated thyroid cancer have endogenous circulating anti-Tg antibodies (a three-fold greater prevalence than that found in the general population) [<xref rid="B193" ref-type="bibr">193</xref>], which can interfere with the assays, usually producing low or undetectable Tg levels, impairing the use of this biomarker for follow-up purposes. On the contrary, the presence of heterophile antibodies (such as human anti-mouse antibodies) may result in falsely high Tg levels [<xref rid="B186" ref-type="bibr">186</xref>]. Finally, total Tg serum concentration levels cannot differentiate between benign and malignant thyroid disease [<xref rid="B197" ref-type="bibr">197</xref>], therefore more specific biomarkers are needed for the diagnosis of thyroid cancer.</p><p id="p-39">In several chronic thyroid diseases, such as cancer and autoimmunity, alterations in Tg glycosylation have been observed [<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B198" ref-type="bibr">198</xref>]. In thyroid carcinogenesis, changes in sialylation and fucosylation, increased &#x003b2;1,6 branching of <italic toggle="yes">N</italic>-glycans, alterations in the content and structure of poly-LacNAc chains, and changes in <italic toggle="yes">O</italic>-GlcNAcylation have been reported (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B63" ref-type="bibr">63</xref>&#x02013;<xref rid="B66" ref-type="bibr">66</xref>]. Plasma <italic toggle="yes">N</italic>-glycomes from samples of thyroid cancer, benign thyroid nodules, and matched healthy controls were analyzed by MALDI time-of-flight MS (MALDI-TOF MS) and they were found to differ between the three groups in several aspects, namely complexity, galactosylation, fucosylation and sialylation [<xref rid="B199" ref-type="bibr">199</xref>]. Histochemical analysis of tissue specimens from human thyroid carcinomas showed increased sialylation (especially &#x003b1;2,3-linked sialic acid) on follicular epithelial cells [<xref rid="B65" ref-type="bibr">65</xref>]. Nonetheless, Tg displayed decreased sialylation in cancer transformation (<xref rid="fig1" ref-type="fig">Figure 1</xref>) [<xref rid="B67" ref-type="bibr">67</xref>]. Furthermore, differences in the lectin binding profile between normal Tg and Tg from thyroid carcinoma have been described. Tg from thyroid carcinoma showed a lower affinity for Con A and a higher affinity for WGA, in contrast with Tg from normal thyroid tissue [<xref rid="B200" ref-type="bibr">200</xref>]. Asialo-glycan chains with truncated structures were also found in malignant Tg, and carbohydrate chains of higher molecular mass, which have repeating Gal-GlcNAc disaccharides and peripheral &#x003b1;-fucosyl residues were present in metastatic papillary carcinoma [<xref rid="B68" ref-type="bibr">68</xref>]. In papillary thyroid carcinoma, phosphorylated high-mannose type and hybrid-type oligosaccharides each containing one phosphate group in a diester linkage were also found to be present instead of sialylated oligosaccharides [<xref rid="B69" ref-type="bibr">69</xref>].</p><p id="p-40">Additionally, Tg from patients with metastatic thyroid cancer showed increased binding to LCA, which has an affinity for mannose and glucose residues, allowing to discriminate between benign thyroid disease and thyroid cancer, with the LCA-binding Tg fraction being significantly lower in patients with thyroid cancer [<xref rid="B201" ref-type="bibr">201</xref>]. In the referred study, the immunocaptured Tg was incubated with LCA and both LCA-bound and unbound fractions were measured. The LCA-reactive Tg ratio (%) was calculated as [(total Tg concentration &#x02013; LCA-nonreactive Tg concentration)/total Tg concentration &#x000d7; 100]. For total Tg concentration &#x0003c; 50 ng/mL, the LCA-reactive Tg ratio could not distinguish between healthy volunteers, patients with benign tumours, and patients with thyroid carcinoma without metastasis but, for total Tg concentration &#x0003e; 200 ng/mL, the calculated parameter could discriminate between benign thyroid tumours and thyroid carcinoma without metastasis or with lymph node metastasis. For total Tg concentrations between 51 ng/mL and 200 ng/mL, the LCA-reactive Tg ratio did not differ between patients with benign tumours and those with thyroid carcinoma without metastasis, but significant differences in it were observed between patients with thyroid carcinoma with lymph node metastasis and those with benign thyroid tumour or thyroid carcinoma without metastasis. Therefore, the LCA-reactive Tg ratio showed to be a valuable marker for distinguishing between thyroid carcinoma and benign thyroid tumours. The same method was applied to another set of samples, and the results confirmed that it could be used as a screening method for primary thyroid carcinoma [<xref rid="B62" ref-type="bibr">62</xref>]. For an LCA-reactive Tg ratio cut-off of 81.8%, with patients below this level defined as positive, the rate of positivity was 11.3% in the benign group and 61.4% in the malignant group. Total Tg serum concentration measured in the same samples did not significantly differ between benign and malignant groups, which demonstrates the enhanced performance of the LCA-reactive Tg ratio over the total Tg concentration as a sensitive and specific biomarker for thyroid cancer.</p></sec></sec><sec id="s3"><title>Conclusions</title><p id="p-41">The majority of approved and clinically-used biomarkers for cancer diagnosis and monitoring are serum glycoproteins that are produced and secreted by tumours. Nevertheless, the corresponding analytical assays quantify total protein concentrations, regardless of the glycans that the proteins may carry. In many disease situations, there is no clear distinction between benign and malignant status in what concerns protein concentrations, and, therefore, the assays based on the quantification of total protein concentration show insufficient sensitivity and specificity for cancer screening and early diagnosis.</p><p id="p-42">As research progresses, cancer-associated glycosylation has been reported and fully characterized for many currently-used cancer biomarkers. Being a hallmark of cancer, aberrant glycosylation enables to differentiate between normal and cancer-related glycoproteins and should be exploited in order to develop more specific and accurate biomarker assays. The examples reported in this review visibly demonstrate the value of glycomic analysis for improved cancer detection and monitoring. Whenever the analytical assay combines quantification of glycoprotein serum concentration and glycoform analysis, the clinical performance significantly improves, achieving higher sensitivity and specificity percentages in discriminating benign from malignant diseases and even in differentiating malignant disease stages. This enhanced performance may further expand the use of a glycobiomarker for other clinical applications, such as screening and early diagnosis, for which it cannot be used if only the total protein concentration is measured. Moreover, the detection of multiple glycobiomarkers could achieve an even higher degree of sensitivity and specificity, as already demonstrated in several studies [<xref rid="B202" ref-type="bibr">202</xref>&#x02013;<xref rid="B204" ref-type="bibr">204</xref>].</p><p id="p-43">The discovery of novel cancer serum glycobiomarkers is an ongoing task, with numerous studies reporting the identification of aberrant glycoforms of glycoproteins and their potential use as clinical markers [<xref rid="B205" ref-type="bibr">205</xref>&#x02013;<xref rid="B207" ref-type="bibr">207</xref>]. From all serum glycoproteins recently reported as potential cancer serum markers, haptoglobin seems to be a promising glycobiomarker, in which the strategy of combined protein quantification and glycan characterization could be employed. On one hand, increased levels of serum haptoglobin are typical of diverse solid tumours, being considered a prognostic marker [<xref rid="B208" ref-type="bibr">208</xref>]. On the other hand, it presents aberrant glycoforms associated with gastric [<xref rid="B209" ref-type="bibr">209</xref>], pancreatic [<xref rid="B210" ref-type="bibr">210</xref>], colon [<xref rid="B211" ref-type="bibr">211</xref>], HCC [<xref rid="B212" ref-type="bibr">212</xref>], and lung [<xref rid="B213" ref-type="bibr">213</xref>] cancers, which could give additional specificity and improved analytical performance to the analytical assays. Further studies are needed in order to assess this possibility.</p><p id="p-44">So far, a two-step assay appears to be the method of choice for rapid and decentralized analytical tests, where the glycobiomarker is first captured by a monoclonal anti-protein antibody, providing the required specificity and allowing quantification, followed by lectin-based fractionation of the captured glycoprotein, for glycoform characterization. The first immunocapture step allows to minimize the problem of relevant cancer biomarkers being present in minute amounts in serum, masked by high-abundant proteins and glycoproteins. In the second step, lectin-based analysis of glycoforms is preferred to antibody-based analysis due to the low antigenicity of glycans. Nonetheless, some drawbacks persist, demanding further technological development. Namely, standardization of detection for uniformized clinical implementation has to be improved, together with efforts to increase automation and miniaturization of the assays.</p><p id="p-45">Maturation of more sophisticated analytical techniques like MS and related methods, and their wider application in clinical analysis have enabled to perform a comprehensive characterization of cancer-associated glycans carried by glycoproteins, providing site information [<xref rid="B214" ref-type="bibr">214</xref>&#x02013;<xref rid="B220" ref-type="bibr">220</xref>]. However, MS-based techniques are not yet the methods of choice for rapid and decentralized glycobiomarker quantification/characterization assays, due to the inherent instrumental and bioinformatics requirements, and high costs.</p></sec></body><back><glossary><title>Abbreviation</title><def-list><def-item><term>%fPSA</term><def><p>percentage of free prostate-specific antigen</p></def></def-item><def-item><term>AAL</term><def><p>
<italic toggle="yes">Aleuria aurantia</italic> lectin</p></def></def-item><def-item><term>AFP</term><def><p>&#x003b1;-fetoprotein</p></def></def-item><def-item><term>AFP-L3%</term><def><p>&#x003b1;-fetoprotein-L3 percentage of the total &#x003b1;-fetoprotein</p></def></def-item><def-item><term>AUC</term><def><p>area under the curve</p></def></def-item><def-item><term>BPH</term><def><p>benign prostatic hyperplasia</p></def></def-item><def-item><term>CA19-9</term><def><p>cancer antigen 19-9</p></def></def-item><def-item><term>CEA</term><def><p>carcinoembryonic antigen</p></def></def-item><def-item><term>Con A</term><def><p>concanavalin A</p></def></def-item><def-item><term>CRC</term><def><p>colorectal cancer</p></def></def-item><def-item><term>CV</term><def><p>coefficient of variation</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>GalNAc</term><def><p>
<italic toggle="yes">N</italic>-acetylgalactosamine</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>LacdiNAc</term><def><p>
<italic toggle="yes">N</italic>-acetylgalactosamine &#x003b2;1,4-GlcNAc</p></def></def-item><def-item><term>LacNAc</term><def><p>
<italic toggle="yes">N</italic>-acetyllactosamine</p></def></def-item><def-item><term>LCA</term><def><p>
<italic toggle="yes">Lens culinaris</italic> agglutinin</p></def></def-item><def-item><term>Le<sup>x</sup></term><def><p>Lewis x antigen</p></def></def-item><def-item><term>LiBA</term><def><p>liquid-phase binding assay</p></def></def-item><def-item><term>LLOQ</term><def><p>lower limit of quantification</p></def></def-item><def-item><term>MAA</term><def><p>
<italic toggle="yes">Maackia amurensis</italic> agglutinin</p></def></def-item><def-item><term>MS</term><def><p>mass spectrometry</p></def></def-item><def-item><term>MUC1</term><def><p>mucin 1</p></def></def-item><def-item><term>PSA</term><def><p>prostate-specific antigen</p></def></def-item><def-item><term>SLe<sup>a</sup></term><def><p>sialyl Lewis a antigen</p></def></def-item><def-item><term>SNA</term><def><p>
<italic toggle="yes">Sambucus nigra</italic> agglutinin</p></def></def-item><def-item><term>ST antigen</term><def><p>sialyl-Thomsen-Friedenreich antigen</p></def></def-item><def-item><term>STn antigen</term><def><p>sialyl-Thomsen nouveau antigen</p></def></def-item><def-item><term>T antigen</term><def><p>Thomsen-Friedenreich antigen</p></def></def-item><def-item><term>Tg</term><def><p>thyroglobulin</p></def></def-item><def-item><term>TJA</term><def><p>
<italic toggle="yes">Trichosanthes japonica</italic> agglutinin</p></def></def-item><def-item><term>Tn antigen</term><def><p>Thomsen nouveau antigen</p></def></def-item><def-item><term>UEA</term><def><p>
<italic toggle="yes">Ulex europaeus</italic> agglutinin</p></def></def-item><def-item><term>WFA</term><def><p>
<italic toggle="yes">Wisteria floribunda</italic> agglutinin</p></def></def-item><def-item><term>&#x003bc;TAS</term><def><p>micro-total assay system</p></def></def-item></def-list></glossary><sec id="s4"><title>Declarations</title><sec><title>Author contributions</title><p>MLSS: Conceptualization, Investigation, Data curation, Writing&#x02014;original draft, Writing&#x02014;review and editing, Formal analysis.</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>The author declares that she has no conflicts of interest.</p></sec><sec><title>Ethical approval</title><p>Not applicable.</p></sec><sec><title>Consent to participate</title><p>Not applicable.</p></sec><sec><title>Consent to publication</title><p>Not applicable.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>Not applicable.</p></sec><sec><title>Funding</title><p>Not applicable.</p></sec><sec><title>Copyright</title><p>&#x000a9; The Author(s) 2023.</p></sec></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reily</surname><given-names>C</given-names></name>
<name><surname>Stewart</surname><given-names>TJ</given-names></name>
<name><surname>Renfrow</surname><given-names>MB</given-names></name>
<name><surname>Novak</surname><given-names>J</given-names></name>
</person-group><article-title>Glycosylation in health and disease</article-title><source>Nat Rev Nephrol</source><year iso-8601-date="2019">2019</year><volume>15</volume><fpage>346</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41581-019-0129-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC6590709</pub-id>--><?supplied-pmid 30858582?><pub-id pub-id-type="pmid">30858582</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varki</surname><given-names>A</given-names></name>
</person-group><article-title>Biological roles of glycans</article-title><source>Glycobiology</source><year iso-8601-date="2017">2017</year><volume>27</volume><fpage>3</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/glycob/cww086</pub-id><!--<pub-id pub-id-type="pmcid">PMC5884436</pub-id>--><?supplied-pmid 27558841?><pub-id pub-id-type="pmid">27558841</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schjoldager</surname><given-names>KT</given-names></name>
<name><surname>Narimatsu</surname><given-names>Y</given-names></name>
<name><surname>Joshi</surname><given-names>HJ</given-names></name>
<name><surname>Clausen</surname><given-names>H</given-names></name>
</person-group><article-title>Global view of human protein glycosylation pathways and functions</article-title><source>Nat Rev Mol Cell Biol</source><year iso-8601-date="2020">2020</year><volume>21</volume><fpage>729</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-00294-x</pub-id><?supplied-pmid 33087899?><pub-id pub-id-type="pmid">33087899</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharon</surname><given-names>N</given-names></name>
<name><surname>Lis</surname><given-names>H</given-names></name>
</person-group><article-title>Glycoproteins: research booming on long-ignored ubiquitous compounds</article-title><source>Mol Cell Biochem</source><year iso-8601-date="1982">1982</year><volume>42</volume><fpage>167</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1007/BF00238511</pub-id><?supplied-pmid 7062912?><pub-id pub-id-type="pmid">7062912</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lis</surname><given-names>H</given-names></name>
<name><surname>Sharon</surname><given-names>N</given-names></name>
</person-group><article-title>Protein glycosylation. Structural and functional aspects</article-title><source>Eur J Biochem</source><year iso-8601-date="1993">1993</year><volume>218</volume><fpage>1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1993.tb18347.x</pub-id><?supplied-pmid 8243456?><pub-id pub-id-type="pmid">8243456</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobata</surname><given-names>A</given-names></name>
</person-group><article-title>Structures and functions of the sugar chains of glycoproteins</article-title><source>Eur J Biochem</source><year iso-8601-date="1992">1992</year><volume>209</volume><fpage>483</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1992.tb17313.x</pub-id><?supplied-pmid 1358608?><pub-id pub-id-type="pmid">1358608</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Benallal</surname><given-names>M</given-names></name>
<name><surname>Anner</surname><given-names>BM</given-names></name>
</person-group><article-title>Identification of organ-specific glycosylation of a membrane protein in two tissues using lectins</article-title><source>Experientia</source><year iso-8601-date="1994">1994</year><volume>50</volume><fpage>664</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/BF01952869</pub-id><?supplied-pmid 8033974?><pub-id pub-id-type="pmid">8033974</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lebrilla</surname><given-names>CB</given-names></name>
<name><surname>An</surname><given-names>HJ</given-names></name>
</person-group><article-title>The prospects of glycan biomarkers for the diagnosis of diseases</article-title><source>Mol Biosyst</source><year iso-8601-date="2009">2009</year><volume>5</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1039/b811781k</pub-id><?supplied-pmid 19081926?><pub-id pub-id-type="pmid">19081926</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haukedal</surname><given-names>H</given-names></name>
<name><surname>Freude</surname><given-names>KK</given-names></name>
</person-group><article-title>Implications of glycosylation in Alzheimer&#x02019;s disease</article-title><source>Front Neurosci</source><year iso-8601-date="2021">2021</year><volume>14</volume><elocation-id>625348</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2020.625348</pub-id><!--<pub-id pub-id-type="pmcid">PMC7838500</pub-id>--><?supplied-pmid 33519371?><pub-id pub-id-type="pmid">33519371</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Memarian</surname><given-names>E</given-names></name>
<name><surname>&#x02019;t</surname><given-names>Hart LM</given-names></name>
<name><surname>Slieker</surname><given-names>RC</given-names></name>
<name><surname>Lemmers</surname><given-names>RFL</given-names></name>
<name><surname>van der Heijden</surname><given-names>AA</given-names></name>
<name><surname>Rutters</surname><given-names>F</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Plasma protein <italic toggle="yes">N</italic>-glycosylation is associated with cardiovascular disease, nephropathy, and retinopathy in type 2 diabetes</article-title><source>BMJ Open Diabetes Res Care</source><year iso-8601-date="2021">2021</year><volume>9</volume><elocation-id>e002345</elocation-id><pub-id pub-id-type="doi">10.1136/bmjdrc-2021-002345</pub-id><!--<pub-id pub-id-type="pmcid">PMC8515459</pub-id>--><?supplied-pmid 34645615?><pub-id pub-id-type="pmid">34645615</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vang</surname><given-names>S</given-names></name>
<name><surname>Cochran</surname><given-names>P</given-names></name>
<name><surname>Sebastian</surname><given-names>Domingo J</given-names></name>
<name><surname>Krick</surname><given-names>S</given-names></name>
<name><surname>Barnes</surname><given-names>JW</given-names></name>
</person-group><article-title>The glycobiology of pulmonary arterial hypertension</article-title><source>Metabolites</source><year iso-8601-date="2022">2022</year><volume>12</volume><elocation-id>316</elocation-id><pub-id pub-id-type="doi">10.3390/metabo12040316</pub-id><!--<pub-id pub-id-type="pmcid">PMC9026683</pub-id>--><?supplied-pmid 35448503?><pub-id pub-id-type="pmid">35448503</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>D</given-names></name>
<name><surname>Han</surname><given-names>Q</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Alteration of glycosylation in serum proteins: a new potential indicator to distinguish non-diabetic renal diseases from diabetic nephropathy</article-title><source>RSC Adv</source><year iso-8601-date="2018">2018</year><volume>8</volume><fpage>38872</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1039/c8ra06832a</pub-id><!--<pub-id pub-id-type="pmcid">PMC9090655</pub-id>--><?supplied-pmid 35558281?><pub-id pub-id-type="pmid">35558281</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Blomme</surname><given-names>B</given-names></name>
<name><surname>Van</surname><given-names>Steenkiste C</given-names></name>
<name><surname>Callewaert</surname><given-names>N</given-names></name>
<name><surname>Van</surname><given-names>Vlierberghe H</given-names></name>
</person-group><article-title>Alteration of protein glycosylation in liver diseases</article-title><source>J Hepatol</source><year iso-8601-date="2009">2009</year><volume>50</volume><fpage>592</fpage><lpage>603</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2008.12.010</pub-id><?supplied-pmid 19157620?><pub-id pub-id-type="pmid">19157620</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghazarian</surname><given-names>H</given-names></name>
<name><surname>Idoni</surname><given-names>B</given-names></name>
<name><surname>Oppenheimer</surname><given-names>SB</given-names></name>
</person-group><article-title>A glycobiology review: carbohydrates, lectins and implications in cancer therapeutics</article-title><source>Acta Histochem</source><year iso-8601-date="2011">2011</year><volume>113</volume><fpage>236</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.acthis.2010.02.004</pub-id><!--<pub-id pub-id-type="pmcid">PMC3027850</pub-id>--><?supplied-pmid 20199800?><pub-id pub-id-type="pmid">20199800</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pinho</surname><given-names>SS</given-names></name>
<name><surname>Reis</surname><given-names>CA</given-names></name>
</person-group><article-title>Glycosylation in cancer: mechanisms and clinical implications</article-title><source>Nat Rev Cancer</source><year iso-8601-date="2015">2015</year><volume>15</volume><fpage>540</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1038/nrc3982</pub-id><?supplied-pmid 26289314?><pub-id pub-id-type="pmid">26289314</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moreno-Villanueva</surname><given-names>M</given-names></name>
<name><surname>Morath</surname><given-names>J</given-names></name>
<name><surname>Vanhooren</surname><given-names>V</given-names></name>
<name><surname>Elbert</surname><given-names>T</given-names></name>
<name><surname>Kolassa</surname><given-names>S</given-names></name>
<name><surname>Libert</surname><given-names>C</given-names></name>
<etal>et al.</etal>
</person-group><article-title>
<italic toggle="yes">N</italic>-glycosylation profiling of plasma provides evidence for accelerated physiological aging in post-traumatic stress disorder</article-title><source>Transl Psychiatry</source><year iso-8601-date="2013">2013</year><volume>3</volume><elocation-id>e320</elocation-id><pub-id pub-id-type="doi">10.1038/tp.2013.93</pub-id><!--<pub-id pub-id-type="pmcid">PMC3818009</pub-id>--><?supplied-pmid 24169639?><pub-id pub-id-type="pmid">24169639</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dube</surname><given-names>DH</given-names></name>
<name><surname>Bertozzi</surname><given-names>CR</given-names></name>
</person-group><article-title>Glycans in cancer and inflammation &#x02014; potential for therapeutics and diagnostics</article-title><source>Nat Rev Drug Discov</source><year iso-8601-date="2005">2005</year><volume>4</volume><fpage>477</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/nrd1751</pub-id><?supplied-pmid 15931257?><pub-id pub-id-type="pmid">15931257</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>Pendu J</given-names></name>
<name><surname>Marionneau</surname><given-names>S</given-names></name>
<name><surname>Cailleau-Thomas</surname><given-names>A</given-names></name>
<name><surname>Rocher</surname><given-names>J</given-names></name>
<name><surname>Le</surname><given-names>Moullac-Vaidye B</given-names></name>
<name><surname>Cl&#x000e9;ment</surname><given-names>M</given-names></name>
</person-group><article-title>ABH and Lewis histo-blood group antigens in cancer</article-title><source>APMIS</source><year iso-8601-date="2001">2001</year><volume>109</volume><fpage>9</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0463.2001.tb00011.x</pub-id><?supplied-pmid 11297197?><pub-id pub-id-type="pmid">11297197</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brooks</surname><given-names>SA</given-names></name>
<name><surname>Carter</surname><given-names>TM</given-names></name>
<name><surname>Royle</surname><given-names>L</given-names></name>
<name><surname>Harvey</surname><given-names>DJ</given-names></name>
<name><surname>Fry</surname><given-names>SA</given-names></name>
<name><surname>Kinch</surname><given-names>C</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Altered glycosylation of proteins in cancer: what is the potential for new anti-tumour strategies</article-title><source>Anticancer Agents Med Chem</source><year iso-8601-date="2008">2008</year><volume>8</volume><fpage>2</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.2174/187152008783330860</pub-id><?supplied-pmid 18220502?><pub-id pub-id-type="pmid">18220502</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>YJ</given-names></name>
<name><surname>Varki</surname><given-names>A</given-names></name>
</person-group><article-title>Perspectives on the significance of altered glycosylation of glycoproteins in cancer</article-title><source>Glycoconj J</source><year iso-8601-date="1997">1997</year><volume>14</volume><fpage>569</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1023/a:1018580324971</pub-id><?supplied-pmid 9298689?><pub-id pub-id-type="pmid">9298689</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stowell</surname><given-names>SR</given-names></name>
<name><surname>Ju</surname><given-names>T</given-names></name>
<name><surname>Cummings</surname><given-names>RD</given-names></name>
</person-group><article-title>Protein glycosylation in cancer</article-title><source>Annu Rev Pathol</source><year iso-8601-date="2015">2015</year><volume>10</volume><fpage>473</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-012414-040438</pub-id><!--<pub-id pub-id-type="pmcid">PMC4396820</pub-id>--><?supplied-pmid 25621663?><pub-id pub-id-type="pmid">25621663</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peixoto</surname><given-names>A</given-names></name>
<name><surname>Relvas-Santos</surname><given-names>M</given-names></name>
<name><surname>Azevedo</surname><given-names>R</given-names></name>
<name><surname>Santos</surname><given-names>LL</given-names></name>
<name><surname>Ferreira</surname><given-names>JA</given-names></name>
</person-group><article-title>Protein glycosylation and tumor microenvironment alterations driving cancer Hallmarks</article-title><source>Front Oncol</source><year iso-8601-date="2019">2019</year><volume>9</volume><elocation-id>380</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2019.00380</pub-id><!--<pub-id pub-id-type="pmcid">PMC6530332</pub-id>--><?supplied-pmid 31157165?><pub-id pub-id-type="pmid">31157165</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>F&#x000fc;z&#x000e9;ry</surname><given-names>AK</given-names></name>
<name><surname>Levin</surname><given-names>J</given-names></name>
<name><surname>Chan</surname><given-names>MM</given-names></name>
<name><surname>Chan</surname><given-names>DW</given-names></name>
</person-group><article-title>Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges</article-title><source>Clin Proteomics</source><year iso-8601-date="2013">2013</year><volume>10</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/1559-0275-10-13</pub-id><!--<pub-id pub-id-type="pmcid">PMC3850675</pub-id>--><?supplied-pmid 24088261?><pub-id pub-id-type="pmid">24088261</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gutman</surname><given-names>S</given-names></name>
<name><surname>Kessler</surname><given-names>LG</given-names></name>
</person-group><article-title>The US Food and Drug Administration perspective on cancer biomarker development</article-title><source>Nat Rev Cancer</source><year iso-8601-date="2006">2006</year><volume>6</volume><fpage>565</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1038/nrc1911</pub-id><?supplied-pmid 16794639?><pub-id pub-id-type="pmid">16794639</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kirwan</surname><given-names>A</given-names></name>
<name><surname>Utratna</surname><given-names>M</given-names></name>
<name><surname>O&#x02019;Dwyer</surname><given-names>ME</given-names></name>
<name><surname>Joshi</surname><given-names>L</given-names></name>
<name><surname>Kilcoyne</surname><given-names>M</given-names></name>
</person-group><article-title>Glycosylation-based serum biomarkers for cancer diagnostics and prognostics</article-title><source>Biomed Res Int</source><year iso-8601-date="2015">2015</year><volume>2015</volume><elocation-id>490531</elocation-id><pub-id pub-id-type="doi">10.1155/2015/490531</pub-id><!--<pub-id pub-id-type="pmcid">PMC4609776</pub-id>--><?supplied-pmid 26509158?><pub-id pub-id-type="pmid">26509158</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Mallory</surname><given-names>T</given-names></name>
<name><surname>Satomura</surname><given-names>S</given-names></name>
</person-group><article-title>AFP-L3: a new generation of tumor marker for hepatocellular carcinoma</article-title><source>Clin Chim Acta</source><year iso-8601-date="2001">2001</year><volume>313</volume><fpage>15</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0009-8981(01)00644-1</pub-id><?supplied-pmid 11694234?><pub-id pub-id-type="pmid">11694234</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leerapun</surname><given-names>A</given-names></name>
<name><surname>Suravarapu</surname><given-names>SV</given-names></name>
<name><surname>Bida</surname><given-names>JP</given-names></name>
<name><surname>Clark</surname><given-names>RJ</given-names></name>
<name><surname>Sanders</surname><given-names>EL</given-names></name>
<name><surname>Mettler</surname><given-names>TA</given-names></name>
<etal>et al.</etal>
</person-group><article-title>The utility of Lens culinaris agglutinin-reactive &#x003b1;-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population</article-title><source>Clin Gastroenterol Hepatol</source><year iso-8601-date="2007">2007</year><volume>5</volume><fpage>394</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2006.12.005</pub-id><!--<pub-id pub-id-type="pmcid">PMC1931510</pub-id>--><?supplied-pmid 17368240?><pub-id pub-id-type="pmid">17368240</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y</given-names></name>
<name><surname>Nakata</surname><given-names>K</given-names></name>
<name><surname>Kato</surname><given-names>Y</given-names></name>
<name><surname>Shima</surname><given-names>M</given-names></name>
<name><surname>Ishii</surname><given-names>N</given-names></name>
<name><surname>Koji</surname><given-names>T</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein</article-title><source>N Engl J Med</source><year iso-8601-date="1993">1993</year><volume>328</volume><fpage>1802</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1056/NEJM199306243282502</pub-id><?supplied-pmid 7684823?><pub-id pub-id-type="pmid">7684823</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miyoshi</surname><given-names>E</given-names></name>
<name><surname>Moriwaki</surname><given-names>K</given-names></name>
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
</person-group><article-title>Biological function of fucosylation in cancer biology</article-title><source>J Biochem</source><year iso-8601-date="2008">2008</year><volume>143</volume><fpage>725</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/jb/mvn011</pub-id><?supplied-pmid 18218651?><pub-id pub-id-type="pmid">18218651</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Okuda</surname><given-names>K</given-names></name>
<name><surname>Tanaka</surname><given-names>M</given-names></name>
<name><surname>Kanazawa</surname><given-names>N</given-names></name>
<name><surname>Nagashima</surname><given-names>J</given-names></name>
<name><surname>Satomura</surname><given-names>S</given-names></name>
<name><surname>Kinoshita</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Evaluation of curability and prediction of prognosis after surgical treatment for hepatocellular carcinoma by lens culinaris agglutinin-reactive alpha-fetoprotein</article-title><source>Int J Oncol</source><year iso-8601-date="1999">1999</year><volume>14</volume><fpage>265</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.3892/ijo.14.2.265</pub-id><?supplied-pmid 9917501?><pub-id pub-id-type="pmid">9917501</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hayashi</surname><given-names>K</given-names></name>
<name><surname>Kumada</surname><given-names>T</given-names></name>
<name><surname>Nakano</surname><given-names>S</given-names></name>
<name><surname>Takeda</surname><given-names>I</given-names></name>
<name><surname>Sugiyama</surname><given-names>K</given-names></name>
<name><surname>Kiriyama</surname><given-names>S</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Usefulness of measurement of <italic toggle="yes">Lens culinaris</italic> agglutinin-reactive fraction of &#x003b1;-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma</article-title><source>Am J Gastroenterol</source><year iso-8601-date="1999">1999</year><volume>94</volume><fpage>3028</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.1999.01378.x</pub-id><?supplied-pmid 10520864?><pub-id pub-id-type="pmid">10520864</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>M</given-names></name>
<name><surname>Hosaka</surname><given-names>T</given-names></name>
<name><surname>Ikeda</surname><given-names>K</given-names></name>
<name><surname>Seko</surname><given-names>Y</given-names></name>
<name><surname>Kawamura</surname><given-names>Y</given-names></name>
<name><surname>Sezaki</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively</article-title><source>Hepatol Res</source><year iso-8601-date="2011">2011</year><volume>41</volume><fpage>1036</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1872-034X.2011.00858.x</pub-id><?supplied-pmid 21883741?><pub-id pub-id-type="pmid">21883741</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsuda</surname><given-names>M</given-names></name>
<name><surname>Asakawa</surname><given-names>M</given-names></name>
<name><surname>Amemiya</surname><given-names>H</given-names></name>
<name><surname>Fujii</surname><given-names>H</given-names></name>
</person-group><article-title>Lens culinaris agglutinin-reactive fraction of AFP is a useful prognostic biomarker for survival after repeat hepatic resection for HCC</article-title><source>J Gastroenterol Hepatol</source><year iso-8601-date="2011">2011</year><volume>26</volume><fpage>731</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2010.06532.x</pub-id><?supplied-pmid 21155886?><pub-id pub-id-type="pmid">21155886</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>JM</given-names></name>
<name><surname>Wang</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>KH</given-names></name>
</person-group><article-title>AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis</article-title><source>Medicine (Baltimore)</source><year iso-8601-date="2021">2021</year><volume>100</volume><elocation-id>e27673</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000027673</pub-id><!--<pub-id pub-id-type="pmcid">PMC8556013</pub-id>--><?supplied-pmid 34713864?><pub-id pub-id-type="pmid">34713864</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Choi</surname><given-names>JW</given-names></name>
<name><surname>Moon</surname><given-names>BI</given-names></name>
<name><surname>Lee</surname><given-names>JW</given-names></name>
<name><surname>Kim</surname><given-names>HJ</given-names></name>
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Kim</surname><given-names>HJ</given-names></name>
</person-group><article-title>Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera</article-title><source>Oncol Rep</source><year iso-8601-date="2018">2018</year><volume>40</volume><fpage>145</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.3892/or.2018.6433</pub-id><!--<pub-id pub-id-type="pmcid">PMC6059737</pub-id>--><?supplied-pmid 29749490?><pub-id pub-id-type="pmid">29749490</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumpulainen</surname><given-names>EJ</given-names></name>
<name><surname>Keskikuru</surname><given-names>RJ</given-names></name>
<name><surname>Johansson</surname><given-names>RT</given-names></name>
</person-group><article-title>Serum tumor marker CA 15.3 and stage are the two most powerful predictors of survival in primary breast cancer</article-title><source>Breast Cancer Res Treat</source><year iso-8601-date="2002">2002</year><volume>76</volume><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1023/a:1020514925143</pub-id><?supplied-pmid 12452445?><pub-id pub-id-type="pmid">12452445</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ebeling</surname><given-names>FG</given-names></name>
<name><surname>Stieber</surname><given-names>P</given-names></name>
<name><surname>Untch</surname><given-names>M</given-names></name>
<name><surname>Nagel</surname><given-names>D</given-names></name>
<name><surname>Konecny</surname><given-names>GE</given-names></name>
<name><surname>Schmitt</surname><given-names>UM</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Serum CEA and CA 15-3 as prognostic factors in primary breast cancer</article-title><source>Br J Cancer</source><year iso-8601-date="2002">2002</year><volume>86</volume><fpage>1217</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600248</pub-id><!--<pub-id pub-id-type="pmcid">PMC2375330</pub-id>--><?supplied-pmid 11953875?><pub-id pub-id-type="pmid">11953875</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serdarevic</surname><given-names>N</given-names></name>
</person-group><article-title>The comparison between different immunoassays for serum carbohydrate antigen (CA 19-9) concentration measurement</article-title><source>Acta Inform Med</source><year iso-8601-date="2018">2018</year><volume>26</volume><fpage>235</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.5455/aim.2018.26.235-239</pub-id><!--<pub-id pub-id-type="pmcid">PMC6311231</pub-id>--><?supplied-pmid 30692705?><pub-id pub-id-type="pmid">30692705</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>Q</given-names></name>
<name><surname>Yang</surname><given-names>XH</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Jing</surname><given-names>W</given-names></name>
<name><surname>Zheng</surname><given-names>LQ</given-names></name>
<name><surname>Liu</surname><given-names>YP</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study</article-title><source>World J Surg Oncol</source><year iso-8601-date="2014">2014</year><volume>12</volume><elocation-id>171</elocation-id><pub-id pub-id-type="doi">10.1186/1477-7819-12-171</pub-id><!--<pub-id pub-id-type="pmcid">PMC4064278</pub-id>--><?supplied-pmid 24890327?><pub-id pub-id-type="pmid">24890327</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Locker</surname><given-names>GY</given-names></name>
<name><surname>Hamilton</surname><given-names>S</given-names></name>
<name><surname>Harris</surname><given-names>J</given-names></name>
<name><surname>Jessup</surname><given-names>JM</given-names></name>
<name><surname>Kemeny</surname><given-names>N</given-names></name>
<name><surname>Macdonald</surname><given-names>JS</given-names></name>
<etal>et al.</etal>
<collab>ASCO</collab>
</person-group><article-title>ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer</article-title><source>J Clin Oncol</source><year iso-8601-date="2006">2006</year><volume>24</volume><fpage>5313</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.2644</pub-id><?supplied-pmid 17060676?><pub-id pub-id-type="pmid">17060676</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Scar&#x000e0;</surname><given-names>S</given-names></name>
<name><surname>Bottoni</surname><given-names>P</given-names></name>
<name><surname>Scatena</surname><given-names>R</given-names></name>
</person-group><article-title>CA 19-9: biochemical and clinical aspects</article-title><person-group person-group-type="editor">
<name><surname>Scatena</surname><given-names>R</given-names></name>
</person-group><source>Advances in Cancer Biomarkers</source><publisher-loc>Advances in Experimental Medicine and Biology. Dordrecht</publisher-loc><publisher-name>Springer Netherlands</publisher-name><year iso-8601-date="2015">2015</year><comment>pp. 247&#x02013;60.</comment><pub-id pub-id-type="doi">10.1007/978-94-017-7215-0_15</pub-id><?supplied-pmid 26530370?></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haglund</surname><given-names>C</given-names></name>
<name><surname>Roberts</surname><given-names>PJ</given-names></name>
<name><surname>Kuusela</surname><given-names>P</given-names></name>
<name><surname>Scheinin</surname><given-names>TM</given-names></name>
<name><surname>M&#x000e4;kel&#x000e4;</surname><given-names>O</given-names></name>
<name><surname>Jalanko</surname><given-names>H</given-names></name>
</person-group><article-title>Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer</article-title><source>Br J Cancer</source><year iso-8601-date="1986">1986</year><volume>53</volume><fpage>197</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1038/bjc.1986.35</pub-id><!--<pub-id pub-id-type="pmcid">PMC2001324</pub-id>--><?supplied-pmid 3456787?><pub-id pub-id-type="pmid">3456787</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goonetilleke</surname><given-names>KS</given-names></name>
<name><surname>Siriwardena</surname><given-names>AK</given-names></name>
</person-group><article-title>Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer</article-title><source>Eur J Surg Oncol</source><year iso-8601-date="2007">2007</year><volume>33</volume><fpage>266</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2006.10.004</pub-id><?supplied-pmid 17097848?><pub-id pub-id-type="pmid">17097848</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Azizian</surname><given-names>A</given-names></name>
<name><surname>R&#x000fc;hlmann</surname><given-names>F</given-names></name>
<name><surname>Krause</surname><given-names>T</given-names></name>
<name><surname>Bernhardt</surname><given-names>M</given-names></name>
<name><surname>Jo</surname><given-names>P</given-names></name>
<name><surname>K&#x000f6;nig</surname><given-names>A</given-names></name>
<etal>et al.</etal>
</person-group><article-title>CA19-9 for detecting recurrence of pancreatic cancer</article-title><source>Sci Rep</source><year iso-8601-date="2020">2020</year><volume>10</volume><elocation-id>1332</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-57930-x</pub-id><!--<pub-id pub-id-type="pmcid">PMC6987233</pub-id>--><?supplied-pmid 31992753?><pub-id pub-id-type="pmid">31992753</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zurawski</surname><given-names>VR Jr</given-names></name>
<name><surname>Orjaseter</surname><given-names>H</given-names></name>
<name><surname>Andersen</surname><given-names>A</given-names></name>
<name><surname>Jellum</surname><given-names>E</given-names></name>
</person-group><article-title>Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer</article-title><source>Int J Cancer</source><year iso-8601-date="1988">1988</year><volume>42</volume><fpage>677</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910420507</pub-id><?supplied-pmid 3182103?><pub-id pub-id-type="pmid">3182103</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jankovic</surname><given-names>MM</given-names></name>
<name><surname>Milutinovic</surname><given-names>BS</given-names></name>
</person-group><article-title>Glycoforms of CA125 antigen as a possible cancer marker</article-title><source>Cancer Biomark</source><year iso-8601-date="2008">2008</year><volume>4</volume><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.3233/cbm-2008-4104</pub-id><?supplied-pmid 18334732?><pub-id pub-id-type="pmid">18334732</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>NK</given-names></name>
<name><surname>Easton</surname><given-names>RL</given-names></name>
<name><surname>Panico</surname><given-names>M</given-names></name>
<name><surname>Sutton-Smith</surname><given-names>M</given-names></name>
<name><surname>Morrison</surname><given-names>JC</given-names></name>
<name><surname>Lattanzio</surname><given-names>FA</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125</article-title><source>J Biol Chem</source><year iso-8601-date="2003">2003</year><volume>278</volume><fpage>28619</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1074/jbc.M302741200</pub-id><?supplied-pmid 12734200?><pub-id pub-id-type="pmid">12734200</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>G</given-names></name>
<name><surname>Ge</surname><given-names>B</given-names></name>
<name><surname>Huang</surname><given-names>TK</given-names></name>
<name><surname>Zheng</surname><given-names>G</given-names></name>
<name><surname>Duan</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>IH</given-names></name>
</person-group><article-title>Positive identification of CA215 pan cancer biomarker from serum specimens of cancer patients</article-title><source>Cancer Biomark</source><year iso-8601-date="2010">2010</year><volume>6</volume><fpage>111</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3233/CBM-2009-0134</pub-id><?supplied-pmid 20571237?><pub-id pub-id-type="pmid">20571237</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>SM</given-names></name>
<name><surname>Xing</surname><given-names>F</given-names></name>
<name><surname>Sui</surname><given-names>H</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer</article-title><source>Med Sci Monit</source><year iso-8601-date="2011">2011</year><volume>17</volume><fpage>CR618</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.12659/msm.882046</pub-id><!--<pub-id pub-id-type="pmcid">PMC3539493</pub-id>--><?supplied-pmid 22037740?><pub-id pub-id-type="pmid">22037740</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akita</surname><given-names>K</given-names></name>
<name><surname>Yoshida</surname><given-names>S</given-names></name>
<name><surname>Ikehara</surname><given-names>Y</given-names></name>
<name><surname>Shirakawa</surname><given-names>S</given-names></name>
<name><surname>Toda</surname><given-names>M</given-names></name>
<name><surname>Inoue</surname><given-names>M</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer</article-title><source>Int J Gynecol Cancer</source><year iso-8601-date="2012">2012</year><volume>22</volume><fpage>531</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/IGC.0b013e3182473292</pub-id><?supplied-pmid 22367369?><pub-id pub-id-type="pmid">22367369</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>K</given-names></name>
<name><surname>Gentry-Maharaj</surname><given-names>A</given-names></name>
<name><surname>Burnell</surname><given-names>M</given-names></name>
<name><surname>Steentoft</surname><given-names>C</given-names></name>
<name><surname>Marcos-Silva</surname><given-names>L</given-names></name>
<name><surname>Mandel</surname><given-names>U</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer</article-title><source>J Proteome Res</source><year iso-8601-date="2013">2013</year><volume>12</volume><fpage>1408</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1021/pr3010474</pub-id><?supplied-pmid 23360124?><pub-id pub-id-type="pmid">23360124</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goldstein</surname><given-names>MJ</given-names></name>
<name><surname>Mitchell</surname><given-names>EP</given-names></name>
</person-group><article-title>Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer</article-title><source>Cancer Invest</source><year iso-8601-date="2005">2005</year><volume>23</volume><fpage>338</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1081/cnv-58878</pub-id><?supplied-pmid 16100946?><pub-id pub-id-type="pmid">16100946</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pont</surname><given-names>L</given-names></name>
<name><surname>Kuzyk</surname><given-names>V</given-names></name>
<name><surname>Benavente</surname><given-names>F</given-names></name>
<name><surname>Sanz-Nebot</surname><given-names>V</given-names></name>
<name><surname>Mayboroda</surname><given-names>OA</given-names></name>
<name><surname>Wuhrer</surname><given-names>M</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Site-specific <italic toggle="yes">N</italic>-linked glycosylation analysis of human carcinoembryonic antigen by sheathless capillary electrophoresis&#x02013;tandem mass spectrometry</article-title><source>J Proteome Res</source><year iso-8601-date="2021">2021</year><volume>20</volume><fpage>1666</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00875</pub-id><!--<pub-id pub-id-type="pmcid">PMC8023805</pub-id>--><?supplied-pmid 33560857?><pub-id pub-id-type="pmid">33560857</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Zhan</surname><given-names>T</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Wu</surname><given-names>H</given-names></name>
<name><surname>Ji</surname><given-names>D</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glycomic profiling of carcinoembryonic antigen isolated from human tumor tissue</article-title><source>Clin Proteomics</source><year iso-8601-date="2015">2015</year><volume>12</volume><elocation-id>17</elocation-id><pub-id pub-id-type="doi">10.1186/s12014-015-9088-3</pub-id><!--<pub-id pub-id-type="pmcid">PMC4495800</pub-id>--><?supplied-pmid 26157355?><pub-id pub-id-type="pmid">26157355</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saeland</surname><given-names>E</given-names></name>
<name><surname>Belo</surname><given-names>AI</given-names></name>
<name><surname>Mongera</surname><given-names>S</given-names></name>
<name><surname>van Die</surname><given-names>I</given-names></name>
<name><surname>Meijer</surname><given-names>GA</given-names></name>
<name><surname>van Kooyk</surname><given-names>Y</given-names></name>
</person-group><article-title>Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients</article-title><source>Int J Cancer</source><year iso-8601-date="2012">2012</year><volume>131</volume><fpage>117</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1002/ijc.26354</pub-id><?supplied-pmid 21823122?><pub-id pub-id-type="pmid">21823122</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Q</given-names></name>
<name><surname>Zhan</surname><given-names>T</given-names></name>
<name><surname>Deng</surname><given-names>Z</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>S</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glycan analysis of colorectal cancer samples reveals stage-dependent changes in CEA glycosylation patterns</article-title><source>Clin Proteomics</source><year iso-8601-date="2018">2018</year><volume>15</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1186/s12014-018-9182-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC5834848</pub-id>--><?supplied-pmid 29507546?><pub-id pub-id-type="pmid">29507546</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oikawa</surname><given-names>S</given-names></name>
<name><surname>Nakazato</surname><given-names>H</given-names></name>
<name><surname>Kosaki</surname><given-names>G</given-names></name>
</person-group><article-title>Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence</article-title><source>Biochem Biophys Res Commun</source><year iso-8601-date="1987">1987</year><volume>142</volume><fpage>511</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0006-291x(87)90304-4</pub-id><?supplied-pmid 3814146?><pub-id pub-id-type="pmid">3814146</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peracaula</surname><given-names>R</given-names></name>
<name><surname>Tabar&#x000e9;s</surname><given-names>G</given-names></name>
<name><surname>Royle</surname><given-names>L</given-names></name>
<name><surname>Harvey</surname><given-names>DJ</given-names></name>
<name><surname>Dwek</surname><given-names>RA</given-names></name>
<name><surname>Rudd</surname><given-names>PM</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins</article-title><source>Glycobiology</source><year iso-8601-date="2003">2003</year><volume>13</volume><fpage>457</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwg041</pub-id><?supplied-pmid 12626390?><pub-id pub-id-type="pmid">12626390</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilgunn</surname><given-names>S</given-names></name>
<name><surname>Conroy</surname><given-names>PJ</given-names></name>
<name><surname>Saldova</surname><given-names>R</given-names></name>
<name><surname>Rudd</surname><given-names>PM</given-names></name>
<name><surname>O&#x02019;Kennedy</surname><given-names>RJ</given-names></name>
</person-group><article-title>Aberrant PSA glycosylation&#x02014;a sweet predictor of prostate cancer</article-title><source>Nat Rev Urol</source><year iso-8601-date="2013">2013</year><volume>10</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nrurol.2012.258</pub-id><?supplied-pmid 23318363?><pub-id pub-id-type="pmid">23318363</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ohyama</surname><given-names>C</given-names></name>
<name><surname>Hosono</surname><given-names>M</given-names></name>
<name><surname>Nitta</surname><given-names>K</given-names></name>
<name><surname>Oh-eda</surname><given-names>M</given-names></name>
<name><surname>Yoshikawa</surname><given-names>K</given-names></name>
<name><surname>Habuchi</surname><given-names>T</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy</article-title><source>Glycobiology</source><year iso-8601-date="2004">2004</year><volume>14</volume><fpage>671</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwh071</pub-id><?supplied-pmid 15044396?><pub-id pub-id-type="pmid">15044396</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fukushima</surname><given-names>K</given-names></name>
<name><surname>Satoh</surname><given-names>T</given-names></name>
<name><surname>Baba</surname><given-names>S</given-names></name>
<name><surname>Yamashita</surname><given-names>K</given-names></name>
</person-group><article-title>&#x003b1;1,2-Fucosylated and &#x003b2;-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer</article-title><source>Glycobiology</source><year iso-8601-date="2010">2010</year><volume>20</volume><fpage>452</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwp197</pub-id><?supplied-pmid 20008118?><pub-id pub-id-type="pmid">20008118</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanai</surname><given-names>T</given-names></name>
<name><surname>Amakawa</surname><given-names>M</given-names></name>
<name><surname>Kato</surname><given-names>R</given-names></name>
<name><surname>Shimizu</surname><given-names>K</given-names></name>
<name><surname>Nakamura</surname><given-names>K</given-names></name>
<name><surname>Ito</surname><given-names>K</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Evaluation of a new method for the diagnosis of alterations of Lens culinaris agglutinin binding of thyroglobulin molecules in thyroid carcinoma</article-title><source>Clin Chem Lab Med</source><year iso-8601-date="2009">2009</year><volume>47</volume><fpage>1285</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1515/CCLM.2009.277</pub-id><?supplied-pmid 19743952?><pub-id pub-id-type="pmid">19743952</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Z&#x00105;bczy&#x00144;ska</surname><given-names>M</given-names></name>
<name><surname>Koz&#x00142;owska</surname><given-names>K</given-names></name>
<name><surname>Poche&#x00107;</surname><given-names>E</given-names></name>
</person-group><article-title>Glycosylation in the thyroid gland: vital aspects of glycoprotein function in thyrocyte physiology and thyroid disorders</article-title><source>Int J Mol Sci</source><year iso-8601-date="2018">2018</year><volume>19</volume><elocation-id>2792</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19092792</pub-id><!--<pub-id pub-id-type="pmcid">PMC6163523</pub-id>--><?supplied-pmid 30227620?><pub-id pub-id-type="pmid">30227620</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miyoshi</surname><given-names>E</given-names></name>
<name><surname>Ito</surname><given-names>Y</given-names></name>
<name><surname>Miyoshi</surname><given-names>Y</given-names></name>
</person-group><article-title>Involvement of aberrant glycosylation in thyroid cancer</article-title><source>J Oncol</source><year iso-8601-date="2010">2010</year><volume>2010</volume><elocation-id>816595</elocation-id><pub-id pub-id-type="doi">10.1155/2010/816595</pub-id><!--<pub-id pub-id-type="pmcid">PMC2906155</pub-id>--><?supplied-pmid 20652009?><pub-id pub-id-type="pmid">20652009</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bab&#x000e1;l</surname><given-names>P</given-names></name>
<name><surname>Janega</surname><given-names>P</given-names></name>
<name><surname>Cern&#x000e1;</surname><given-names>A</given-names></name>
<name><surname>Kholov&#x000e1;</surname><given-names>I</given-names></name>
<name><surname>Brabencov&#x000e1;</surname><given-names>E</given-names></name>
</person-group><article-title>Neoplastic transformation of the thyroid gland is accompanied by changes in cellular sialylation</article-title><source>Acta Histochem</source><year iso-8601-date="2006">2006</year><volume>108</volume><fpage>133</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.acthis.2006.03.003</pub-id><?supplied-pmid 16720036?><pub-id pub-id-type="pmid">16720036</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krzeslak</surname><given-names>A</given-names></name>
<name><surname>Pomorski</surname><given-names>L</given-names></name>
<name><surname>Lipinska</surname><given-names>A</given-names></name>
</person-group><article-title>Elevation of nucleocytoplasmic &#x003b2;-N-acetylglucosaminidase (O-GlcNAcase) activity in thyroid cancers</article-title><source>Int J Mol Med</source><year iso-8601-date="2010">2010</year><volume>25</volume><fpage>643</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3892/ijmm_00000387</pub-id><?supplied-pmid 20198314?><pub-id pub-id-type="pmid">20198314</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sinadinovi&#x00107;</surname><given-names>J</given-names></name>
<name><surname>Cveji&#x00107;</surname><given-names>D</given-names></name>
<name><surname>Savin</surname><given-names>S</given-names></name>
<name><surname>Janci&#x00107;-Zuguricas</surname><given-names>M</given-names></name>
<name><surname>Mi&#x00107;i&#x00107;</surname><given-names>JV</given-names></name>
</person-group><article-title>Altered terminal glycosylation of thyroglobulin in papillary thyroid carcinoma</article-title><source>Exp Clin Endocrinol</source><year iso-8601-date="1992">1992</year><volume>100</volume><fpage>124</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1055/s-0029-1211191</pub-id><?supplied-pmid 1305063?><pub-id pub-id-type="pmid">1305063</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Tsuji</surname><given-names>T</given-names></name>
<name><surname>Tarutani</surname><given-names>O</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
</person-group><article-title>Structural changes of carbohydrate chains of human thyroglobulin accompanying malignant transformations of thyroid glands</article-title><source>Eur J Biochem</source><year iso-8601-date="1984">1984</year><volume>143</volume><elocation-id>133-44</elocation-id><pub-id pub-id-type="doi">10.1111/j.1432-1033.1984.tb08352.x</pub-id><?supplied-pmid 6468384?><pub-id pub-id-type="pmid">6468384</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Tsuji</surname><given-names>T</given-names></name>
<name><surname>Tarutani</surname><given-names>O</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
</person-group><article-title>Phosphorylated high mannose-type and hybrid-type oligosaccharide chains of human thyroglobulin isolated from malignant thyroid tissue</article-title><source>Biochim Biophys Acta</source><year iso-8601-date="1985">1985</year><volume>838</volume><fpage>84</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/0304-4165(85)90253-3</pub-id><?supplied-pmid 3917691?><pub-id pub-id-type="pmid">3917691</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crandall</surname><given-names>BF</given-names></name>
</person-group><article-title>Alpha-fetoprotein: a review</article-title><source>Crit Rev Clin Lab Sci</source><year iso-8601-date="1981">1981</year><volume>15</volume><fpage>127</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.3109/10408368109105870</pub-id><?supplied-pmid 6169490?><pub-id pub-id-type="pmid">6169490</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eleftheriou</surname><given-names>N</given-names></name>
<name><surname>Heathcote</surname><given-names>J</given-names></name>
<name><surname>Thomas</surname><given-names>HC</given-names></name>
<name><surname>Sherlock</surname><given-names>S</given-names></name>
</person-group><article-title>Serum alpha-fetoprotein levels in patients with acute and chronic liver disease. Relation to hepatocellular regeneration and development of primary liver cell carcinoma</article-title><source>J Clin Pathol</source><year iso-8601-date="1977">1977</year><volume>30</volume><fpage>704</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1136/jcp.30.8.704</pub-id><!--<pub-id pub-id-type="pmcid">PMC476528</pub-id>--><?supplied-pmid 74380?><pub-id pub-id-type="pmid">74380</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senturk</surname><given-names>H</given-names></name>
<name><surname>Cumali</surname><given-names>R</given-names></name>
</person-group><article-title>Extreme elevation of serum alpha fetoprotein in decompensated cirrhosis without HCC: an ominous sign</article-title><source>Int J Biol Markers</source><year iso-8601-date="2007">2007</year><volume>22</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.5301/jbm.2008.1034</pub-id><?supplied-pmid 17393357?><pub-id pub-id-type="pmid">17393357</pub-id></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bialecki</surname><given-names>ES</given-names></name>
<name><surname>Di</surname><given-names>Bisceglie AM</given-names></name>
</person-group><article-title>Diagnosis of hepatocellular carcinoma</article-title><source>HPB (Oxford)</source><year iso-8601-date="2005">2005</year><volume>7</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1080/13651820410024049</pub-id><!--<pub-id pub-id-type="pmcid">PMC2023919</pub-id>--><?supplied-pmid 18333158?><pub-id pub-id-type="pmid">18333158</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koteish</surname><given-names>A</given-names></name>
<name><surname>Thuluvath</surname><given-names>PJ</given-names></name>
</person-group><article-title>Screening for hepatocellular carcinoma</article-title><source>J Vasc Interv Radiol</source><year iso-8601-date="2002">2002</year><volume>13</volume><fpage>S185</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/s1051-0443(07)61785-0</pub-id><?supplied-pmid 12354835?><pub-id pub-id-type="pmid">12354835</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Colombo</surname><given-names>M</given-names></name>
</person-group><article-title>Screening for cancer in viral hepatitis</article-title><source>Clin Liver Dis</source><year iso-8601-date="2001">2001</year><volume>5</volume><fpage>109</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/s1089-3261(05)70156-2</pub-id><?supplied-pmid 11218910?><pub-id pub-id-type="pmid">11218910</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Farinati</surname><given-names>F</given-names></name>
<name><surname>Marino</surname><given-names>D</given-names></name>
<name><surname>De</surname><given-names>Giorgio M</given-names></name>
<name><surname>Baldan</surname><given-names>A</given-names></name>
<name><surname>Cantarini</surname><given-names>M</given-names></name>
<name><surname>Cursaro</surname><given-names>C</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?</article-title><source>Am J Gastroenterol</source><year iso-8601-date="2006">2006</year><volume>101</volume><fpage>524</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2006.00443.x</pub-id><?supplied-pmid 16542289?><pub-id pub-id-type="pmid">16542289</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>S</given-names></name>
<name><surname>Bent</surname><given-names>S</given-names></name>
<name><surname>Kohlwes</surname><given-names>J</given-names></name>
</person-group><article-title>Test characteristics of &#x003b1;-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis</article-title><source>Ann Intern Med</source><year iso-8601-date="2003">2003</year><volume>139</volume><fpage>46</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-139-1-200307010-00012</pub-id><?supplied-pmid 12834318?><pub-id pub-id-type="pmid">12834318</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Donati</surname><given-names>M</given-names></name>
<name><surname>Brancato</surname><given-names>G</given-names></name>
<name><surname>Donati</surname><given-names>A</given-names></name>
</person-group><article-title>Clinical biomarkers in hepatocellular carcinoma (HCC)</article-title><source>Front Biosci (Schol Ed)</source><year iso-8601-date="2010">2010</year><volume>2</volume><fpage>571</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.2741/s86</pub-id><?supplied-pmid 20036969?><pub-id pub-id-type="pmid">20036969</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Noda</surname><given-names>K</given-names></name>
<name><surname>Miyoshi</surname><given-names>E</given-names></name>
<name><surname>Uozumi</surname><given-names>N</given-names></name>
<name><surname>Yanagidani</surname><given-names>S</given-names></name>
<name><surname>Ikeda</surname><given-names>Y</given-names></name>
<name><surname>Gao</surname><given-names>C</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Gene expression of &#x003b1;1-6 fucosyltransferase in human hepatoma tissues: a possible implication for increased fucosylation of &#x003b1;-fetoprotein</article-title><source>Hepatology</source><year iso-8601-date="1998">1998</year><volume>28</volume><fpage>944</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1002/hep.510280408</pub-id><?supplied-pmid 9755230?><pub-id pub-id-type="pmid">9755230</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
<name><surname>Takeishi</surname><given-names>S</given-names></name>
<name><surname>Kameyama</surname><given-names>A</given-names></name>
<name><surname>Yagi</surname><given-names>H</given-names></name>
<name><surname>Yoshioka</surname><given-names>T</given-names></name>
<name><surname>Moriwaki</surname><given-names>K</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glycomic analyses of glycoproteins in bile and serum during rat hepatocarcinogenesis</article-title><source>J Proteome Res</source><year iso-8601-date="2010">2010</year><volume>9</volume><fpage>4888</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1021/pr100414r</pub-id><?supplied-pmid 20731380?><pub-id pub-id-type="pmid">20731380</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Sohn</surname><given-names>A</given-names></name>
<name><surname>Yeo</surname><given-names>I</given-names></name>
<name><surname>Yu</surname><given-names>SJ</given-names></name>
<name><surname>Yoon</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>Y</given-names></name>
</person-group><article-title>Clinical assay for AFP-L3 by using multiple reaction monitoring-mass spectrometry for diagnosing hepatocellular carcinoma</article-title><source>Clin Chem</source><year iso-8601-date="2018">2018</year><volume>64</volume><fpage>1230</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2018.289702</pub-id><?supplied-pmid 29875214?><pub-id pub-id-type="pmid">29875214</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>Y</given-names></name>
<name><surname>Igarashi</surname><given-names>M</given-names></name>
<name><surname>Kawai</surname><given-names>H</given-names></name>
<name><surname>Suda</surname><given-names>T</given-names></name>
<name><surname>Satomura</surname><given-names>S</given-names></name>
<name><surname>Aoyagi</surname><given-names>Y</given-names></name>
</person-group><article-title>Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma</article-title><source>Dig Dis Sci</source><year iso-8601-date="2010">2010</year><volume>55</volume><fpage>3576</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s10620-010-1222-5</pub-id><?supplied-pmid 20407827?><pub-id pub-id-type="pmid">20407827</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>KH</given-names></name>
<name><surname>Lee</surname><given-names>SY</given-names></name>
<name><surname>Baek</surname><given-names>JH</given-names></name>
<name><surname>Lee</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Yoo</surname><given-names>JS</given-names></name>
</person-group><article-title>Measuring fucosylated alpha-fetoprotein in hepatocellular carcinoma: a comparison of &#x003bc;TAS and parallel reaction monitoring</article-title><source>Proteomics Clin Appl</source><year iso-8601-date="2021">2021</year><volume>15</volume><elocation-id>e2000096</elocation-id><pub-id pub-id-type="doi">10.1002/prca.202000096</pub-id><?supplied-pmid 33764665?><pub-id pub-id-type="pmid">33764665</pub-id></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toyoda</surname><given-names>H</given-names></name>
<name><surname>Kumada</surname><given-names>T</given-names></name>
<name><surname>Tada</surname><given-names>T</given-names></name>
<name><surname>Kaneoka</surname><given-names>Y</given-names></name>
<name><surname>Maeda</surname><given-names>A</given-names></name>
<name><surname>Kanke</surname><given-names>F</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Clinical utility of highly sensitive <italic toggle="yes">Lens culinaris</italic> agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein &#x0003c;20 ng/mL</article-title><source>Cancer Sci</source><year iso-8601-date="2011">2011</year><volume>102</volume><fpage>1025</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2011.01875.x</pub-id><?supplied-pmid 21244578?><pub-id pub-id-type="pmid">21244578</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ang</surname><given-names>IL</given-names></name>
<name><surname>Poon</surname><given-names>TC</given-names></name>
<name><surname>Lai</surname><given-names>PB</given-names></name>
<name><surname>Chan</surname><given-names>AT</given-names></name>
<name><surname>Ngai</surname><given-names>SM</given-names></name>
<name><surname>Hui</surname><given-names>AY</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach</article-title><source>J Proteome Res</source><year iso-8601-date="2006">2006</year><volume>5</volume><fpage>2691</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1021/pr060109r</pub-id><?supplied-pmid 17022640?><pub-id pub-id-type="pmid">17022640</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>M</given-names></name>
<name><surname>Long</surname><given-names>RE</given-names></name>
<name><surname>Comunale</surname><given-names>MA</given-names></name>
<name><surname>Junaidi</surname><given-names>O</given-names></name>
<name><surname>Marrero</surname><given-names>J</given-names></name>
<name><surname>Di</surname><given-names>Bisceglie AM</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year iso-8601-date="2009">2009</year><volume>18</volume><fpage>1914</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-08-0980</pub-id><!--<pub-id pub-id-type="pmcid">PMC4413450</pub-id>--><?supplied-pmid 19454616?><pub-id pub-id-type="pmid">19454616</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poon</surname><given-names>TC</given-names></name>
<name><surname>Mok</surname><given-names>TS</given-names></name>
<name><surname>Chan</surname><given-names>AT</given-names></name>
<name><surname>Chan</surname><given-names>CM</given-names></name>
<name><surname>Leong</surname><given-names>V</given-names></name>
<name><surname>Tsui</surname><given-names>SH</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Quantification and utility of monosialylated &#x003b1;-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total &#x003b1;-fetoprotein</article-title><source>Clin Chem</source><year iso-8601-date="2002">2002</year><volume>48</volume><fpage>1021</fpage><lpage>7</lpage><?supplied-pmid 12089170?><pub-id pub-id-type="pmid">12089170</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gendler</surname><given-names>SJ</given-names></name>
</person-group><article-title>MUC1, the renaissance molecule</article-title><source>J Mammary Gland Biol Neoplasia</source><year iso-8601-date="2001">2001</year><volume>6</volume><fpage>339</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1023/a:1011379725811</pub-id><?supplied-pmid 11547902?><pub-id pub-id-type="pmid">11547902</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lau</surname><given-names>SK</given-names></name>
<name><surname>Weiss</surname><given-names>LM</given-names></name>
<name><surname>Chu</surname><given-names>PG</given-names></name>
</person-group><article-title>Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study</article-title><source>Am J Clin Pathol</source><year iso-8601-date="2004">2004</year><volume>122</volume><fpage>61</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1309/9R66-73QE-C06D-86Y4</pub-id><?supplied-pmid 15272531?><pub-id pub-id-type="pmid">15272531</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Irimura</surname><given-names>T</given-names></name>
<name><surname>Denda</surname><given-names>K</given-names></name>
<name><surname>Iida</surname><given-names>Si</given-names></name>
<name><surname>Takeuchi</surname><given-names>H</given-names></name>
<name><surname>Kato</surname><given-names>K</given-names></name>
</person-group><article-title>Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity</article-title><source>J Biochem</source><year iso-8601-date="1999">1999</year><volume>126</volume><fpage>975</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022565</pub-id><?supplied-pmid 10578046?><pub-id pub-id-type="pmid">10578046</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nath</surname><given-names>S</given-names></name>
<name><surname>Mukherjee</surname><given-names>P</given-names></name>
</person-group><article-title>MUC1: a multifaceted oncoprotein with a key role in cancer progression</article-title><source>Trends Mol Med</source><year iso-8601-date="2014">2014</year><volume>20</volume><fpage>332</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2014.02.007</pub-id><!--<pub-id pub-id-type="pmcid">PMC5500204</pub-id>--><?supplied-pmid 24667139?><pub-id pub-id-type="pmid">24667139</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Taylor-Papadimitriou</surname><given-names>J</given-names></name>
<name><surname>Burchell</surname><given-names>J</given-names></name>
<name><surname>Miles</surname><given-names>DW</given-names></name>
<name><surname>Dalziel</surname><given-names>M</given-names></name>
</person-group><article-title>MUC1 and cancer</article-title><source>Biochim Biophys Acta</source><year iso-8601-date="1999">1999</year><volume>1455</volume><fpage>301</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/s0925-4439(99)00055-1</pub-id><?supplied-pmid 10571020?><pub-id pub-id-type="pmid">10571020</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Whitehouse</surname><given-names>C</given-names></name>
<name><surname>Burchell</surname><given-names>J</given-names></name>
<name><surname>Gschmeissner</surname><given-names>S</given-names></name>
<name><surname>Brockhausen</surname><given-names>I</given-names></name>
<name><surname>Lloyd</surname><given-names>KO</given-names></name>
<name><surname>Taylor-Papadimitriou</surname><given-names>J</given-names></name>
</person-group><article-title>A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/<italic toggle="yes">trans</italic>-Golgi apparatus inhibits the development of core-2-based O-glycans</article-title><source>J Cell Biol</source><year iso-8601-date="1997">1997</year><volume>137</volume><fpage>1229</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1083/jcb.137.6.1229</pub-id><!--<pub-id pub-id-type="pmcid">PMC2132526</pub-id>--><?supplied-pmid 9182658?><pub-id pub-id-type="pmid">9182658</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Picco</surname><given-names>G</given-names></name>
<name><surname>Julien</surname><given-names>S</given-names></name>
<name><surname>Brockhausen</surname><given-names>I</given-names></name>
<name><surname>Beatson</surname><given-names>R</given-names></name>
<name><surname>Antonopoulos</surname><given-names>A</given-names></name>
<name><surname>Haslam</surname><given-names>S</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Over-expression of ST3Gal-I promotes mammary tumorigenesis</article-title><source>Glycobiology</source><year iso-8601-date="2010">2010</year><volume>20</volume><fpage>1241</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwq085</pub-id><!--<pub-id pub-id-type="pmcid">PMC2934706</pub-id>--><?supplied-pmid 20534593?><pub-id pub-id-type="pmid">20534593</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Storr</surname><given-names>SJ</given-names></name>
<name><surname>Royle</surname><given-names>L</given-names></name>
<name><surname>Chapman</surname><given-names>CJ</given-names></name>
<name><surname>Hamid</surname><given-names>UM</given-names></name>
<name><surname>Robertson</surname><given-names>JF</given-names></name>
<name><surname>Murray</surname><given-names>A</given-names></name>
<etal>et al.</etal>
</person-group><article-title>The <italic toggle="yes">O</italic>-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient&#x02019;s serum</article-title><source>Glycobiology</source><year iso-8601-date="2008">2008</year><volume>18</volume><fpage>456</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwn022</pub-id><?supplied-pmid 18332077?><pub-id pub-id-type="pmid">18332077</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Leoz</surname><given-names>ML</given-names></name>
<name><surname>Young</surname><given-names>LJ</given-names></name>
<name><surname>An</surname><given-names>HJ</given-names></name>
<name><surname>Kronewitter</surname><given-names>SR</given-names></name>
<name><surname>Kim</surname><given-names>J</given-names></name>
<name><surname>Miyamoto</surname><given-names>S</given-names></name>
<etal>et al.</etal>
</person-group><article-title>High-mannose glycans are elevated during breast cancer progression</article-title><source>Mol Cell Proteomics</source><year iso-8601-date="2011">2011</year><volume>10</volume><elocation-id>M110.002717</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.M110.002717</pub-id><!--<pub-id pub-id-type="pmcid">PMC3013453</pub-id>--><?supplied-pmid 21097542?><pub-id pub-id-type="pmid">21097542</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mann</surname><given-names>B</given-names></name>
<name><surname>Klussmann</surname><given-names>E</given-names></name>
<name><surname>Vandamme-Feldhaus</surname><given-names>V</given-names></name>
<name><surname>Iwersen</surname><given-names>M</given-names></name>
<name><surname>Hanski</surname><given-names>ML</given-names></name>
<name><surname>Riecken</surname><given-names>EO</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Low <italic toggle="yes">O</italic>-acetylation of sialyl-LE<sup>X</sup> contributes to its overexpression in colon carcinoma metastases</article-title><source>Int J Cancer</source><year iso-8601-date="1997">1997</year><volume>72</volume><fpage>258</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970717)72:2&#x0003c;258::AID-IJC10&#x0003e;3.0.CO;2-C</pub-id><?supplied-pmid 9219830?><pub-id pub-id-type="pmid">9219830</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duffy</surname><given-names>MJ</given-names></name>
<name><surname>Evoy</surname><given-names>D</given-names></name>
<name><surname>McDermott</surname><given-names>EW</given-names></name>
</person-group><article-title>CA 15-3: uses and limitation as a biomarker for breast cancer</article-title><source>Clin Chim Acta</source><year iso-8601-date="2010">2010</year><volume>411</volume><fpage>1869</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2010.08.039</pub-id><?supplied-pmid 20816948?><pub-id pub-id-type="pmid">20816948</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sturgeon</surname><given-names>CM</given-names></name>
<name><surname>Duffy</surname><given-names>MJ</given-names></name>
<name><surname>Stenman</surname><given-names>UH</given-names></name>
<name><surname>Lilja</surname><given-names>H</given-names></name>
<name><surname>Br&#x000fc;nner</surname><given-names>N</given-names></name>
<name><surname>Chan</surname><given-names>DW</given-names></name>
<etal>et al.</etal>
<collab>National Academy of Clinical Biochemistry</collab>
</person-group><article-title>National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers</article-title><source>Clin Chem</source><year iso-8601-date="2008">2008</year><volume>54</volume><fpage>e11</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2008.105601</pub-id><?supplied-pmid 19042984?><pub-id pub-id-type="pmid">19042984</pub-id></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harris</surname><given-names>L</given-names></name>
<name><surname>Fritsche</surname><given-names>H</given-names></name>
<name><surname>Mennel</surname><given-names>R</given-names></name>
<name><surname>Norton</surname><given-names>L</given-names></name>
<name><surname>Ravdin</surname><given-names>P</given-names></name>
<name><surname>Taube</surname><given-names>S</given-names></name>
<etal>et al.</etal>
<collab>American Society of Clinical Oncology</collab>
</person-group><article-title>American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer</article-title><source>J Clin Oncol</source><year iso-8601-date="2007">2007</year><volume>25</volume><fpage>5287</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.14.2364</pub-id><?supplied-pmid 17954709?><pub-id pub-id-type="pmid">17954709</pub-id></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Klee</surname><given-names>GG</given-names></name>
<name><surname>Schreiber</surname><given-names>WE</given-names></name>
</person-group><article-title>MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27.29, BR): are they measuring the same antigen?</article-title><source>Arch Pathol Lab Med</source><year iso-8601-date="2004">2004</year><volume>128</volume><fpage>1131</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.5858/2004-128-1131-MGGAFM</pub-id><?supplied-pmid 15387710?><pub-id pub-id-type="pmid">15387710</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gion</surname><given-names>M</given-names></name>
<name><surname>Mione</surname><given-names>R</given-names></name>
<name><surname>Leon</surname><given-names>AE</given-names></name>
<name><surname>Dittadi</surname><given-names>R</given-names></name>
</person-group><article-title>Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer</article-title><source>Clin Chem</source><year iso-8601-date="1999">1999</year><volume>45</volume><fpage>630</fpage><lpage>7</lpage><?supplied-pmid 10222349?><pub-id pub-id-type="pmid">10222349</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bast</surname><given-names>RC Jr</given-names></name>
<name><surname>Ravdin</surname><given-names>P</given-names></name>
<name><surname>Hayes</surname><given-names>DF</given-names></name>
<name><surname>Bates</surname><given-names>S</given-names></name>
<name><surname>Fritsche</surname><given-names>H Jr</given-names></name>
<name><surname>Jessup</surname><given-names>JM</given-names></name>
<etal>et al.</etal>
<collab>American Society of Clinical Oncology Tumor Markers Expert Panel</collab>
</person-group><article-title>2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology</article-title><source>J Clin Oncol</source><year iso-8601-date="2001">2001</year><volume>19</volume><fpage>1865</fpage><lpage>78</lpage><comment>Erratum in: J Clin Oncol. 2001;19:4185&#x02013;8. Erratum in: J Clin Oncol. 2002;20:2213.</comment><pub-id pub-id-type="doi">10.1200/JCO.2001.19.6.1865</pub-id><?supplied-pmid 11251019?><pub-id pub-id-type="pmid">11251019</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lloyd</surname><given-names>KO</given-names></name>
<name><surname>Yin</surname><given-names>BW</given-names></name>
<name><surname>Kudryashov</surname><given-names>V</given-names></name>
</person-group><article-title>Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): identification as a mucin-type molecule</article-title><source>Int J Cancer</source><year iso-8601-date="1997">1997</year><volume>71</volume><fpage>842</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19970529)71:5&#x0003c;842::aid-ijc24&#x0003e;3.0.co;2-8</pub-id><?supplied-pmid 9180155?><pub-id pub-id-type="pmid">9180155</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marcos-Silva</surname><given-names>L</given-names></name>
<name><surname>Narimatsu</surname><given-names>Y</given-names></name>
<name><surname>Halim</surname><given-names>A</given-names></name>
<name><surname>Campos</surname><given-names>D</given-names></name>
<name><surname>Yang</surname><given-names>Z</given-names></name>
<name><surname>Tarp</surname><given-names>MA</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Characterization of binding epitopes of CA125 monoclonal antibodies</article-title><source>J Proteome Res</source><year iso-8601-date="2014">2014</year><volume>13</volume><fpage>3349</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1021/pr500215g</pub-id><?supplied-pmid 24850311?><pub-id pub-id-type="pmid">24850311</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haridas</surname><given-names>D</given-names></name>
<name><surname>Ponnusamy</surname><given-names>MP</given-names></name>
<name><surname>Chugh</surname><given-names>S</given-names></name>
<name><surname>Lakshmanan</surname><given-names>I</given-names></name>
<name><surname>Seshacharyulu</surname><given-names>P</given-names></name>
<name><surname>Batra</surname><given-names>SK</given-names></name>
</person-group><article-title>MUC16: molecular analysis and its functional implications in benign and malignant conditions</article-title><source>FASEB J</source><year iso-8601-date="2014">2014</year><volume>28</volume><fpage>4183</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1096/fj.14-257352</pub-id><?supplied-pmid 25002120?><pub-id pub-id-type="pmid">25002120</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bast</surname><given-names>RC Jr</given-names></name>
<name><surname>Klug</surname><given-names>TL</given-names></name>
<name><surname>St</surname><given-names>John E</given-names></name>
<name><surname>Jenison</surname><given-names>E</given-names></name>
<name><surname>Niloff</surname><given-names>JM</given-names></name>
<name><surname>Lazarus</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer</article-title><source>N Engl J Med</source><year iso-8601-date="1983">1983</year><volume>309</volume><fpage>883</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1056/NEJM198310133091503</pub-id><?supplied-pmid 6310399?><pub-id pub-id-type="pmid">6310399</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lehtovirta</surname><given-names>P</given-names></name>
<name><surname>Apter</surname><given-names>D</given-names></name>
<name><surname>Stenman</surname><given-names>UH</given-names></name>
</person-group><article-title>Serum CA 125 levels during the menstrual cycle</article-title><source>Br J Obstet Gynaecol</source><year iso-8601-date="1990">1990</year><volume>97</volume><fpage>930</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.1990.tb02449.x</pub-id><?supplied-pmid 2223685?><pub-id pub-id-type="pmid">2223685</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spitzer</surname><given-names>M</given-names></name>
<name><surname>Kaushal</surname><given-names>N</given-names></name>
<name><surname>Benjamin</surname><given-names>F</given-names></name>
</person-group><article-title>Maternal CA-125 levels in pregnancy and the puerperium</article-title><source>J Reprod Med</source><year iso-8601-date="1998">1998</year><volume>43</volume><fpage>387</fpage><lpage>92</lpage><?supplied-pmid 9583073?><pub-id pub-id-type="pmid">9583073</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edula</surname><given-names>RG</given-names></name>
<name><surname>Muthukuru</surname><given-names>S</given-names></name>
<name><surname>Moroianu</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Lingiah</surname><given-names>V</given-names></name>
<name><surname>Fung</surname><given-names>P</given-names></name>
<etal>et al.</etal>
</person-group><article-title>CA-125 significance in cirrhosis and correlation with disease severity and portal hypertension: a retrospective study</article-title><source>J Clin Transl Hepatol</source><year iso-8601-date="2018">2018</year><volume>6</volume><fpage>241</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2017.00070</pub-id><!--<pub-id pub-id-type="pmcid">PMC6160305</pub-id>--><?supplied-pmid 30271734?><pub-id pub-id-type="pmid">30271734</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>RH</given-names></name>
<name><surname>Yao</surname><given-names>WM</given-names></name>
<name><surname>Wu</surname><given-names>LY</given-names></name>
<name><surname>Mao</surname><given-names>YY</given-names></name>
</person-group><article-title>Highly elevated serum CA-125 levels in patients with non-malignant gynecological diseases</article-title><source>Arch Gynecol Obstet</source><year iso-8601-date="2011">2011</year><volume>283</volume><fpage>107</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s00404-010-1717-5</pub-id><?supplied-pmid 21069368?><pub-id pub-id-type="pmid">21069368</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>D</given-names></name>
<name><surname>Vinocha</surname><given-names>A</given-names></name>
</person-group><article-title>Benign ovarian cysts with raised CA-125 levels: do we need to evaluate the fallopian tubes?</article-title><source>J Lab Physicians</source><year iso-8601-date="2020">2020</year><volume>12</volume><fpage>276</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1055/s-0040-1722547</pub-id><!--<pub-id pub-id-type="pmcid">PMC7773439</pub-id>--><?supplied-pmid 33390678?><pub-id pub-id-type="pmid">33390678</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aithal</surname><given-names>A</given-names></name>
<name><surname>Rauth</surname><given-names>S</given-names></name>
<name><surname>Kshirsagar</surname><given-names>P</given-names></name>
<name><surname>Shah</surname><given-names>A</given-names></name>
<name><surname>Lakshmanan</surname><given-names>I</given-names></name>
<name><surname>Junker</surname><given-names>WM</given-names></name>
<etal>et al.</etal>
</person-group><article-title>MUC16 as a novel target for cancer therapy</article-title><source>Expert Opin Ther Targets</source><year iso-8601-date="2018">2018</year><volume>22</volume><fpage>675</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1080/14728222.2018.1498845</pub-id><!--<pub-id pub-id-type="pmcid">PMC6300140</pub-id>--><?supplied-pmid 29999426?><pub-id pub-id-type="pmid">29999426</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giamougiannis</surname><given-names>P</given-names></name>
<name><surname>Martin-Hirsch</surname><given-names>PL</given-names></name>
<name><surname>Martin</surname><given-names>FL</given-names></name>
</person-group><article-title>The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia</article-title><source>Carcinogenesis</source><year iso-8601-date="2021">2021</year><volume>42</volume><fpage>327</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgab010</pub-id><?supplied-pmid 33608706?><pub-id pub-id-type="pmid">33608706</pub-id></element-citation></ref><ref id="B115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Charkhchi</surname><given-names>P</given-names></name>
<name><surname>Cybulski</surname><given-names>C</given-names></name>
<name><surname>Gronwald</surname><given-names>J</given-names></name>
<name><surname>Wong</surname><given-names>FO</given-names></name>
<name><surname>Narod</surname><given-names>SA</given-names></name>
<name><surname>Akbari</surname><given-names>MR</given-names></name>
</person-group><article-title>CA125 and ovarian cancer: a comprehensive review</article-title><source>Cancers (Basel)</source><year iso-8601-date="2020">2020</year><volume>12</volume><elocation-id>3730</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12123730</pub-id><!--<pub-id pub-id-type="pmcid">PMC7763876</pub-id>--><?supplied-pmid 33322519?><pub-id pub-id-type="pmid">33322519</pub-id></element-citation></ref><ref id="B116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van</surname><given-names>Gorp T</given-names></name>
<name><surname>Cadron</surname><given-names>I</given-names></name>
<name><surname>Despierre</surname><given-names>E</given-names></name>
<name><surname>Daemen</surname><given-names>A</given-names></name>
<name><surname>Leunen</surname><given-names>K</given-names></name>
<name><surname>Amant</surname><given-names>F</given-names></name>
<etal>et al.</etal>
</person-group><article-title>HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of Ovarian Malignancy Algorithm</article-title><source>Br J Cancer</source><year iso-8601-date="2011">2011</year><volume>104</volume><fpage>863</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6606092</pub-id><!--<pub-id pub-id-type="pmcid">PMC3048204</pub-id>--><?supplied-pmid 21304524?><pub-id pub-id-type="pmid">21304524</pub-id></element-citation></ref><ref id="B117"><label>117</label><element-citation publication-type="webpage"><comment>510(k) Substantial equivalence determination decision summary [Internet]. [cited 2022 Sep 18]. Available from: <uri xlink:href="https://www.accessdata.fda.gov/cdrh_docs/reviews/K103358.pdf">https://www.accessdata.fda.gov/cdrh_docs/reviews/K103358.pdf</uri></comment></element-citation></ref><ref id="B118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leung</surname><given-names>F</given-names></name>
<name><surname>Diamandis</surname><given-names>EP</given-names></name>
<name><surname>Kulasingam</surname><given-names>V</given-names></name>
</person-group><article-title>From bench to bedside: discovery of ovarian cancer biomarkers using high-throughput technologies in the past decade</article-title><source>Biomark Med</source><year iso-8601-date="2012">2012</year><volume>6</volume><fpage>613</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.2217/bmm.12.70</pub-id><?supplied-pmid 23075239?><pub-id pub-id-type="pmid">23075239</pub-id></element-citation></ref><ref id="B119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ricardo</surname><given-names>S</given-names></name>
<name><surname>Marcos-Silva</surname><given-names>L</given-names></name>
<name><surname>Pereira</surname><given-names>D</given-names></name>
<name><surname>Pinto</surname><given-names>R</given-names></name>
<name><surname>Almeida</surname><given-names>R</given-names></name>
<name><surname>S&#x000f6;derberg</surname><given-names>O</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours</article-title><source>Mol Oncol</source><year iso-8601-date="2015">2015</year><volume>9</volume><fpage>503</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.10.005</pub-id><!--<pub-id pub-id-type="pmcid">PMC5528651</pub-id>--><?supplied-pmid 25454345?><pub-id pub-id-type="pmid">25454345</pub-id></element-citation></ref><ref id="B120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itzkowitz</surname><given-names>SH</given-names></name>
<name><surname>Kim</surname><given-names>YS</given-names></name>
</person-group><article-title>New carbohydrate tumor markers</article-title><source>Gastroenterology</source><year iso-8601-date="1986">1986</year><volume>90</volume><fpage>491</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(86)90954-6</pub-id><?supplied-pmid 2416629?><pub-id pub-id-type="pmid">2416629</pub-id></element-citation></ref><ref id="B121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duffy</surname><given-names>MJ</given-names></name>
</person-group><article-title>CA 19-9 as a marker for gastrointestinal cancers: a review</article-title><source>Ann Clin Biochem</source><year iso-8601-date="1998">1998</year><volume>35</volume><fpage>364</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1177/000456329803500304</pub-id><?supplied-pmid 9635101?><pub-id pub-id-type="pmid">9635101</pub-id></element-citation></ref><ref id="B122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vestergaard</surname><given-names>EM</given-names></name>
<name><surname>Hein</surname><given-names>HO</given-names></name>
<name><surname>Meyer</surname><given-names>H</given-names></name>
<name><surname>Grunnet</surname><given-names>N</given-names></name>
<name><surname>J&#x000f8;rgensen</surname><given-names>J</given-names></name>
<name><surname>Wolf</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population</article-title><source>Clin Chem</source><year iso-8601-date="1999">1999</year><volume>45</volume><fpage>54</fpage><lpage>61</lpage><?supplied-pmid 9895338?><pub-id pub-id-type="pmid">9895338</pub-id></element-citation></ref><ref id="B123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Munkley</surname><given-names>J</given-names></name>
</person-group><article-title>The glycosylation landscape of pancreatic cancer (review)</article-title><source>Oncol Lett</source><year iso-8601-date="2019">2019</year><volume>17</volume><fpage>2569</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.3892/ol.2019.9885</pub-id><!--<pub-id pub-id-type="pmcid">PMC6388511</pub-id>--><?supplied-pmid 30854032?><pub-id pub-id-type="pmid">30854032</pub-id></element-citation></ref><ref id="B124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yue</surname><given-names>T</given-names></name>
<name><surname>Goldstein</surname><given-names>IJ</given-names></name>
<name><surname>Hollingsworth</surname><given-names>MA</given-names></name>
<name><surname>Kaul</surname><given-names>K</given-names></name>
<name><surname>Brand</surname><given-names>RE</given-names></name>
<name><surname>Haab</surname><given-names>BB</given-names></name>
</person-group><article-title>The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays</article-title><source>Mol Cell Proteomics</source><year iso-8601-date="2009">2009</year><volume>8</volume><fpage>1697</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1074/mcp.M900135-MCP200</pub-id><!--<pub-id pub-id-type="pmcid">PMC2709194</pub-id>--><?supplied-pmid 19377061?><pub-id pub-id-type="pmid">19377061</pub-id></element-citation></ref><ref id="B125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhao</surname><given-names>T</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Tian</surname><given-names>L</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer</article-title><source>World J Surg Oncol</source><year iso-8601-date="2020">2020</year><volume>18</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.1186/s12957-020-1809-z</pub-id><!--<pub-id pub-id-type="pmcid">PMC7006398</pub-id>--><?supplied-pmid 32028958?><pub-id pub-id-type="pmid">32028958</pub-id></element-citation></ref><ref id="B126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parker</surname><given-names>N</given-names></name>
<name><surname>Makin</surname><given-names>CA</given-names></name>
<name><surname>Ching</surname><given-names>CK</given-names></name>
<name><surname>Eccleston</surname><given-names>D</given-names></name>
<name><surname>Taylor</surname><given-names>OM</given-names></name>
<name><surname>Milton</surname><given-names>JD</given-names></name>
<etal>et al.</etal>
</person-group><article-title>A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer</article-title><source>Cancer</source><year iso-8601-date="1992">1992</year><volume>70</volume><fpage>1062</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19920901)70:5&#x0003c;1062::aid-cncr2820700509&#x0003e;3.0.co;2-p</pub-id><?supplied-pmid 1515982?><pub-id pub-id-type="pmid">1515982</pub-id></element-citation></ref><ref id="B127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>R&#x000f6;thlin</surname><given-names>MA</given-names></name>
<name><surname>Joller</surname><given-names>H</given-names></name>
<name><surname>Largiad&#x000e8;r</surname><given-names>F</given-names></name>
</person-group><article-title>CA 242 is a new tumor marker for pancreatic cancer</article-title><source>Cancer</source><year iso-8601-date="1993">1993</year><volume>71</volume><fpage>701</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19930201)71:3&#x0003c;701::aid-cncr2820710308&#x0003e;3.0.co;2-c</pub-id><?supplied-pmid 8431849?><pub-id pub-id-type="pmid">8431849</pub-id></element-citation></ref><ref id="B128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carpelan-Holmstr&#x000f6;m</surname><given-names>M</given-names></name>
<name><surname>Louhimo</surname><given-names>J</given-names></name>
<name><surname>Stenman</surname><given-names>UH</given-names></name>
<name><surname>Alfthan</surname><given-names>H</given-names></name>
<name><surname>Haglund</surname><given-names>C</given-names></name>
</person-group><article-title>CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers</article-title><source>Anticancer Res</source><year iso-8601-date="2002">2002</year><volume>22</volume><fpage>2311</fpage><lpage>6</lpage><?supplied-pmid 12174919?><pub-id pub-id-type="pmid">12174919</pub-id></element-citation></ref><ref id="B129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Tian</surname><given-names>YP</given-names></name>
</person-group><article-title>Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma</article-title><source>Mol Clin Oncol</source><year iso-8601-date="2014">2014</year><volume>2</volume><fpage>265</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3892/mco.2013.226</pub-id><!--<pub-id pub-id-type="pmcid">PMC3917775</pub-id>--><?supplied-pmid 24649344?><pub-id pub-id-type="pmid">24649344</pub-id></element-citation></ref><ref id="B130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>H</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
<name><surname>Partyka</surname><given-names>K</given-names></name>
<name><surname>Kletter</surname><given-names>D</given-names></name>
<name><surname>Hsueh</surname><given-names>P</given-names></name>
<name><surname>Yadav</surname><given-names>J</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A</article-title><source>Mol Cell Proteomics</source><year iso-8601-date="2015">2015</year><volume>14</volume><fpage>1323</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.047837</pub-id><!--<pub-id pub-id-type="pmcid">PMC4424402</pub-id>--><?supplied-pmid 25733690?><pub-id pub-id-type="pmid">25733690</pub-id></element-citation></ref><ref id="B131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tang</surname><given-names>H</given-names></name>
<name><surname>Partyka</surname><given-names>K</given-names></name>
<name><surname>Hsueh</surname><given-names>P</given-names></name>
<name><surname>Sinha</surname><given-names>JY</given-names></name>
<name><surname>Kletter</surname><given-names>D</given-names></name>
<name><surname>Zeh</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9</article-title><source>Cell Mol Gastroenterol Hepatol</source><year iso-8601-date="2016">2016</year><volume>2</volume><fpage>201</fpage><lpage>21.E15</lpage><pub-id pub-id-type="doi">10.1016/j.jcmgh.2015.12.003</pub-id><!--<pub-id pub-id-type="pmcid">PMC4792034</pub-id>--><?supplied-pmid 26998508?><pub-id pub-id-type="pmid">26998508</pub-id></element-citation></ref><ref id="B132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>B</given-names></name>
</person-group><article-title>Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer</article-title><source>Mol Clin Oncol</source><year iso-8601-date="2016">2016</year><volume>4</volume><fpage>441</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3892/mco.2015.712</pub-id><!--<pub-id pub-id-type="pmcid">PMC4774443</pub-id>--><?supplied-pmid 26998301?><pub-id pub-id-type="pmid">26998301</pub-id></element-citation></ref><ref id="B133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marrelli</surname><given-names>D</given-names></name>
<name><surname>Pinto</surname><given-names>E</given-names></name>
<name><surname>De</surname><given-names>Stefano A</given-names></name>
<name><surname>Farnetani</surname><given-names>M</given-names></name>
<name><surname>Garosi</surname><given-names>L</given-names></name>
<name><surname>Roviello</surname><given-names>F</given-names></name>
</person-group><article-title>Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer</article-title><source>Am J Surg</source><year iso-8601-date="2001">2001</year><volume>181</volume><fpage>16</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0002-9610(00)00549-3</pub-id><?supplied-pmid 11248169?><pub-id pub-id-type="pmid">11248169</pub-id></element-citation></ref><ref id="B134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JC</given-names></name>
<name><surname>Lee</surname><given-names>SY</given-names></name>
<name><surname>Kim</surname><given-names>CY</given-names></name>
<name><surname>Yang</surname><given-names>DH</given-names></name>
</person-group><article-title>Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer</article-title><source>J Korean Surg Soc</source><year iso-8601-date="2013">2013</year><volume>85</volume><fpage>283</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4174/jkss.2013.85.6.283</pub-id><!--<pub-id pub-id-type="pmcid">PMC3868680</pub-id>--><?supplied-pmid 24368986?><pub-id pub-id-type="pmid">24368986</pub-id></element-citation></ref><ref id="B135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>J</given-names></name>
<name><surname>Zimmermann</surname><given-names>W</given-names></name>
</person-group><article-title>The carcinoembryonic antigen gene family: structure, expression and evolution</article-title><source>Tumour Biol</source><year iso-8601-date="1988">1988</year><volume>9</volume><fpage>63</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1159/000217547</pub-id><?supplied-pmid 3041547?><pub-id pub-id-type="pmid">3041547</pub-id></element-citation></ref><ref id="B136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hammarstr&#x000f6;m</surname><given-names>S</given-names></name>
</person-group><article-title>The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues</article-title><source>Semin Cancer Biol</source><year iso-8601-date="1999">1999</year><volume>9</volume><fpage>67</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1006/scbi.1998.0119</pub-id><?supplied-pmid 10202129?><pub-id pub-id-type="pmid">10202129</pub-id></element-citation></ref><ref id="B137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Brien</surname><given-names>MJ</given-names></name>
<name><surname>Zamcheck</surname><given-names>N</given-names></name>
<name><surname>Burke</surname><given-names>B</given-names></name>
<name><surname>Kirkham</surname><given-names>SE</given-names></name>
<name><surname>Saravis</surname><given-names>CA</given-names></name>
<name><surname>Gottlieb</surname><given-names>LS</given-names></name>
</person-group><article-title>Immunocytochemical localization of carcinoembryonic antigen in benign and malignant colorectal tissues. Assessment of diagnostic value</article-title><source>Am J Clin Pathol</source><year iso-8601-date="1981">1981</year><volume>75</volume><fpage>283</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1093/ajcp/75.3.283</pub-id><?supplied-pmid 7010989?><pub-id pub-id-type="pmid">7010989</pub-id></element-citation></ref><ref id="B138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fletcher</surname><given-names>RH</given-names></name>
</person-group><article-title>Carcinoembryonic antigen</article-title><source>Ann Intern Med</source><year iso-8601-date="1986">1986</year><volume>104</volume><fpage>66</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-104-1-66</pub-id><?supplied-pmid 3510056?><pub-id pub-id-type="pmid">3510056</pub-id></element-citation></ref><ref id="B139"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexander</surname><given-names>JC</given-names></name>
<name><surname>Silverman</surname><given-names>NA</given-names></name>
<name><surname>Chretien</surname><given-names>PB</given-names></name>
</person-group><article-title>Effect of age and cigarette smoking on carcinoembryonic antigen levels</article-title><source>JAMA</source><year iso-8601-date="1976">1976</year><volume>235</volume><fpage>1975</fpage><lpage>9</lpage><?supplied-pmid 56468?><pub-id pub-id-type="pmid">56468</pub-id></element-citation></ref><ref id="B140"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loewenstein</surname><given-names>MS</given-names></name>
<name><surname>Zamcheck</surname><given-names>N</given-names></name>
</person-group><article-title>Carcinoembryonic antigen (CEA) levels in benign gastrointestinal disease states</article-title><source>Cancer</source><year iso-8601-date="1978">1978</year><volume>42</volume><fpage>1412</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(197809)42:3+&#x0003c;1412::aid-cncr2820420805&#x0003e;3.0.co;2-8</pub-id><?supplied-pmid 361200?><pub-id pub-id-type="pmid">361200</pub-id></element-citation></ref><ref id="B141"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hao</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>G</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
</person-group><article-title>Serum CEA levels in 49 different types of cancer and noncancer diseases</article-title><source>Prog Mol Biol Transl Sci</source><year iso-8601-date="2019">2019</year><volume>162</volume><fpage>213</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2018.12.011</pub-id><?supplied-pmid 30905451?><pub-id pub-id-type="pmid">30905451</pub-id></element-citation></ref><ref id="B142"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Tian</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Du</surname><given-names>L</given-names></name>
<name><surname>Sun</surname><given-names>T</given-names></name>
<etal>et al.</etal>
</person-group><article-title>The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer</article-title><source>Clin Chim Acta</source><year iso-8601-date="2017">2017</year><volume>470</volume><fpage>51</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2017.04.023</pub-id><?supplied-pmid 28457854?><pub-id pub-id-type="pmid">28457854</pub-id></element-citation></ref><ref id="B143"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deng</surname><given-names>K</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Hu</surname><given-names>B</given-names></name>
<name><surname>Wu</surname><given-names>H</given-names></name>
<name><surname>Zhu</surname><given-names>H</given-names></name>
<name><surname>Tang</surname><given-names>C</given-names></name>
</person-group><article-title>The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients</article-title><source>PLoS One</source><year iso-8601-date="2015">2015</year><volume>10</volume><elocation-id>e0124151</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0124151</pub-id><!--<pub-id pub-id-type="pmcid">PMC4400039</pub-id>--><?supplied-pmid 25879931?><pub-id pub-id-type="pmid">25879931</pub-id></element-citation></ref><ref id="B144"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>L</given-names></name>
<name><surname>Huang</surname><given-names>P</given-names></name>
<name><surname>Wang</surname><given-names>F</given-names></name>
<name><surname>Li</surname><given-names>D</given-names></name>
<name><surname>Xie</surname><given-names>E</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer</article-title><source>Ann Transl Med</source><year iso-8601-date="2015">2015</year><volume>3</volume><elocation-id>328</elocation-id><pub-id pub-id-type="doi">10.3978/j.issn.2305-5839.2015.11.17</pub-id><!--<pub-id pub-id-type="pmcid">PMC4690989</pub-id>--><?supplied-pmid 26734638?><pub-id pub-id-type="pmid">26734638</pub-id></element-citation></ref><ref id="B145"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ye</surname><given-names>YL</given-names></name>
<name><surname>Bian</surname><given-names>J</given-names></name>
<name><surname>Huang</surname><given-names>YP</given-names></name>
<name><surname>Guo</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>ZX</given-names></name>
<name><surname>Deng</surname><given-names>CH</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Primary mucinous adenocarcinoma of the renal pelvis with elevated CEA and CA19-9</article-title><source>Urol Int</source><year iso-8601-date="2011">2011</year><volume>87</volume><fpage>484</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1159/000329767</pub-id><?supplied-pmid 21893942?><pub-id pub-id-type="pmid">21893942</pub-id></element-citation></ref><ref id="B146"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shintani</surname><given-names>T</given-names></name>
<name><surname>Matsuo</surname><given-names>Y</given-names></name>
<name><surname>Iizuka</surname><given-names>Y</given-names></name>
<name><surname>Mitsuyoshi</surname><given-names>T</given-names></name>
<name><surname>Mizowaki</surname><given-names>T</given-names></name>
<name><surname>Hiraoka</surname><given-names>M</given-names></name>
</person-group><article-title>Prognostic significance of serum CEA for non-small cell lung cancer patients receiving stereotactic body radiotherapy</article-title><source>Anticancer Res</source><year iso-8601-date="2017">2017</year><volume>37</volume><fpage>5161</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11937</pub-id><?supplied-pmid 28870949?><pub-id pub-id-type="pmid">28870949</pub-id></element-citation></ref><ref id="B147"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Screaton</surname><given-names>RA</given-names></name>
<name><surname>Penn</surname><given-names>LZ</given-names></name>
<name><surname>Stanners</surname><given-names>CP</given-names></name>
</person-group><article-title>Carcinoembryonic antigen, a human tumor marker, cooperates with Myc and Bcl-2 in cellular transformation</article-title><source>J Cell Biol</source><year iso-8601-date="1997">1997</year><volume>137</volume><fpage>939</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1083/jcb.137.4.939</pub-id><!--<pub-id pub-id-type="pmcid">PMC2139844</pub-id>--><?supplied-pmid 9151695?><pub-id pub-id-type="pmid">9151695</pub-id></element-citation></ref><ref id="B148"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hostetter</surname><given-names>RB</given-names></name>
<name><surname>Augustus</surname><given-names>LB</given-names></name>
<name><surname>Mankarious</surname><given-names>R</given-names></name>
<name><surname>Chi</surname><given-names>KF</given-names></name>
<name><surname>Fan</surname><given-names>D</given-names></name>
<name><surname>Toth</surname><given-names>C</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis</article-title><source>J Natl Cancer Inst</source><year iso-8601-date="1990">1990</year><volume>82</volume><fpage>380</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1093/jnci/82.5.380</pub-id><?supplied-pmid 2304087?><pub-id pub-id-type="pmid">2304087</pub-id></element-citation></ref><ref id="B149"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabuchi</surname><given-names>Y</given-names></name>
<name><surname>Deguchi</surname><given-names>H</given-names></name>
<name><surname>Imanishi</surname><given-names>K</given-names></name>
<name><surname>Saitoh</surname><given-names>Y</given-names></name>
</person-group><article-title>Comparison of carcinoembryonic antigen levels between portal and peripheral blood in patients with colorectal cancer. Correlation with histopathologic variables</article-title><source>Cancer</source><year iso-8601-date="1987">1987</year><volume>59</volume><fpage>1283</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19870401)59:7&#x0003c;1283::aid-cncr2820590709&#x0003e;3.0.co;2-g</pub-id><?supplied-pmid 3815304?><pub-id pub-id-type="pmid">3815304</pub-id></element-citation></ref><ref id="B150"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>P</given-names></name>
<name><surname>Toth</surname><given-names>CA</given-names></name>
<name><surname>Saini</surname><given-names>KS</given-names></name>
<name><surname>Jessup</surname><given-names>JM</given-names></name>
<name><surname>Steele</surname><given-names>G Jr</given-names></name>
</person-group><article-title>The structure, metabolism and function of the carcinoembryonic antigen gene family</article-title><source>Biochim Biophys Acta Rev Cancer</source><year iso-8601-date="1990">1990</year><volume>1032</volume><fpage>177</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/0304-419x(90)90003-j</pub-id><?supplied-pmid 2261493?><pub-id pub-id-type="pmid">2261493</pub-id></element-citation></ref><ref id="B151"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duffy</surname><given-names>MJ</given-names></name>
</person-group><article-title>Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?</article-title><source>Clin Chem</source><year iso-8601-date="2001">2001</year><volume>47</volume><fpage>624</fpage><lpage>30</lpage><?supplied-pmid 11274010?><pub-id pub-id-type="pmid">11274010</pub-id></element-citation></ref><ref id="B152"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balk</surname><given-names>SP</given-names></name>
<name><surname>Ko</surname><given-names>YJ</given-names></name>
<name><surname>Bubley</surname><given-names>GJ</given-names></name>
</person-group><article-title>Biology of prostate-specific antigen</article-title><source>J Clin Oncol</source><year iso-8601-date="2003">2003</year><volume>21</volume><fpage>383</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.02.083</pub-id><?supplied-pmid 12525533?><pub-id pub-id-type="pmid">12525533</pub-id></element-citation></ref><ref id="B153"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Roehrborn</surname><given-names>CG</given-names></name>
<name><surname>Boyle</surname><given-names>P</given-names></name>
<name><surname>Gould</surname><given-names>AL</given-names></name>
<name><surname>Waldstreicher</surname><given-names>J</given-names></name>
</person-group><article-title>Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia</article-title><source>Urology</source><year iso-8601-date="1999">1999</year><volume>53</volume><fpage>581</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/s0090-4295(98)00655-4</pub-id><?supplied-pmid 10096388?><pub-id pub-id-type="pmid">10096388</pub-id></element-citation></ref><ref id="B154"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liotta</surname><given-names>RF</given-names></name>
<name><surname>Tarantino</surname><given-names>ML</given-names></name>
<name><surname>Melloni</surname><given-names>D</given-names></name>
</person-group><article-title>Chronic prostatitis and PSA values</article-title><source>Urologia J</source><year iso-8601-date="2008">2008</year><volume>75</volume><fpage>102</fpage><lpage>4. Italian</lpage><?supplied-pmid 21086359?><pub-id pub-id-type="pmid">21086359</pub-id></element-citation></ref><ref id="B155"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lojanapiwat</surname><given-names>B</given-names></name>
<name><surname>Anutrakulchai</surname><given-names>W</given-names></name>
<name><surname>Chongruksut</surname><given-names>W</given-names></name>
<name><surname>Udomphot</surname><given-names>C</given-names></name>
</person-group><article-title>Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice</article-title><source>Prostate Int</source><year iso-8601-date="2014">2014</year><volume>2</volume><fpage>133</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.12954/PI.14054</pub-id><!--<pub-id pub-id-type="pmcid">PMC4186957</pub-id>--><?supplied-pmid 25325025?><pub-id pub-id-type="pmid">25325025</pub-id></element-citation></ref><ref id="B156"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lilja</surname><given-names>H</given-names></name>
<name><surname>Ulmert</surname><given-names>D</given-names></name>
<name><surname>Vickers</surname><given-names>AJ</given-names></name>
</person-group><article-title>Prostate-specific antigen and prostate cancer: prediction, detection and monitoring</article-title><source>Nat Rev Cancer</source><year iso-8601-date="2008">2008</year><volume>8</volume><fpage>268</fpage><lpage>78</lpage><comment>Erratum in: Nat Rev Cancer. 2008;8:403.</comment><pub-id pub-id-type="doi">10.1038/nrc2351</pub-id><?supplied-pmid 18337732?><pub-id pub-id-type="pmid">18337732</pub-id></element-citation></ref><ref id="B157"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holmstr&#x000f6;m</surname><given-names>B</given-names></name>
<name><surname>Johansson</surname><given-names>M</given-names></name>
<name><surname>Bergh</surname><given-names>A</given-names></name>
<name><surname>Stenman</surname><given-names>UH</given-names></name>
<name><surname>Hallmans</surname><given-names>G</given-names></name>
<name><surname>Stattin</surname><given-names>P</given-names></name>
</person-group><article-title>Prostate specific antigen for early detection of prostate cancer: longitudinal study</article-title><source>BMJ</source><year iso-8601-date="2009">2009</year><volume>339</volume><elocation-id>b3537</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.b3537</pub-id><!--<pub-id pub-id-type="pmcid">PMC2751815</pub-id>--><?supplied-pmid 19778969?><pub-id pub-id-type="pmid">19778969</pub-id></element-citation></ref><ref id="B158"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ankerst</surname><given-names>DP</given-names></name>
<name><surname>Thompson</surname><given-names>IM</given-names></name>
</person-group><article-title>Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification</article-title><source>Arch Ital Urol Androl</source><year iso-8601-date="2006">2006</year><volume>78</volume><fpage>125</fpage><lpage>9</lpage><?supplied-pmid 17269614?><pub-id pub-id-type="pmid">17269614</pub-id></element-citation></ref><ref id="B159"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Merriel</surname><given-names>SWD</given-names></name>
<name><surname>Pocock</surname><given-names>L</given-names></name>
<name><surname>Gilbert</surname><given-names>E</given-names></name>
<name><surname>Creavin</surname><given-names>S</given-names></name>
<name><surname>Walter</surname><given-names>FM</given-names></name>
<name><surname>Spencer</surname><given-names>A</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients</article-title><source>BMC Med</source><year iso-8601-date="2022">2022</year><volume>20</volume><elocation-id>54</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-021-02230-y</pub-id><!--<pub-id pub-id-type="pmcid">PMC8819971</pub-id>--><?supplied-pmid 35125113?><pub-id pub-id-type="pmid">35125113</pub-id></element-citation></ref><ref id="B160"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thompson</surname><given-names>IM</given-names></name>
<name><surname>Ankerst</surname><given-names>DP</given-names></name>
<name><surname>Chi</surname><given-names>C</given-names></name>
<name><surname>Lucia</surname><given-names>MS</given-names></name>
<name><surname>Goodman</surname><given-names>PJ</given-names></name>
<name><surname>Crowley</surname><given-names>JJ</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower</article-title><source>JAMA</source><year iso-8601-date="2005">2005</year><volume>294</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1001/jama.294.1.66</pub-id><?supplied-pmid 15998892?><pub-id pub-id-type="pmid">15998892</pub-id></element-citation></ref><ref id="B161"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carter</surname><given-names>HB</given-names></name>
</person-group><article-title>Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics</article-title><source>Asian J Androl</source><year iso-8601-date="2012">2012</year><volume>14</volume><fpage>355</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1038/aja.2011.141</pub-id><!--<pub-id pub-id-type="pmcid">PMC3720162</pub-id>--><?supplied-pmid 22343493?><pub-id pub-id-type="pmid">22343493</pub-id></element-citation></ref><ref id="B162"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vickers</surname><given-names>AJ</given-names></name>
<name><surname>Sjoberg</surname><given-names>DD</given-names></name>
<name><surname>Ulmert</surname><given-names>D</given-names></name>
<name><surname>Vertosick</surname><given-names>E</given-names></name>
<name><surname>Roobol</surname><given-names>MJ</given-names></name>
<name><surname>Thompson</surname><given-names>I</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen</article-title><source>BMC Med</source><year iso-8601-date="2014">2014</year><volume>12</volume><elocation-id>26</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7015-12-26</pub-id><!--<pub-id pub-id-type="pmcid">PMC3922189</pub-id>--><?supplied-pmid 24512643?><pub-id pub-id-type="pmid">24512643</pub-id></element-citation></ref><ref id="B163"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weber</surname><given-names>BA</given-names></name>
<name><surname>Roberts</surname><given-names>BL</given-names></name>
<name><surname>Chumbler</surname><given-names>NR</given-names></name>
<name><surname>Mills</surname><given-names>TL</given-names></name>
<name><surname>Algood</surname><given-names>CB</given-names></name>
</person-group><article-title>Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy</article-title><source>Urol Nurs</source><year iso-8601-date="2007">2007</year><volume>27</volume><fpage>527</fpage><lpage>33</lpage><?supplied-pmid 18217536?><pub-id pub-id-type="pmid">18217536</pub-id></element-citation></ref><ref id="B164"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Catalona</surname><given-names>WJ</given-names></name>
<name><surname>Partin</surname><given-names>AW</given-names></name>
<name><surname>Slawin</surname><given-names>KM</given-names></name>
<name><surname>Brawer</surname><given-names>MK</given-names></name>
<name><surname>Flanigan</surname><given-names>RC</given-names></name>
<name><surname>Patel</surname><given-names>A</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial</article-title><source>JAMA</source><year iso-8601-date="1998">1998</year><volume>279</volume><fpage>1542</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1001/jama.279.19.1542</pub-id><?supplied-pmid 9605898?><pub-id pub-id-type="pmid">9605898</pub-id></element-citation></ref><ref id="B165"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>BV</given-names></name>
<name><surname>Griffin</surname><given-names>CR</given-names></name>
<name><surname>Loeb</surname><given-names>S</given-names></name>
<name><surname>Carvalhal</surname><given-names>GF</given-names></name>
<name><surname>Kan</surname><given-names>D</given-names></name>
<name><surname>Baumann</surname><given-names>NA</given-names></name>
<etal>et al.</etal>
</person-group><article-title>[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study</article-title><source>J Urol</source><year iso-8601-date="2010">2010</year><volume>183</volume><fpage>1355</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.juro.2009.12.056</pub-id><!--<pub-id pub-id-type="pmcid">PMC3537165</pub-id>--><?supplied-pmid 20171670?><pub-id pub-id-type="pmid">20171670</pub-id></element-citation></ref><ref id="B166"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gnanapragasam</surname><given-names>VJ</given-names></name>
<name><surname>Burling</surname><given-names>K</given-names></name>
<name><surname>George</surname><given-names>A</given-names></name>
<name><surname>Stearn</surname><given-names>S</given-names></name>
<name><surname>Warren</surname><given-names>A</given-names></name>
<name><surname>Barrett</surname><given-names>T</given-names></name>
<etal>et al.</etal>
</person-group><article-title>The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population</article-title><source>Sci Rep</source><year iso-8601-date="2016">2016</year><volume>6</volume><elocation-id>35364</elocation-id><pub-id pub-id-type="doi">10.1038/srep35364</pub-id><!--<pub-id pub-id-type="pmcid">PMC5066204</pub-id>--><?supplied-pmid 27748407?><pub-id pub-id-type="pmid">27748407</pub-id></element-citation></ref><ref id="B167"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Escudero</surname><given-names>JJ</given-names></name>
<name><surname>Duran-Rivera</surname><given-names>A</given-names></name>
<name><surname>Escudero</surname><given-names>E</given-names></name>
<name><surname>Montoro</surname><given-names>A</given-names></name>
<name><surname>del Toro</surname><given-names>MF</given-names></name>
<name><surname>de Campos</surname><given-names>MR</given-names></name>
<etal>et al.</etal>
</person-group><article-title>-2ProPSA and Prostate Health Index usefulness for the diagnosis of prostate cancer for PSA range between 3 and 10 ng/ml</article-title><source>Int Arch Urol Complic</source><year iso-8601-date="2018">2018</year><volume>4</volume><elocation-id>041</elocation-id><pub-id pub-id-type="doi">10.23937/2469-5742/1510041</pub-id></element-citation></ref><ref id="B168"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoffman</surname><given-names>RM</given-names></name>
<name><surname>Clanon</surname><given-names>DL</given-names></name>
<name><surname>Littenberg</surname><given-names>B</given-names></name>
<name><surname>Frank</surname><given-names>JJ</given-names></name>
<name><surname>Peirce</surname><given-names>JC</given-names></name>
</person-group><article-title>Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levels</article-title><source>J Gen Intern Med</source><year iso-8601-date="2000">2000</year><volume>15</volume><fpage>739</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1497.2000.90907.x</pub-id><!--<pub-id pub-id-type="pmcid">PMC1495603</pub-id>--><?supplied-pmid 11089718?><pub-id pub-id-type="pmid">11089718</pub-id></element-citation></ref><ref id="B169"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vickers</surname><given-names>AJ</given-names></name>
<name><surname>Brewster</surname><given-names>SF</given-names></name>
</person-group><article-title>PSA velocity and doubling time in diagnosis and prognosis of prostate cancer</article-title><source>Br J Med Surg Urol</source><year iso-8601-date="2012">2012</year><volume>5</volume><fpage>162</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.bjmsu.2011.08.006</pub-id><!--<pub-id pub-id-type="pmcid">PMC3375697</pub-id>--><?supplied-pmid 22712027?><pub-id pub-id-type="pmid">22712027</pub-id></element-citation></ref><ref id="B170"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyselova</surname><given-names>Z</given-names></name>
<name><surname>Mechref</surname><given-names>Y</given-names></name>
<name><surname>Al</surname><given-names>Bataineh MM</given-names></name>
<name><surname>Dobrolecki</surname><given-names>LE</given-names></name>
<name><surname>Hickey</surname><given-names>RJ</given-names></name>
<name><surname>Vinson</surname><given-names>J</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Alterations in the serum glycome due to metastatic prostate cancer</article-title><source>J Proteome Res</source><year iso-8601-date="2007">2007</year><volume>6</volume><fpage>1822</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1021/pr060664t</pub-id><!--<pub-id pub-id-type="pmcid">PMC3685170</pub-id>--><?supplied-pmid 17432893?><pub-id pub-id-type="pmid">17432893</pub-id></element-citation></ref><ref id="B171"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meany</surname><given-names>DL</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Sokoll</surname><given-names>LJ</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Chan</surname><given-names>DW</given-names></name>
</person-group><article-title>Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns</article-title><source>J Proteome Res</source><year iso-8601-date="2009">2009</year><volume>8</volume><fpage>613</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1021/pr8007539</pub-id><!--<pub-id pub-id-type="pmcid">PMC2997339</pub-id>--><?supplied-pmid 19035787?><pub-id pub-id-type="pmid">19035787</pub-id></element-citation></ref><ref id="B172"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dwek</surname><given-names>MV</given-names></name>
<name><surname>Jenks</surname><given-names>A</given-names></name>
<name><surname>Leathem</surname><given-names>AJ</given-names></name>
</person-group><article-title>A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia</article-title><source>Clin Chim Acta</source><year iso-8601-date="2010">2010</year><volume>411</volume><fpage>1935</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2010.08.009</pub-id><?supplied-pmid 20708609?><pub-id pub-id-type="pmid">20708609</pub-id></element-citation></ref><ref id="B173"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saldova</surname><given-names>R</given-names></name>
<name><surname>Fan</surname><given-names>Y</given-names></name>
<name><surname>Fitzpatrick</surname><given-names>JM</given-names></name>
<name><surname>Watson</surname><given-names>RW</given-names></name>
<name><surname>Rudd</surname><given-names>PM</given-names></name>
</person-group><article-title>Core fucosylation and &#x003b1;2-3 sialylation in serum <italic toggle="yes">N</italic>-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia</article-title><source>Glycobiology</source><year iso-8601-date="2011">2011</year><volume>21</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1093/glycob/cwq147</pub-id><?supplied-pmid 20861084?><pub-id pub-id-type="pmid">20861084</pub-id></element-citation></ref><ref id="B174"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaya</surname><given-names>T</given-names></name>
<name><surname>Kaneko</surname><given-names>T</given-names></name>
<name><surname>Kojima</surname><given-names>S</given-names></name>
<name><surname>Nakamura</surname><given-names>Y</given-names></name>
<name><surname>Ide</surname><given-names>Y</given-names></name>
<name><surname>Ishida</surname><given-names>K</given-names></name>
<etal>et al.</etal>
</person-group><article-title>High-sensitivity immunoassay with surface plasmon field-enhanced fluorescence spectroscopy using a plastic sensor chip: application to quantitative analysis of total prostate-specific antigen and GalNAc&#x003b2;1-4GlcNAc-linked prostate-specific antigen for prostate cancer diagnosis</article-title><source>Anal Chem</source><year iso-8601-date="2015">2015</year><volume>87</volume><fpage>1797</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1021/ac503735e</pub-id><?supplied-pmid 25546230?><pub-id pub-id-type="pmid">25546230</pub-id></element-citation></ref><ref id="B175"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yoneyama</surname><given-names>T</given-names></name>
<name><surname>Ohyama</surname><given-names>C</given-names></name>
<name><surname>Hatakeyama</surname><given-names>S</given-names></name>
<name><surname>Narita</surname><given-names>S</given-names></name>
<name><surname>Habuchi</surname><given-names>T</given-names></name>
<name><surname>Koie</surname><given-names>T</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer</article-title><source>Biochem Biophys Res Commun</source><year iso-8601-date="2014">2014</year><volume>448</volume><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2014.04.107</pub-id><?supplied-pmid 24814705?><pub-id pub-id-type="pmid">24814705</pub-id></element-citation></ref><ref id="B176"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>QK</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Ao</surname><given-names>MH</given-names></name>
<name><surname>Chiu</surname><given-names>JH</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers</article-title><source>Theranostics</source><year iso-8601-date="2015">2015</year><volume>5</volume><fpage>267</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.7150/thno.10349</pub-id><!--<pub-id pub-id-type="pmcid">PMC4279190</pub-id>--><?supplied-pmid 25553114?><pub-id pub-id-type="pmid">25553114</pub-id></element-citation></ref><ref id="B177"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Llop</surname><given-names>E</given-names></name>
<name><surname>Ferrer-Batall&#x000e9;</surname><given-names>M</given-names></name>
<name><surname>Barrab&#x000e9;s</surname><given-names>S</given-names></name>
<name><surname>Guerrero</surname><given-names>PE</given-names></name>
<name><surname>Ram&#x000ed;rez</surname><given-names>M</given-names></name>
<name><surname>Saldova</surname><given-names>R</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Improvement of prostate cancer diagnosis by detecting PSA glycosylation-specific changes</article-title><source>Theranostics</source><year iso-8601-date="2016">2016</year><volume>6</volume><fpage>1190</fpage><lpage>204</lpage><comment>Erratum in: Theranostics. 2018;8:746&#x02013;8.</comment><pub-id pub-id-type="doi">10.7150/thno.15226</pub-id><!--<pub-id pub-id-type="pmcid">PMC4893645</pub-id>--><?supplied-pmid 27279911?><pub-id pub-id-type="pmid">27279911</pub-id></element-citation></ref><ref id="B178"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishikawa</surname><given-names>T</given-names></name>
<name><surname>Yoneyama</surname><given-names>T</given-names></name>
<name><surname>Tobisawa</surname><given-names>Y</given-names></name>
<name><surname>Hatakeyama</surname><given-names>S</given-names></name>
<name><surname>Kurosawa</surname><given-names>T</given-names></name>
<name><surname>Nakamura</surname><given-names>K</given-names></name>
<etal>et al.</etal>
</person-group><article-title>An automated micro-total immunoassay system for measuring cancer-associated &#x003b1;2,3-linked sialyl <italic toggle="yes">N</italic>-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis</article-title><source>Int J Mol Sci</source><year iso-8601-date="2017">2017</year><volume>18</volume><elocation-id>470</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18020470</pub-id><!--<pub-id pub-id-type="pmcid">PMC5344002</pub-id>--><?supplied-pmid 28241428?><pub-id pub-id-type="pmid">28241428</pub-id></element-citation></ref><ref id="B179"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>H&#x000f6;ti</surname><given-names>N</given-names></name>
<name><surname>Lih</surname><given-names>TM</given-names></name>
<name><surname>Sokoll</surname><given-names>LJ</given-names></name>
<name><surname>Zhang</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Development of a glycoproteomic strategy to detect more aggressive prostate cancer using lectin-immunoassays for serum fucosylated PSA</article-title><source>Clin Proteomics</source><year iso-8601-date="2019">2019</year><volume>16</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/s12014-019-9234-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC6451306</pub-id>--><?supplied-pmid 30996714?><pub-id pub-id-type="pmid">30996714</pub-id></element-citation></ref><ref id="B180"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tkac</surname><given-names>J</given-names></name>
<name><surname>Gajdosova</surname><given-names>V</given-names></name>
<name><surname>Hroncekova</surname><given-names>S</given-names></name>
<name><surname>Bertok</surname><given-names>T</given-names></name>
<name><surname>Hires</surname><given-names>M</given-names></name>
<name><surname>Jane</surname><given-names>E</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Prostate-specific antigen glycoprofiling as diagnostic and prognostic biomarker of prostate cancer</article-title><source>Interface Focus</source><year iso-8601-date="2019">2019</year><volume>9</volume><elocation-id>20180077</elocation-id><pub-id pub-id-type="doi">10.1098/rsfs.2018.0077</pub-id><!--<pub-id pub-id-type="pmcid">PMC6388024</pub-id>--><?supplied-pmid 30842876?><pub-id pub-id-type="pmid">30842876</pub-id></element-citation></ref><ref id="B181"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Citterio</surname><given-names>CE</given-names></name>
<name><surname>Targovnik</surname><given-names>HM</given-names></name>
<name><surname>Arvan</surname><given-names>P</given-names></name>
</person-group><article-title>The role of thyroglobulin in thyroid hormonogenesis</article-title><source>Nat Rev Endocrinol</source><year iso-8601-date="2019">2019</year><volume>15</volume><fpage>323</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1038/s41574-019-0184-8</pub-id><?supplied-pmid 30886364?><pub-id pub-id-type="pmid">30886364</pub-id></element-citation></ref><ref id="B182"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>SX</given-names></name>
<name><surname>Pollock</surname><given-names>HG</given-names></name>
<name><surname>Rawitch</surname><given-names>AB</given-names></name>
</person-group><article-title>Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin</article-title><source>Arch Biochem Biophys</source><year iso-8601-date="1996">1996</year><volume>327</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1006/abbi.1996.0093</pub-id><?supplied-pmid 8615697?><pub-id pub-id-type="pmid">8615697</pub-id></element-citation></ref><ref id="B183"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spiro</surname><given-names>RG</given-names></name>
</person-group><article-title>The carbohydrate units of thyroglobulin</article-title><source>J Biol Chem</source><year iso-8601-date="1965">1965</year><volume>240</volume><fpage>1603</fpage><lpage>10</lpage><?supplied-pmid 14285497?><pub-id pub-id-type="pmid">14285497</pub-id></element-citation></ref><ref id="B184"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Tsuji</surname><given-names>T</given-names></name>
<name><surname>Irimura</surname><given-names>T</given-names></name>
<name><surname>Osawa</surname><given-names>T</given-names></name>
</person-group><article-title>The structure of carbohydrate unit B of porcine thyroglobulin</article-title><source>Biochem J</source><year iso-8601-date="1981">1981</year><volume>195</volume><fpage>701</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1042/bj1950701</pub-id><!--<pub-id pub-id-type="pmcid">PMC1162943</pub-id>--><?supplied-pmid 7316980?><pub-id pub-id-type="pmid">7316980</pub-id></element-citation></ref><ref id="B185"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ronin</surname><given-names>C</given-names></name>
<name><surname>Fenouillet</surname><given-names>E</given-names></name>
<name><surname>Hovsepian</surname><given-names>S</given-names></name>
<name><surname>Fayet</surname><given-names>G</given-names></name>
<name><surname>Fournet</surname><given-names>B</given-names></name>
</person-group><article-title>Regulation of thyroglobulin glycosylation. A comparative study of the thyroglobulins from porcine thyroid glands and follicles in serum-free culture</article-title><source>J Biol Chem</source><year iso-8601-date="1986">1986</year><volume>261</volume><fpage>7287</fpage><lpage>93</lpage><?supplied-pmid 2423517?><pub-id pub-id-type="pmid">2423517</pub-id></element-citation></ref><ref id="B186"><label>186</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xavier</surname><given-names>AC</given-names></name>
<name><surname>Maciel</surname><given-names>RM</given-names></name>
<name><surname>Vieira</surname><given-names>JG</given-names></name>
<name><surname>Dias-da-Silva</surname><given-names>MR</given-names></name>
<name><surname>Martins</surname><given-names>JR</given-names></name>
</person-group><article-title>Insights into the posttranslational structural heterogeneity of thyroglobulin and its role in the development, diagnosis, and management of benign and malignant thyroid diseases</article-title><source>Arch Endocrinol Metab</source><year iso-8601-date="2016">2016</year><volume>60</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1590/2359-3997000000103</pub-id><!--<pub-id pub-id-type="pmcid">PMC10118920</pub-id>--><?supplied-pmid 26909485?><pub-id pub-id-type="pmid">26909485</pub-id></element-citation></ref><ref id="B187"><label>187</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mallet</surname><given-names>B</given-names></name>
<name><surname>Lejeune</surname><given-names>PJ</given-names></name>
<name><surname>Baudry</surname><given-names>N</given-names></name>
<name><surname>Niccoli</surname><given-names>P</given-names></name>
<name><surname>Carayon</surname><given-names>P</given-names></name>
<name><surname>Franc</surname><given-names>JL</given-names></name>
</person-group><article-title>
<italic toggle="yes">N</italic>-glycans modulate <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> thyroid hormone synthesis. Study at the N-terminal domain of thyroglobulin</article-title><source>J Biol Chem</source><year iso-8601-date="1995">1995</year><volume>270</volume><fpage>29881</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.50.29881</pub-id><?supplied-pmid 8530385?><pub-id pub-id-type="pmid">8530385</pub-id></element-citation></ref><ref id="B188"><label>188</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Persani</surname><given-names>L</given-names></name>
<name><surname>Borgato</surname><given-names>S</given-names></name>
<name><surname>Romoli</surname><given-names>R</given-names></name>
<name><surname>Asteria</surname><given-names>C</given-names></name>
<name><surname>Pizzocaro</surname><given-names>A</given-names></name>
<name><surname>Beck-Peccoz</surname><given-names>P</given-names></name>
</person-group><article-title>Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states</article-title><source>J Clin Endocrinol Metab</source><year iso-8601-date="1998">1998</year><volume>83</volume><fpage>2486</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1210/jcem.83.7.4970</pub-id><?supplied-pmid 9661632?><pub-id pub-id-type="pmid">9661632</pub-id></element-citation></ref><ref id="B189"><label>189</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fenouillet</surname><given-names>E</given-names></name>
<name><surname>Fayet</surname><given-names>G</given-names></name>
<name><surname>Hovsepian</surname><given-names>S</given-names></name>
<name><surname>Bahraoui</surname><given-names>EM</given-names></name>
<name><surname>Ronin</surname><given-names>C</given-names></name>
</person-group><article-title>Immunochemical evidence for a role of complex carbohydrate chains in thyroglobulin antigenicity</article-title><source>J Biol Chem</source><year iso-8601-date="1986">1986</year><volume>261</volume><fpage>15153</fpage><lpage>8</lpage><?supplied-pmid 2429965?><pub-id pub-id-type="pmid">2429965</pub-id></element-citation></ref><ref id="B190"><label>190</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salab&#x000e8;</surname><given-names>H</given-names></name>
<name><surname>Dominici</surname><given-names>R</given-names></name>
<name><surname>Salab&#x000e8;</surname><given-names>GB</given-names></name>
</person-group><article-title>Immunological properties of Tg carbohydrates: enhancement of Tg immunoreaction by removal of sialic acid</article-title><source>Clin Exp Immunol</source><year iso-8601-date="1976">1976</year><volume>25</volume><fpage>234</fpage><lpage>43</lpage><!--<pub-id pub-id-type="pmcid">PMC1541358</pub-id>--><?supplied-pmid 60186?><pub-id pub-id-type="pmid">60186</pub-id></element-citation></ref><ref id="B191"><label>191</label><element-citation publication-type="journal"><person-group person-group-type="author">
<collab>American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer</collab>
</person-group><article-title>Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer</article-title><source>Thyroid</source><year iso-8601-date="2009">2009</year><volume>19</volume><fpage>1167</fpage><lpage>214</lpage><comment>Erratum in: Thyroid. 2010;20:942. Erratum in: Thyroid. 2010;20:674&#x02013;5.</comment><pub-id pub-id-type="doi">10.1089/thy.2009.0110</pub-id><?supplied-pmid 19860577?><pub-id pub-id-type="pmid">19860577</pub-id></element-citation></ref><ref id="B192"><label>192</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Van</surname><given-names>Herle AJ</given-names></name>
<name><surname>Uller</surname><given-names>RP</given-names></name>
<name><surname>Matthews</surname><given-names>NI</given-names></name>
<name><surname>Brown</surname><given-names>J</given-names></name>
</person-group><article-title>Radioimmunoassay for measurement of thyroglobulin in human serum</article-title><source>J Clin Invest</source><year iso-8601-date="1973">1973</year><volume>52</volume><fpage>1320</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1172/JCI107303</pub-id><!--<pub-id pub-id-type="pmcid">PMC302394</pub-id>--><?supplied-pmid 4739914?><pub-id pub-id-type="pmid">4739914</pub-id></element-citation></ref><ref id="B193"><label>193</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spencer</surname><given-names>C</given-names></name>
<name><surname>LoPresti</surname><given-names>J</given-names></name>
<name><surname>Fatemi</surname><given-names>S</given-names></name>
</person-group><article-title>How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies</article-title><source>Curr Opin Endocrinol Diabetes Obes</source><year iso-8601-date="2014">2014</year><volume>21</volume><fpage>394</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1097/MED.0000000000000092</pub-id><!--<pub-id pub-id-type="pmcid">PMC4154792</pub-id>--><?supplied-pmid 25122493?><pub-id pub-id-type="pmid">25122493</pub-id></element-citation></ref><ref id="B194"><label>194</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iervasi</surname><given-names>A</given-names></name>
<name><surname>Iervasi</surname><given-names>G</given-names></name>
<name><surname>Carpi</surname><given-names>A</given-names></name>
<name><surname>Zucchelli</surname><given-names>GC</given-names></name>
</person-group><article-title>Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact</article-title><source>Biomed Pharmacother</source><year iso-8601-date="2006">2006</year><volume>60</volume><fpage>414</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2006.07.007</pub-id><?supplied-pmid 16959467?><pub-id pub-id-type="pmid">16959467</pub-id></element-citation></ref><ref id="B195"><label>195</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spencer</surname><given-names>C</given-names></name>
<name><surname>Petrovic</surname><given-names>I</given-names></name>
<name><surname>Fatemi</surname><given-names>S</given-names></name>
</person-group><article-title>Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/undetectable serum Tg IMA values for patients with differentiated thyroid cancer</article-title><source>J Clin Endocrinol Metab</source><year iso-8601-date="2011">2011</year><volume>96</volume><fpage>1283</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1210/jc.2010-2762</pub-id><?supplied-pmid 21325460?><pub-id pub-id-type="pmid">21325460</pub-id></element-citation></ref><ref id="B196"><label>196</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schulz</surname><given-names>R</given-names></name>
<name><surname>Beth&#x000e4;user</surname><given-names>H</given-names></name>
<name><surname>Stempka</surname><given-names>L</given-names></name>
<name><surname>Heilig</surname><given-names>B</given-names></name>
<name><surname>Moll</surname><given-names>A</given-names></name>
<name><surname>H&#x000fc;fner</surname><given-names>M</given-names></name>
</person-group><article-title>Evidence for immunological differences between circulating and thyroid tissue-derived thyroglobulin in men</article-title><source>Eur J Clin Invest</source><year iso-8601-date="1989">1989</year><volume>19</volume><fpage>459</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2362.1989.tb00259.x</pub-id><?supplied-pmid 2479559?><pub-id pub-id-type="pmid">2479559</pub-id></element-citation></ref><ref id="B197"><label>197</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pacini</surname><given-names>F</given-names></name>
<name><surname>Pinchera</surname><given-names>A</given-names></name>
<name><surname>Giani</surname><given-names>C</given-names></name>
<name><surname>Grasso</surname><given-names>L</given-names></name>
<name><surname>Doveri</surname><given-names>F</given-names></name>
<name><surname>Baschieri</surname><given-names>L</given-names></name>
</person-group><article-title>Serum thyroglobulin in thyroid carcinoma and other thyroid disorders</article-title><source>J Endocrinol Invest</source><year iso-8601-date="1980">1980</year><volume>3</volume><fpage>283</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/BF03348277</pub-id><?supplied-pmid 7430557?><pub-id pub-id-type="pmid">7430557</pub-id></element-citation></ref><ref id="B198"><label>198</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trzos</surname><given-names>S</given-names></name>
<name><surname>Link-Lenczowski</surname><given-names>P</given-names></name>
<name><surname>Soko&#x00142;owski</surname><given-names>G</given-names></name>
<name><surname>Poche&#x00107;</surname><given-names>E</given-names></name>
</person-group><article-title>Changes of IgG <italic toggle="yes">N</italic>-glycosylation in thyroid autoimmunity: the modulatory effect of methimazole in Graves&#x02019; disease and the association with the severity of inflammation in Hashimoto&#x02019;s thyroiditis</article-title><source>Front Immunol</source><year iso-8601-date="2022">2022</year><volume>13</volume><elocation-id>841710</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.841710</pub-id><!--<pub-id pub-id-type="pmcid">PMC8965101</pub-id>--><?supplied-pmid 35370997?><pub-id pub-id-type="pmid">35370997</pub-id></element-citation></ref><ref id="B199"><label>199</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Reiding</surname><given-names>KR</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
</person-group><article-title>Distinguishing benign and malignant thyroid nodules and identifying lymph node metastasis in papillary thyroid cancer by plasma <italic toggle="yes">N</italic>-glycomics</article-title><source>Front Endocrinol (Lausanne)</source><year iso-8601-date="2021">2021</year><volume>12</volume><elocation-id>692910</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2021.692910</pub-id><!--<pub-id pub-id-type="pmcid">PMC8267918</pub-id>--><?supplied-pmid 34248851?><pub-id pub-id-type="pmid">34248851</pub-id></element-citation></ref><ref id="B200"><label>200</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tarutani</surname><given-names>O</given-names></name>
<name><surname>Ui</surname><given-names>N</given-names></name>
</person-group><article-title>Properties of thyroglobulins from normal thyroid and thyroid tumor on a concanavalin A-sepharose column</article-title><source>J Biochem</source><year iso-8601-date="1985">1985</year><volume>98</volume><fpage>851</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a135344</pub-id><?supplied-pmid 3936845?><pub-id pub-id-type="pmid">3936845</pub-id></element-citation></ref><ref id="B201"><label>201</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>K</given-names></name>
<name><surname>Nakamura</surname><given-names>K</given-names></name>
<name><surname>Kobatake</surname><given-names>S</given-names></name>
<name><surname>Satomura</surname><given-names>S</given-names></name>
<name><surname>Maruyama</surname><given-names>M</given-names></name>
<name><surname>Kameko</surname><given-names>F</given-names></name>
<etal>et al.</etal>
</person-group><article-title>The clinical utility of <italic toggle="yes">Lens culinaris</italic> agglutinin-reactive thyroglobulin ratio in serum for distinguishing benign from malignant conditions of the thyroid</article-title><source>Clin Chim Acta</source><year iso-8601-date="2007">2007</year><volume>379</volume><fpage>101</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2006.12.017</pub-id><?supplied-pmid 17270168?><pub-id pub-id-type="pmid">17270168</pub-id></element-citation></ref><ref id="B202"><label>202</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>JN</given-names></name>
<name><surname>Saldova</surname><given-names>R</given-names></name>
<name><surname>Galligan</surname><given-names>MC</given-names></name>
<name><surname>Murphy</surname><given-names>TB</given-names></name>
<name><surname>Mimura-Kimura</surname><given-names>Y</given-names></name>
<name><surname>Telford</surname><given-names>JE</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Novel glycan biomarkers for the detection of lung cancer</article-title><source>J Proteome Res</source><year iso-8601-date="2011">2011</year><volume>10</volume><fpage>1755</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1021/pr101034t</pub-id><?supplied-pmid 21214223?><pub-id pub-id-type="pmid">21214223</pub-id></element-citation></ref><ref id="B203"><label>203</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Russell</surname><given-names>MR</given-names></name>
<name><surname>Graham</surname><given-names>C</given-names></name>
<name><surname>D&#x02019;Amato</surname><given-names>A</given-names></name>
<name><surname>Gentry-Maharaj</surname><given-names>A</given-names></name>
<name><surname>Ryan</surname><given-names>A</given-names></name>
<name><surname>Kalsi</surname><given-names>JK</given-names></name>
<etal>et al.</etal>
</person-group><article-title>A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours</article-title><source>Br J Cancer</source><year iso-8601-date="2017">2017</year><volume>117</volume><fpage>666</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.199</pub-id><!--<pub-id pub-id-type="pmcid">PMC5572165</pub-id>--><?supplied-pmid 28664912?><pub-id pub-id-type="pmid">28664912</pub-id></element-citation></ref><ref id="B204"><label>204</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bertok</surname><given-names>T</given-names></name>
<name><surname>Bertokova</surname><given-names>A</given-names></name>
<name><surname>Jane</surname><given-names>E</given-names></name>
<name><surname>Hires</surname><given-names>M</given-names></name>
<name><surname>Aguedo</surname><given-names>J</given-names></name>
<name><surname>Potocarova</surname><given-names>M</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Identification of whole-serum glycobiomarkers for colorectal carcinoma using reverse-phase lectin microarray</article-title><source>Front Oncol</source><year iso-8601-date="2021">2021</year><volume>11</volume><elocation-id>735338</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.735338</pub-id><!--<pub-id pub-id-type="pmcid">PMC8695905</pub-id>--><?supplied-pmid 34956866?><pub-id pub-id-type="pmid">34956866</pub-id></element-citation></ref><ref id="B205"><label>205</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saldova</surname><given-names>R</given-names></name>
<name><surname>Wormald</surname><given-names>MR</given-names></name>
<name><surname>Dwek</surname><given-names>RA</given-names></name>
<name><surname>Rudd</surname><given-names>PM</given-names></name>
</person-group><article-title>Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis</article-title><source>is Markers</source><year iso-8601-date="2008">2008</year><volume>25</volume><fpage>219</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1155/2008/601583</pub-id><!--<pub-id pub-id-type="pmcid">PMC3827796</pub-id>--><?supplied-pmid 19126966?><pub-id pub-id-type="pmid">19126966</pub-id></element-citation></ref><ref id="B206"><label>206</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sug&#x000e1;r</surname><given-names>S</given-names></name>
<name><surname>T&#x000f3;th</surname><given-names>G</given-names></name>
<name><surname>Bugyi</surname><given-names>F</given-names></name>
<name><surname>V&#x000e9;key</surname><given-names>K</given-names></name>
<name><surname>Kar&#x000e1;szi</surname><given-names>K</given-names></name>
<name><surname>Drahos</surname><given-names>L</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Alterations in protein expression and site-specific <italic toggle="yes">N</italic>-glycosylation of prostate cancer tissues</article-title><source>Sci Rep</source><year iso-8601-date="2021">2021</year><volume>11</volume><elocation-id>15886</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-95417-5</pub-id><!--<pub-id pub-id-type="pmcid">PMC8342536</pub-id>--><?supplied-pmid 34354152?><pub-id pub-id-type="pmid">34354152</pub-id></element-citation></ref><ref id="B207"><label>207</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hautala</surname><given-names>LC</given-names></name>
<name><surname>Pang</surname><given-names>PC</given-names></name>
<name><surname>Antonopoulos</surname><given-names>A</given-names></name>
<name><surname>Pasanen</surname><given-names>A</given-names></name>
<name><surname>Lee</surname><given-names>CL</given-names></name>
<name><surname>Chiu</surname><given-names>PCN</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Altered glycosylation of glycodelin in endometrial carcinoma</article-title><source>Lab Invest</source><year iso-8601-date="2020">2020</year><volume>100</volume><fpage>1014</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1038/s41374-020-0411-x</pub-id><!--<pub-id pub-id-type="pmcid">PMC7312397</pub-id>--><?supplied-pmid 32205858?><pub-id pub-id-type="pmid">32205858</pub-id></element-citation></ref><ref id="B208"><label>208</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Naryzny</surname><given-names>SN</given-names></name>
<name><surname>Legina</surname><given-names>OK</given-names></name>
</person-group><article-title>Haptoglobin as a biomarker</article-title><source>Biochem Mosc Suppl B Biomed Chem</source><year iso-8601-date="2021">2021</year><volume>15</volume><fpage>184</fpage><lpage>98</lpage><comment>Russian</comment><pub-id pub-id-type="doi">10.18097/PBMC20216702105</pub-id><?supplied-pmid 33860767?><pub-id pub-id-type="pmid">34422226</pub-id></element-citation></ref><ref id="B209"><label>209</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jeong</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>U</given-names></name>
<name><surname>Oh</surname><given-names>M</given-names></name>
<name><surname>Nam</surname><given-names>J</given-names></name>
<name><surname>Park</surname><given-names>S</given-names></name>
<name><surname>Choi</surname><given-names>Y</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Detection of aberrant glycosylation of serum haptoglobin for gastric cancer diagnosis using a middle-up-down glycoproteome platform</article-title><source>J Pers Med</source><year iso-8601-date="2021">2021</year><volume>11</volume><elocation-id>575</elocation-id><pub-id pub-id-type="doi">10.1134/S1990750821030069</pub-id><!--<pub-id pub-id-type="pmcid">PMC8365284</pub-id>--><?supplied-pmid 34422226?><pub-id pub-id-type="pmid">34207451</pub-id></element-citation></ref><ref id="B210"><label>210</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakano</surname><given-names>M</given-names></name>
<name><surname>Nakagawa</surname><given-names>T</given-names></name>
<name><surname>Ito</surname><given-names>T</given-names></name>
<name><surname>Kitada</surname><given-names>T</given-names></name>
<name><surname>Hijioka</surname><given-names>T</given-names></name>
<name><surname>Kasahara</surname><given-names>A</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Site-specific analysis of <italic toggle="yes">N</italic>-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers</article-title><source>Int J Cancer</source><year iso-8601-date="2008">2008</year><volume>122</volume><fpage>2301</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/ijc.23364</pub-id><?supplied-pmid 18214858?><pub-id pub-id-type="pmid">18214858</pub-id></element-citation></ref><ref id="B211"><label>211</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>SY</given-names></name>
<name><surname>Yoon</surname><given-names>SJ</given-names></name>
<name><surname>Jeong</surname><given-names>YT</given-names></name>
<name><surname>Kim</surname><given-names>JM</given-names></name>
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Bernert</surname><given-names>B</given-names></name>
<etal>et al.</etal>
</person-group><article-title>N-glycosylation status of &#x003b2;-haptoglobin in sera of patients with colon cancer, chronic inflammatory diseases and normal subjects</article-title><source>Int J Cancer</source><year iso-8601-date="2010">2010</year><volume>126</volume><fpage>142</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/ijc.24685</pub-id><?supplied-pmid 19551866?><pub-id pub-id-type="pmid">19551866</pub-id></element-citation></ref><ref id="B212"><label>212</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pompach</surname><given-names>P</given-names></name>
<name><surname>Brnakova</surname><given-names>Z</given-names></name>
<name><surname>Sanda</surname><given-names>M</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Edwards</surname><given-names>N</given-names></name>
<name><surname>Goldman</surname><given-names>R</given-names></name>
</person-group><article-title>Site-specific glycoforms of haptoglobin in liver cirrhosis and hepatocellular carcinoma</article-title><source>Mol Cell Proteomics</source><year iso-8601-date="2013">2013</year><volume>12</volume><fpage>1281</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1074/mcp.M112.023259</pub-id><!--<pub-id pub-id-type="pmcid">PMC3650339</pub-id>--><?supplied-pmid 23389049?><pub-id pub-id-type="pmid">23389049</pub-id></element-citation></ref><ref id="B213"><label>213</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>T</given-names></name>
<name><surname>He</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Disease-specific haptoglobin-&#x003b2; chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases</article-title><source>J Cancer</source><year iso-8601-date="2019">2019</year><volume>10</volume><fpage>5628</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.7150/jca.32690</pub-id><!--<pub-id pub-id-type="pmcid">PMC6843889</pub-id>--><?supplied-pmid 31737099?><pub-id pub-id-type="pmid">31737099</pub-id></element-citation></ref><ref id="B214"><label>214</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grzeski</surname><given-names>M</given-names></name>
<name><surname>Taube</surname><given-names>ET</given-names></name>
<name><surname>Braicu</surname><given-names>EI</given-names></name>
<name><surname>Sehouli</surname><given-names>J</given-names></name>
<name><surname>Blanchard</surname><given-names>V</given-names></name>
<name><surname>Klein</surname><given-names>O</given-names></name>
</person-group><article-title>
<italic toggle="yes">In situ N</italic>-glycosylation signatures of epithelial ovarian cancer tissue as defined by MALDI mass spectrometry imaging</article-title><source>Cancers (Basel)</source><year iso-8601-date="2022">2022</year><volume>14</volume><elocation-id>1021</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14041021</pub-id><!--<pub-id pub-id-type="pmcid">PMC8870006</pub-id>--><?supplied-pmid 35205768?><pub-id pub-id-type="pmid">35205768</pub-id></element-citation></ref><ref id="B215"><label>215</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishnan</surname><given-names>S</given-names></name>
<name><surname>Whitwell</surname><given-names>HJ</given-names></name>
<name><surname>Cuenco</surname><given-names>J</given-names></name>
<name><surname>Gentry-Maharaj</surname><given-names>A</given-names></name>
<name><surname>Menon</surname><given-names>U</given-names></name>
<name><surname>Pereira</surname><given-names>SP</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Evidence of altered glycosylation of serum proteins prior to pancreatic cancer diagnosis</article-title><source>Int J Mol Sci</source><year iso-8601-date="2017">2017</year><volume>18</volume><elocation-id>2670</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18122670</pub-id><!--<pub-id pub-id-type="pmcid">PMC5751272</pub-id>--><?supplied-pmid 29232830?><pub-id pub-id-type="pmid">29232830</pub-id></element-citation></ref><ref id="B216"><label>216</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>M</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Lubman</surname><given-names>DM</given-names></name>
<name><surname>Gao</surname><given-names>C</given-names></name>
</person-group><article-title>Aberrant glycosylation and cancer biomarker discovery: a promising and thorny journey</article-title><source>Clin Chem Lab Med</source><year iso-8601-date="2019">2019</year><volume>57</volume><fpage>407</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1515/cclm-2018-0379</pub-id><!--<pub-id pub-id-type="pmcid">PMC6785348</pub-id>--><?supplied-pmid 30138110?><pub-id pub-id-type="pmid">30138110</pub-id></element-citation></ref><ref id="B217"><label>217</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kailemia</surname><given-names>MJ</given-names></name>
<name><surname>Park</surname><given-names>D</given-names></name>
<name><surname>Lebrilla</surname><given-names>CB</given-names></name>
</person-group><article-title>Glycans and glycoproteins as specific biomarkers for cancer</article-title><source>Anal Bioanal Chem</source><year iso-8601-date="2017">2017</year><volume>409</volume><fpage>395</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1007/s00216-016-9880-6</pub-id><!--<pub-id pub-id-type="pmcid">PMC5203967</pub-id>--><?supplied-pmid 27590322?><pub-id pub-id-type="pmid">27590322</pub-id></element-citation></ref><ref id="B218"><label>218</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>WF</given-names></name>
<name><surname>Cao</surname><given-names>WQ</given-names></name>
<name><surname>Liu</surname><given-names>MQ</given-names></name>
<name><surname>He</surname><given-names>SM</given-names></name>
<name><surname>Yang</surname><given-names>PY</given-names></name>
</person-group><article-title>Precise, fast and comprehensive analysis of intact glycopeptides and modified glycans with pGlyco3</article-title><source>Nat Methods</source><year iso-8601-date="2021">2021</year><volume>18</volume><fpage>1515</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/s41592-021-01306-0</pub-id><!--<pub-id pub-id-type="pmcid">PMC8648562</pub-id>--><?supplied-pmid 34824474?><pub-id pub-id-type="pmid">34824474</pub-id></element-citation></ref><ref id="B219"><label>219</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>Z</given-names></name>
<name><surname>Qin</surname><given-names>H</given-names></name>
<name><surname>Mao</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>N</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<etal>et al.</etal>
</person-group><article-title>Glyco-Decipher enables glycan database-independent peptide matching and in-depth characterization of site-specific N-glycosylation</article-title><source>Nat Commun</source><year iso-8601-date="2022">2022</year><volume>13</volume><elocation-id>1900</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-29530-y</pub-id><!--<pub-id pub-id-type="pmcid">PMC8990002</pub-id>--><?supplied-pmid 35393418?><pub-id pub-id-type="pmid">35393418</pub-id></element-citation></ref><ref id="B220"><label>220</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>W</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Kong</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>P</given-names></name>
</person-group><article-title>Recent advances in software tools for more generic and precise intact glycopeptide analysis</article-title><source>Mol Cell Proteomics</source><year iso-8601-date="2021">2021</year><volume>20</volume><elocation-id>100060</elocation-id><pub-id pub-id-type="doi">10.1074/mcp.R120.002090</pub-id><!--<pub-id pub-id-type="pmcid">PMC8724820</pub-id>--><?supplied-pmid 33556625?><pub-id pub-id-type="pmid">33556625</pub-id></element-citation></ref></ref-list></back></article>